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 OBJECTIVES 
 
Structure-based drug discovery relies on the three dimensional interactions of ligand 
molecules with their target. Generally, by inserting themselves in the binding site of 
the target protein, (drug) molecules can influence protein activity. Affinity of these 
ligands to their respective target proteins is due to their structural and chemical 
complementarity.  
 
Today, fundamental understanding of the molecular details of ligand/G-protein 
coupled receptor (GPCR) interactions remain very rudimentary. In absence of high-
resolution structural knowledge of different GPCRs, this matter can only be 
addressed by building (homology) models, which are validated through biochemical 
and pharmacological studies. 
 
In this thesis, we will focus on the design of novel ligands for the adenosine receptors 
(ARs), an interesting family of GPCRs. Four AR subtypes have been identified today, 
i.e. A , A , A  and A1 2A 2B 3. We will evaluate the potential (i.e. binding properties, intrinsic 
activity and selectivity) of synthetic adenosine analogues, modified at the 3’- and 5’-
positions of the ribofuranosyl moiety and at the purine 2- and N6-positions as human 
A AR ligands.  3
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 All planned analogues are characterised by an azido/amino(methyl) modification at 
the 3’-position (i.e. 3’-(CH )-N  or 3’-(CH )-NH2 3 2 2) of the ribofuranose moiety. Since 
such structural modifications have not been explored intensively for ARs, they might 
open interesting perspectives towards tuning the efficacy and selectivity for the 
human A AR. 3
 
The envisaged adenosine analogues will also be valuable tools to explore a 
“chemical genetics” approach on ARs. In such approach individual proteins are 
modified so that they can be modulated with small molecules and hence improve our 
understanding of target function. In collaboration with the group of Dr. Kenneth A. 
Jacobson, we aim to integrate organic synthesis and molecular engineering to 
explore the “neoceptor concept”, i.e. investigation of molecular complementarity at 
both wild-type and mutant A  and A  adenosine receptors. 3 2A
 
In another part of this thesis, we will design and evaluate a number of 2’- and 3’-
modified thymidine analogues as Mycobacterium tuberculosis thymidine 
monophosphate kinase (TMPKmt) inhibitors, based on its crystal structure. 
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 PART I 
SYNTHESIS OF MODIFIED 
ADENOSINE AND THYMIDINE ANALOGUES 
 
 
 
 
 
 
 
 
 
 
Synthesis discussed in this part gives an overview of the chemistry published in: 
 
 
Bioorg. Med. Chem. 2004, Accepted. 
J. Med. Chem. 2003, 46, 4847. 
Eur. J. Org. Chem. 2003, 15, 2911. 
J. Med. Chem. 2001, 44, 4125. 
 3
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 CHAPTER 1 
GENERAL BACKGROUND 
 
1.1 Nucleoside synthesis 
  
“Nucleosides and their analogues are of enormous importance. They are 
an established class of clinically useful medicinal agents, possessing 
antiviral and anticancer activity.”1
 
The potential activity of the modified nucleoside analogues, of which the synthesis is 
discussed in this part, will be biologically evaluated on adenosine receptor (AR) 
subtypes A  and A2A 3 (Part II) and as inhibitors of thymidine monophosphate kinase of 
Mycobacterium tuberculosis (TMPKmt, Part III).  
 
From a chemical point of view, in this work, we focus on the synthesis of adenosine 
and thymidine nucleoside analogues (Figure 1.1). Both the ribofuranose or 2’-
deoxyribofuranose moieties of adenosine and thymidine are extensively modified, i.e. 
at the 3’- and 5’-position for the former and at the 2’- and 3’-position for the latter. In 
the adenosine nucleoside series the purine base was also altered at the 2- and N6-
position. The rationale for the synthesis of the reported analogues in Part I will be 
explained in Parts II and III.  
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Figure 1.1 The adenosine and thymidine nucleosides and their sugar and base numbering. 
 
 
In general, for the de novo synthesis of modified nucleosides, two synthetic 
strategies are employed. A first approach, uses the parent nucleoside scaffold to 
introduce the intended modifications. When the nucleoside scaffold is not compatible 
with the conditions of the reactions used, a second (more elaborate) approach 
consists of the glycosylation of a (modified) sugar synthon with the desired (modified) 
heterocyclic base. 
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 In the method developed by Vorbrüggen, the glycosidic bond formation is driven by 
the use of a silylated nucleobases in combination with strong Lewis acids, like 
trimethylsilyl triflate (2 in Scheme 1.1).2 This Vorbrüggen coupling reaction is “the” 
reference in nucleoside synthesis and provides a highly reproducible method for 
nucleoside formation in high yield with reliable and predictable stereochemistry, i.e. 
orientation of the glycosidic bond.1,2
 
Scheme 1.1 
The Vorbrüggen coupling reaction for the formation of β-ribonucleosides. 
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In the presence of a 2-α-acetyl group (as in 1), the trimethylsilyl triflate catalyst 2 
converts the 1,2-diacetylated ribofuranosyl sugar 1 into the 1,2-acetyloxonium 
intermediate 3 (as a triflate salt).3 Under these conditions the nucleophilic silylated 
base can only attack the sugar cation from the top (β-side), resulting in the exclusive 
formation of β-nucleoside 4. 
 
Silylation of the base is needed to: 
- convert these quite polar heterocycles into more lipophilic compounds, 
to become soluble in organic solvent and permitting homogeneous 
reactions; 
- promote the nucleophilicity of the heterocycles, due to the electron-
releasing properties of silicon.4 
 
The preferred strategy for the synthesis of adenosine and thymidine analogues 
described in this work, was to couple the modified ribofuranosyl moieties (5-8) with 
the desired purine (9-11) or pyrimidine (12) heterocycles (Scheme 1.2). This 
approach allowed us to keep the main synthetic route as common as possible and 
permitted time-effective and efficient preparation of divergent nucleoside analogues. 
 6
 Scheme 1.2 
Ribofuranose, purine and pyrimidine moieties used for nucleoside formation. 
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The stereoselective introduction of both key modifications, i.e. an azido (13) and 
azidomethyl (14) group at the 3-position of the ribofuranose ring (Scheme 1.3), was 
accomplished via appropriate protection/deprotection strategies, described in detail in 
Chapter 2. The commercially available 1,2-O-isopropylidene-α-D-xylo-furanose sugar 
(15) was used as starting material for both modifications. 
 
Using the key azido (13) and azidomethyl (14) synthons as a secondary starting point 
we could: 
- easily get access to the desired 1,2-diacetylated intermediates 5 and 
7 after isopropylidene deprotection and acetylation; 
- further modify the ribofuranosyl moiety, i.e. introduction of the 
uronamide (methylcarbamoyl) functionality at the 5-position,5 to give 6 
and 8 after isopropylidene deprotection and acetylation. 
 
 
1.2 Comments on the synthesis of the key azido synthons 
 
Throughout this work we used the Ph3P azido reduction as a final step in the 
synthesis of the modified adenosine and thymidine nucleoside derivatives. Azido 
 7
 reduction reactions are of wide applicability and have been effected with a variety of 
reagents, including LiAlH , NaBH , catalytic hydrogenation, Ph P, diborane, Bu4 4 3 3SnH, 
Zn/HCl.6 However, one the mildest and most selective routes to convert azides to 
amines is the Staudinger7 6,8 reaction (with Ph P).3
 
Scheme 1.3 
Retrosynthetic overview for the preparation of the 1,2-diacetylated modified ribofuranose 
sugar scaffolds. 
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The crucial stage in the preparation of the azido modified 1,2-diacetylated sugar 
synthons 5 and 6 (Scheme 1.2 and Scheme 1.3), was the stereoselective 
introduction of the 3-α-oriented azide (13). Synthetic routes to puromycine (and its 
analogues) via 3’-amino-3’-deoxyadenosine (Figure 1.2) have already been 
reported.9 Most of these procedures however suffer from a high number of steps and 
a low overall yield. Moreover, these synthetic strategies all use adenosine as a 
starting point, which, contrary to our approach, limits their use for the preparation of 
nucleosides derived from 5-8. 
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Figure 1.2 The puromycine and 3’-amino-3’-deoxyadenosine nucleosides. 
 
 
10Based on the work of Azhayev et al.,  we developed a procedure that made the 
regio- and stereoselective azido functionalisation possible (Chapter 2), starting from 
the isopropylidene protected α-D-xylofuranose sugar. 
 
Formation of the 3-α-oriented azidomethyl intermediate 14 (Scheme 1.3), to give 
access to the 1,2-diacetylated “3-C-branched chain” intermediates 7 and 8, was 
based on the method of Lin et al.11 (Chapter 2). This approach also allowed us to 
start from the isopropylidene protected α-D-xylofuranose 15. Other methods to 
introduce this type of branching have been reported: 
12- Acton et al.,  starting from 1,2:5,6-di-O-isopropylidene-α-D-
glucofuranose;  
- An et al.,13 formation of the 3’-α-hydroxymethyl on 2’-deoxythymidine 
and cytidine derivatives;  
- Filichev et al.,14 via reduction of 3’-α-cyano or 3’-α-nitromethyl as 
amino precursor groups. 
 
During the course of our work, a procedure for the synthesis of the simple 3’-amino / 
azido modified series has been patented15 16 and published  by Pfizer in parallel to our 
reports.17 Based on the work of Acton et al.,12 they prepared their 3’-amino modified 
nucleosides (like CP-608039) through azide displacement of the triflate derived from 
glucose diacetonide (Scheme 1.4). 
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 Scheme 1.4 
Pfizer approach towards the synthesis of the 3’-amino modified analogue CP-608039. 
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Recently Rozners et al. communicated a novel and general approach to 3’,5’-C-
branched pyrimidine ribonucleosides18 16 and 17 (Figure 1.3) that show high 
similarity to our envisaged purine nucleoside analogues. 
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Figure 1.3 3’,5’-C-branched pyrimidine nucleosides analogues reported by Rozners et al.18
 
 
Note on the nucleoside nomenclature used in this work 
 
In nucleosides, as already demonstrated for adenosine and thymidine in Scheme 1.1, 
the ribofuranose ring numbering can be distinguished from purine heterocycle 
numbering by the use of the prime after the arabic numerals. Moreover, this “generic” 
nucleoside notation, i.e. not according to IUPAC conventions, is used to indicate the 
positions of the nucleoside that are chemically modified (like the 3’-branching) or to 
pinpoint particular regions of the nucleoside that interact with the biological (target) 
system (like the N6-substituent in the human A3AR binding site, see Part II).  
 
These conventions can lead to serious misinterpretations when modifications on the 
nucleoside significantly alter the parent nucleoside structure. In this work, such a 
modification is the replacement of the 4’-CH2OH group of the parent nucleoside (18) 
by a uronamide functionality (19) (Figure 1.4). Although the methylcarbamoyl group 
in 19 can be seen as a 4’-substituent, it is dubiously called a 5’-uronamide 
modification. Hence, the generic name of 19 is 5’-methylcarbamoyladenosine or   
 10
 9-[(5-methylcarbamoyl)-β-D-ribofuranosyl]adenosine. However the latter can 
easily be mistaken for compound 20. 
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Figure 1.4 Nomenclature in nucleoside chemistry for modifications at the 5’-position. 
 
 
In fact to accurately describe structure 19 its IUPAC-name should be used, i.e. 
(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-tetrahydro-3,4-dihydroxy-N-
methylfuran-2-carboxamide. Since IUPAC nomenclature does not allow rapid 
visualisation of the described structures, the “generic” nomenclature is generally 
accepted in the nucleoside (bio)chemistry and pharmacology field and will therefore 
be used throughout this work. 
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 CHAPTER 2 
SYNTHESIS AND PREPARATION OF MODIFIED 
ADENOSINE AND THYMIDINE ANALOGUES 
 
2.1 Synthesis of 3’-azido / amino modified iodobenzyladenosine 
 
3-Azido-3-deoxy-1,2-di-O-acetyl-5-O-(toluoyl)-D-ribofuranose (4) was prepared in five 
steps from the commercially available 1,2-O-isopropylidene-α-D-xylofuranose (1) 
following a slightly altered procedure described by Ozols et al (Scheme 2.1).1 
Vorbrüggen2 coupling with N6-(3-iodobenzyl)adenine3 followed by alkaline 
deprotection, gave the β-anomer 5 in low yield. Reduction of the azido moiety of 5 
with triphenylphosphine led to smooth conversion to the desired amine 6, without 
detectable loss of the benzylic N6-substituent. 
 
aScheme 2.1
Synthesis of 3’-azido / amino modified iodobenzyladenosine. 
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aReagents and conditions: (a) toluoyl chloride, dry pyridine, dry CH2Cl2, 0 °C, 71%; (b) (i) 
(CF3SO2)2O, dry pyridine, dry CH2Cl2, -10 °C (ii) NaN3, DMF, rt, 40%; (c) (i) 75 % HCOOH, 50 °C (ii) 
(CH3CO)2O, pyridine, rt, 90%; (d) (i) silylated 3-iodobenzyladenine, (CH3)3SiOSO2CF3, ClC2H4Cl, 85 
°C (ii) 0.1 N NaOCH3 in MeOH, rt, 18%; (e) Ph3P, NH4OH, pyridine, rt, 70%. 
 
 
2.2 Synthesis of the 3’-azido-5’-methylcarbamoyl nucleoside scaffolds 
 
For the synthesis of the fully modified nucleoside scaffolds, the 3-azido intermediate 
74 5, was obtained by simple 5-deprotection of 3 (Scheme 2.2). Periodate oxidation  
followed by esterification of the carboxylic acid and subsequent treatment with 
methylamine3 in a sealed tube afforded the ribofuronamide 86. One pot deprotection-
acetylation gave the 1,2-diacetylated 3,5-modified sugar 9. Vorbrüggen-
 13
 glycosylation2 7 with silylated 6-chloropurine and 2,6-dichloropurine  quantitatively 
yielded the key nucleoside scaffolds 106 and 11. 
 
aScheme 2.2
Synthesis of the 3’-azido-5’-methylcarbamoyl nucleoside scaffolds. 
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aReagents and conditions: (a) 0.1 N NaOCH3 in MeOH, rt, 88%; (b) (i) NaIO4, RuCl3, H2O, CHCl3, 
CH3CN, rt (ii) EDC, DMAP, anhydrous MeOH, rt (iii) 2 M CH3NH2 in THF, 55 °C, 33%; (c) H2SO4, 
(CH3CO)2O, CH3COOH, 55%; (d) silylated 6-chloropurine or 2,6-dichloropurine, (CH3)3SiOSO2CF3, 
ClC2H4Cl, 85 °C, 95% and 70%. 
 
 
The one pot deprotection-acetylation strategy was needed for the preparation of the 
1,2-diacetylated 3,5-modified sugar moiety 9. As pointed out in Scheme 2.3, 
deprotection of 8 with 75% acetic acid and simple acetylation, using an acetic 
anhydride-pyridine (1:2) mixture, resulted in a rearrangement to compound 12, which 
yielded the isolated six-membered nucleoside 13 after Vorbrüggen coupling2 with 6-
chloropurine. 
 
aScheme 2.3
Rearrangement upon deprotection / acetylation of the isopropylidene group. 
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aReagents and conditions: (a) (i) 75 % CH3COOH, 60 °C (ii) (CH3CO)2O, pyridine, rt, 61%; (b) 
silylated 6-chloropurine, (CH3)3SiOSO2CF3, ClC2H4Cl, 85 °C, 93%. 
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 2.3 Synthesis of the 3’-azidomethyl modified nucleoside scaffold 
 
The 3-C-azidomethyl sugar 17 was prepared in six steps from 1 by reported 
procedures (Scheme 2.4).8,9 Removal of the 5-O-(tert-butyldimethyl)silyl (TBS) group 
of 17 with tetrabutylammonium fluoride (TBAF) and protection of the 5-hydroxyl 
group of 1810 as a toluoyl ester gave 19. Acidic deblocking of the 1,2-O-isopropyl 
moiety of 19, followed by acetylation furnished the 1,2-diacetylated 3-C-azidomethyl 
sugar 20. The protecting group exchange was necessary to avoid pyranose ring 
formation that, in our hands, occurred upon acidic deprotection (contrary to what is 
reported9 2 7 of 20 with silylated 6-chloropurine). Vorbrüggen-type coupling  gave the 
nucleoside scaffold 21.  
 
aScheme 2.4
Synthesis of the 3’-azidomethyl modified nucleoside scaffold. 
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aReagents and conditions: (a) TBSCl, DMAP, pyridine, 0°C, 73%; (b) (i) (COCl)2, DMSO, dry 
CH2Cl2, -55 °C (ii) NaH, methyltriphenylphosphonium bromide, DMSO, rt, 56%; (c) (i) 1 M BH3 in THF, 
rt (ii) THF, H2O, NaOH, H2O2, 0 °C, 65%; (d) (i) CH3SOCl, dry pyridine, rt (ii) NaN3, DMF, 95 °C, 77%; 
(e) 1 M TBAF in THF, rt, 96%; (f) toluoyl chloride, dry pyridine, rt, 94%; (g) (i) 75 % CH3COOH, 60 °C 
(ii) (CH3CO)2O, pyridine, rt, 63%; (h) silylated 6-chloropurine, (CH3)3SiOSO2CF3, ClC2H4Cl, 85 °C, 
81%. 
 
 
2.4 Synthesis of the 3’-azidomethyl-5’-methylcarbamoyl nucleoside scaffold 
 
The synthesis of the 3’-azidomethyl-5’-methylcarbamoyl nucleoside scaffold 24 is 
outlined (Scheme 2.5). In analogy to the procedure described under paragraph 2.2, 
intermediate 1810 was converted to the 5-methylcarbamoyl derivative 22. One pot 
 15
 deprotection-acetylation afforded the 1,2-diacetylated 3,5-modified sugar 23, which 
after Vorbrüggen-glycosylation2 with silylated 6-chloropurine quantitatively yielded 24. 
 
aScheme 2.5
Synthesis of the 3’-azidomethyl-5’-methylcarbamoyl nucleoside scaffold. 
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aReagents and conditions: (a) (i) NaIO4, RuCl3, H O, CHCl2 3, CH3CN, rt (ii) EDC, DMAP, anhydrous 
MeOH, rt (iii) 2 M CH3NH2 in THF, 55 °C, 32%; (b) H2SO4, (CH CO)3 2O, CH3COOH, 40%; (c) silylated 
6-chloropurine, (CH3)3SiOSO2CF3, ClC2H4Cl, 85 °C, 95%. 
 
 
2.5 Synthesis of the N6-substituted adenosine analogues 
 
Displacement of the 6-chloro atom in 21 with ammonia, methylamine, 3-
iodobenzylamine and 5-chloro-2-methoxybenzylamine11, followed by deprotection in 
7 N NH3 in MeOH produced the 3’-C-azidomethyl nucleosides 25-28 (Scheme 2.6). 
Triphenylphosphine reduction of the azido moiety gave the 3’-C-aminomethyl 
nucleosides 29-32. Amidation of 31 and 32 was performed with acetyl chloride under 
Schotten-Baumann conditions and furnished derivatives 33 and 34. 
 
Following the same strategy, the 3’-amino / azido(methyl)- 5’-methylcarbamoyl 
nucleoside scaffolds 10, 11 and 24 produced the N6-substituted 3’-azido(methyl)-5’-
methylcarbamoyl adenosine analogues 35-37, 41 and 42 after nucleophilic 
displacement with 3-iodobenzylamine or 5-chloro-2-methoxybenzylamine and 
subsequent deprotection in 7 N NH3 in MeOH (Scheme 2.7). Here also, 
triphenylphosphine reduction of the azido moiety gave smooth conversion to the 
amino-nucleosides 38-40, 43 and 44. 
 
2.6 Synthesis of the thymidine analogues modified at the 2’- and 3’-position 
 
The conversion of 1,2-O-isopropylidene-α-D-xylofuranose 1 into 4 (Scheme 2.8) is 
discussed under paragraph 2.1. 
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 aScheme 2.6
Synthesis of the N6-substituted 3’-amino / azidomethyl adenosine analogues. 
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aReagents and conditions: (a) (i) amine HCl (or ammonia for 25), Et3N, EtOH, reflux (ii) 7 N NH3 in 
MeOH, rt, 35%-68%; (b) Ph3P, NH4OH, pyridine, rt, 64%-70%; (c) CH3COCl, 50% aqueous NaOAc, 
THF, rt, 63% and 60%. 
 
 
aScheme 2.7
Synthesis of the N6-substituted 3’-amino / azido(methyl)- 5’-methylcarbamoyl adenosine 
analogues. 
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aReagents and conditions: (a) (i) amine HCl, Et3N, EtOH, reflux (ii) 7 N NH3 in MeOH, rt, 60%-82%; 
(b) Ph3P, NH4OH, pyridine, rt, 18%-74%. 
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 aScheme 2.8
Synthesis of the thymidine analogues modified at the 2’- and 3’-position. 
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aReagents and conditions: (a) (i) silylated thymine, (CH3)3SiOSO2CF3, ClC2H4Cl, 85 °C (ii) 0.1 N 
NaOCH3 in MeOH, rt, 80%; (b) (i) triphenylmethyl chloride, pyridine, 65°C (ii) CF3SO2Cl, DMAP, 
CH2Cl2, 4°C, 75%; (c) (i) 1 N NaOH, EtOH:H2O (1:1), rt (ii) adjusted to ~pH 7 with CH3COOH, 88%; (d) 
80 % CH3COOH, 90°C, 79%; (e) 4 M HCl in 1,4-dioxane, 92%; (f) (i) DAST, pyridine, toluene, 50°C (ii) 
80 % CH3COOH, 90°C, 58%; (g) Ph3P, NH4OH, pyridine, rt, 30%-71%. 
 
 
Vorbrüggen2 glycosylation with silylated thymine, followed by alkaline deprotection 
afforded the azido nucleoside 4512. After tritylation of the primary hydroxyl group, 45 
was converted into the 2,2’-anhydro-analogue 47.13 Alkaline treatment of 47 yielded 
intermediate 48 with the 2’-hydroxyl group in the arabino (“UP”) configuration.14 
Detritylation with 80 % acetic acid quantitatively yielded nucleoside 4915. Nucleophilic 
chlorination of 47 using 4 M HCl in dioxane16 resulted in the formation of 51. 
Analogue 48 was treated with DAST17 and, after detritylation, afforded nucleoside 
5318 with the fluor atom at the 2’-position in ribo (“DOWN”) configuration. Our 
synthesis is superior to the methods previously described, in that our method starts 
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 from the key azide synthon 45 and avoids the troublesome opening a 2’,3’-lyxo-
epoxide.18 Selective triphenylphosphine reduction of the azido moieties of 
nucleosides 45, 49, 51 and 53 smoothly afforded the novel 3’-amine analogues 46, 
50, 52 and the known 5419. 
 
 
2.7 Experimental part 
 
General Remarks 
1 13H and C spectra were obtained with a Varian 300 MHz spectrometer. The residual 
solvent signal of CDCl  and DMSO-d3 6 was used as a secondary reference. 
Assignment of all 1 1 1H-resonances was confirmed by 2D H- H COSY experiments. 
Signals assigned to amino and hydroxyl groups were exchangeable with D2O. 
Abbreviations used are s = singulet, d = doublet, t = triplet, q = quadruplet, m = 
multiplet, dd = double doublet, app = apparent and br = broad signal. Coupling 
constants (J) are expressed in Hz. 
 
Exact mass measurements were performed on a quadrupole/orthogonal-acceleration 
time-of-flight (Q/oaTOF) tandem mass spectrometer (qTOF 2, Micromass, 
Manchester, UK) equipped with a standard electrospray ionisation (ESI) interface. 
Samples were infused in a 2-propanol:water (1:1) mixture at 3 μl/min. Elemental 
analyses were performed at the University of Konstanz, Germany, and are within 
±0.4% of theoretical values unless otherwise specified. 
 
®Precoated MACHEREY-NAGEL ALUGRAM  SIL G/UV254 silica gel plates were used 
for TLC and spots were examined with UV-light at 254 nm and/or a sulfuric acid-
anisaldehyde solution or a ninhydrine (0.5 % in EtOH) solution. Column 
Chromatography was performed on 560 (0.06-0.2 mm) Uetikon Chemie silicagel. 
 
1,2-O-isopropylidene-α-D-xylofuranose (1), all reagents and (anhydrous) solvents 
were purchased from ACROS ORGANICS. CH Cl2 2, ClCH2CH2Cl and MeOH were 
obtained by distillation after refluxing overnight on CaH2. 
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 2.7.1 Preparation of 3’-azido / amino modified iodobenzyladenosine 
 
1,2-O-Isopropylidene-5-O-(toluoyl)-α-D-xylofuranose (2) 
A solution of toluoyl chloride (13.2 mL, 100 mmol) in dry CH Cl2 2 (40 mL) was added 
dropwise to a solution of 1,2-O-isopropylidene-α-D-xylofuranose 1 (20 g, 105.15 
mmol) in dry pyridine (50 mL) and dry CH2Cl2 (150 mL). The reaction mixture was 
stirred at 0 °C for 2 h and quenched afterwards in water (250 mL). After extraction 
with CH Cl2 2, the organic phase was evaporated in vacuo. The residue was dissolved 
in a minimal amount of warm EtOAc and the product was crystallized upon treatment 
with hexane. The crystals were isolated by filtration to yield 23g (71 %) of 2. 
O
TolO
O
OOH
1
23
4
5
 
Molecular formula: C H O16 20 6
Molecular weight: 308.33 
1H-NMR (300 MHz, CDCl3): 
δ 1.32 and 1.51 (2 x s, 6H, 2 x CH3), 2.42 (s, 3H, Ar-CH3), 2.78 (d, 1H, J = 4.1 Hz, 3-
OH), 4.18 (dd, 1H, J = 2.5 Hz and 5.2 Hz, H-3), 4.24-4.90 (m, 4H, H-2, H-4, H-5B and 
H-5A), 5.96 (d, J = 3.6 Hz, H-1), 7.26 and 8.00 (2 x d, 4H, J = 8.0 Hz, Ar-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C16H21O6 [M+H]+ 309.1338, found 309.1343 
 
3-Azido-3-deoxy-1,2-O-isopropylidene-5-O-(toluoyl)-α-D-ribofuranose (3) 
To a stirred solution of 2 (23g, 74.6 mmol) in CH2Cl2 (250 mL) and pyridine (20 mL) 
trifluoromethanesulfonic anhydride (15 mL, 89.5 mmol) was added and the reaction 
mixture was held at -10 °C for 2 h. 7 % NaHCO3 was added and stirring continued for 
20 min. The organic phase was washed with H2O, dried over MgSO4, filtered and 
evaporated to dryness. The residue was dissolved in DMF (250 mL) and NaN3 (34g, 
522 mmol) was added. The reaction mixture was stirred overnight at room 
temperature. DMF was evaporated in vacuo, and 7 % NaHCO3 (250 mL) and EtOAc 
(250 mL) were added. The organic phase was dried over MgSO4, filtered, evaporated 
to dryness and purified by column chromatography (Pentane/EtOAc, 95/5→85/15) to 
yield 10 g (40 %) of 3. 
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Molecular formula: C H N16 19 3O5
Molecular weight: 333.34 
1H-NMR (300 MHz, CDCl3): 
δ 1.36 and 1.58 (2 x s, 6H, 2 x CH3), 2.38 (s, 3H, Ar-CH3), 3.38 (dd, 1H, J = 8.6 Hz, 
H-3), 4.21-4.61 (m, 3H, H-4, H-5A and H-5B), 4.73 (dd, 1H, J = 4.5 Hz and 8.5 Hz, H-
2), 5.79 (d, 1H, J = 3.6 Hz, H-1), 7.16 and 7.86 (2 x d, 4H, J = 7.9 Hz, Ar-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H N16 19 3O5Na [M+Na]  356.1222, found 356.1235 
 
3-Azido-3-deoxy-1,2-di-O-acetyl-5-O-(toluoyl)- D-ribofuranose (4) 
The azido derivative 3 (5 g, 15 mmol) was added to a 75 % HCOOH solution (150 
mL). The mixture was heated to 50 °C for 2 h and evaporated to dryness. The 
residue was dissolved in a mixture of acetic anhydride/pyridine (125 mL, 2:3, v/v) at 
room temperature. Stirring was continued for 3 h and CH2Cl2 (100 mL) and 7 % 
NaHCO3 (100 mL) were added. The aqueous phase was washed with CH Cl2 2 (100 
mL) and the combined organic phases were dried over MgSO4, filtered and 
evaporated in vacuo. The residue was precipitated from methanol to give 4 as a 
white solid (5.1 g, 90 %). 
O
TolO
OAcN3
OAc
1
23
4
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Molecular formula: C H N17 19 3O7
Molecular weight: 377.35 
1H-NMR (300 MHz, CDCl3) of most polar anomer: 
δ 1.90 and 2.15 (2 x s, 6H, 2 x CH3), 2.48 (s, 3H, Ar-CH3), 4.10-4.68 (m, 4H, H-3, H-
4, H-5B and H-5A), 5.31 (d, 1H, J = 4.6 Hz, H-2), 6.09 (s, 1H, H-1), 7.16 and 7.88 (2 
x d, 4H, J = 8.1 Hz, Ar-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+H Ncalculated for C17 19 3O7Na [M+Na]  400.1120, found 400.1198 
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 General procedure for the silylation of the bases 
The appropriate base (1.0 mmol) was treated with hexamethyldisilazane (HMDS, 5 
mL). Chlorotrimethylsilane (TMSCl, 1.0 mmol) was added and the reaction mixture 
was refluxed at 134 °C under N2 for 20 hours. Solvents were removed in vacuo and 
the concentrated silylated base was used without further purification. 
 
9-(3-Azido-3-deoxy-α-D-ribofuranosyl)-N6-(3-iodobenzyl)adenine (5) 
4 (725 mg, 1.92 mmol) in 1,2-dichloroethane (35 mL) was added to silylated N6-(3-
iodobenzyl)adenine (810 mg, 2.31 mmol). TMSOTf (417 μL, 2.31 mmol) was added 
dropwise under continuous stirring under nitrogen atmosphere to give a clear solution 
after approximately 30 min at 83 °C. After 6 h at 83 °C the reaction mixture was 
cooled and CH2Cl2 (50 mL) and a 7 % NaHCO3 solution (100 mL) were added. The 
organic phase was separated, dried with MgSO4, filtered, and evaporated to dryness. 
The residue was dissolved in 0.1 N NaOCH3 in CH3OH (100 mL), stirred for 2 h, 
neutralized with a 9:1 H2O-CH3COOH mixture, evaporated in vacuo, purified by 
column chromatography (CH2Cl2/MeOH, 100/0 → 97/3) and precipitated from CH3OH 
to yield 176 mg (18 %) of 5  as a white solid. 
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Molecular formula: C H IN17 17 8O3
Molecular weight: 508.28 
1H NMR (300 MHz, DMSO-d6) 
δ 3.58 (app dd, 1H, J = 3.6 Hz and -12.3 Hz, H-5B’), 3.69 (app dd, 1H, J = 3.5 Hz, H-
5A’), 4.00 (app q, 1H, J = 3.5 Hz and 7.0 Hz, H-4’), 4.33 (q, 1H, J = 3.8 Hz and 5.2 
Hz, H-3’), 4.67 (s, 2H, CH2-Ar), 5.02 (t, 1H, J = 5.6 Hz, H-2’), 5.54 (br s, 1H, 5’-OH), 
5.92 (d, 1H, J = 6.0 Hz, H-1’), 6.24 (br s, 1H, 2’-OH), 7.11 (t, 1H, J = 7.8 Hz, H-5’’), 
7.36 (d, 1H, J = 7.6 Hz, H-6’’), 7.59 (d, 1H,J = 7.8 Hz, H-4’’), 7.73 (s, 1H, H-2’’), 8.23 
(s, 1H, H-2), 8.42 (s, 1H, H-8), 8.55 (br s, 1H, N(6)-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C17H18IN8O3 [M+H]+: 509.0548, found 509.0547. 
Elemental analysis (C H IN17 17 8O3) C,H,N. 
 
 22
 9-(3-Amino-3-deoxy-α-D-ribofuranosyl)-N6-(3-iodobenzyl)adenine (6) 
5 (100 mg, 0.197 mmol) was dissolved in pyridine (10 mL), and Ph3P (100 mg, 0.381 
mmol) was added to the solution. After stirring for 1 h at room temperature, 
concentrated NH4OH (5 mL) was added. The reaction mixture was stirred for another 
2 h, evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH, 
9/1) to yield 67 mg (70 %) of 6 as a white solid. 
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Molecular formula: C H IN17 19 6O3
Molecular weight: 482.28 
1H NMR (300 MHz, DMSO-d6) 
δ 1.69 (br s,2H, 3’-NH2), 3.47 (app t, 1H, J = 6.1 Hz, H-3’), 3.57 (app dd, 1H, J = 4.3 
Hz and -12.6 Hz, H-5B’), 3.73 (m, 2H, H-5A’and H-4’), 4.29 (m, 1H, H-2’), 4.65 (s, 2H, 
CH2-Ar), 5.14 (br s, 1H, 5’-OH), 5.77 (br s, 1H, 2’-OH), 5.93 (d, 1H, J = 2.8 Hz, H-1’), 
7.11 (t, 1H, J = 7.8 Hz, H-5’’), 7.35 (d, 1H, J = 7.6 Hz, H-6’’), 7.58 (d, 1H, J = 7.8 Hz, 
H-4’’’), 7.71 (s, 1H, H-2’’), 8.21 (s, 1H, H-2), 8.44 (s, 1H, H-8), 8.48 (br s, 1H, N(6)-H).  
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C17H20IN6O3 [M+H]+: 483.0643, found 483.0631. 
Elemental analysis (C H IN17 19 6O3) C,H,N. 
 
 calculated %  found % 
Compound C H N  C H N 
40.17 3.37 22.05  39.83 3.02 22.27 5 
41.56 4.10 17.11  41.33 3.97 17.01 6 
 
Table 2.1 Elemental analysis of final products 5 and 6. 
 
 
2.7.2 Preparation of the 3’-azido-5’-methylcarbamoyl nucleoside scaffolds 
 
3-Azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (7) 
3 (6 g, 15 mmol) was dissolved in 0.1 N NaOCH3 in CH3OH (150 mL), stirred for 2 h, 
neutralized with a 9:1 H2O-CH3COOH solution, evaporated in vacuo and purified by 
column chromatography (CH /MeOH, 99/1) to yield 3.4 g (88 %) of 7 as a solid.2Cl2
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Molecular formula: C8H N13 3O4
Molecular weight: 215.21 
1H-NMR (300 MHz, DMSO-d6): 
δ 1.28 and 1.44 (2 x s, 6H, 2 x CH3), 3.45-3.52 (m, 2H, H-3 and H-5B), 3.64 (ddd, 1H, 
J = 2.9 Hz, 5.3 Hz and -12.3 Hz, H-5A), 3.94 (ddd, 1H, J = 2.9 Hz, 4.3 Hz and 9.8 Hz, 
H-4), 4.77 (t, 1H, J = 4.3 Hz, H-2), 4.90 (dd, 1H, J = 5.4 Hz and 6.0 Hz, 5-OH), 5.77 
(d, 1H, J = 3.5 Hz, H-1). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C8H N O13 3 4Na [M+Na]  238.0803, found 238.0801 
 
Methyl 3-azido-3-deoxy-1,2-isopropylidene-α-D-ribofuronamide (8) 
A biphasic mixture of water (46 mL), CHCl3 (31 mL) and acetonitrile (31 mL) 
containing compound 7 (3.3 g, 15.33 mmol), RuCl3 hydrate (160 mg, 0.77 mmol) and 
NaIO4 (13.45 g, 62.87 mmol) was vigorously stirred for 4.5 h at room temperature. 
The reaction mixture was then diluted with water (100 mL) and extracted with CH2Cl2 
(3 x 200 mL). The combined organic phase was dried over MgSO4, filtered and 
evaporated. A dark green oily residue was triturated with diethyl ether to precipitate 
the ruthenium salts, that were removed by filtration through celite. The filtrate was 
concentrated in vacuo, leaving 2.7 g (77 %) of 3-azido-3-deoxy-1,2-isopropylidene-α-
D-ribofuronic acid as a lightly coloured oil that was used without further purification. A 
mixture of this ribofuronic acid (2.5 g, 11.78 mmol), EDC (5.2 mL, 29.5 mmol) and 
DMAP (145 mg, 1.2 mmol) in anhydrous methanol (50 mL) was stirred at room 
temperature for 24 h. The reaction mixture was concentrated to dryness and the 
residue was dissolved in CH Cl2 2 (200 mL) and water (100 mL). The aqueous phase 
was extracted with CH2Cl2 (3 x 200 mL) and the combined organic phase was dried 
over MgSO4, filtered and evaporated. The residue was dissolved in 2 M methylamine 
in THF (20 mL) and was heated for 24 h at 55 °C in a sealed tube. After cooling, the 
reaction mixture was concentrated to dryness and purified by silica gel 
chromatography (pentane/EtOAc, 9/1) to give 8 (1.2 g, 33 % from 7) as a transparent 
oil.
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Molecular formula: C9H N14 4O4
Molecular weight: 242.24 
1H-NMR (300 MHz, DMSO-d6): 
δ 1.29 and 1.46 (2s, 6H, 2 x CH ) 2.62 (d, 3H, J = 4.7 Hz, CH3 3-N), 3.75 (dd, 1H, J = 
4.5 Hz and 9.5 Hz, H-3), 4.27 (d, 1H, J = 9.7 Hz, H-4), 4.77 (app t, 1H, J = 4.0 Hz, H-
2), 5.85 (d, 1H, J = 3.5 Hz, H-1), 8.12 (d, 1H, J = 4.4 Hz, NH). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C9H N O14 4 4Na [M+Na] : 265.0912, found 265.0917. 
 
Methyl 3-azido-3-deoxy-1,2-di-O-acetyl-D-ribofuronamide (9) 
A mixture of 8 (1.2 g, 5 mmol), concentrated sulphuric acid (1.47 mL, 27.5 mmol) and 
acetic anhydride (4.95 mL, 52.4 mmol) in glacial acid (25 mL) was stirred for 18 h at 
room temperature. After cooling in an ice bath, a saturated NaHCO3 solution (50 mL) 
and CH2Cl2 (50 mL) were slowly added and the mixture was stirred for another 10 
min. After separation the aqueous phase was extracted with CH2Cl2 (3 x 100 mL). 
The combined organic phase was washed with saturated NaHCO3 solution and brine, 
dried over MgSO4, filtered and evaporated to dryness to yield 787 mg (55 %) of crude 
9 as a yellowish foam. 
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Molecular formula: C H N O10 14 4 6
Molecular weight: 286.25 
1H-NMR (300 MHz, CDCl ) of most polar anomer: 3
δ 2.01 and 2.10 (2s, 6H, 2 x CH ), 2.79 (d, 3H, J = 5.0 Hz, CH3 3-N), 4.33-4.43 (m, 2H, 
H-3 and H-4), 5.24 (dd, 1H, J = 0.8 Hz and 5.0 Hz, H-2), 6.07 (br s, 1H, H-1), 6.53 (d, 
1H, J = 4.7 Hz, NH). 
Exact mass (ESI-MS, iPrOH:H O): 2
calculated for C10H15N4O  [M+H]+: 287.0991, found 287.0987. 6
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 9-[2-O-Acetyl-3-azido-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-6-
chloropurine (10) 
9 (0.87 g, 3.0 mmol) in dry 1,2-dichloroethane (35 mL) was added to silylated 6-
chloropurine (0.61 g, 4.0 mmol) under N2-atmosphere. Under continuous stirring 
TMSOTf (0.3 mL, 1.5 mmol) was added dropwise to the resulting suspension to give 
a clear solution after ± 30 min. The temperature was raised to 83 °C. After 2 h the 
mixture was cooled and CH Cl  (40 mL) and cold 7 % NaHCO2 2 3 solution (80 mL) were 
added. The organic layer was separated, dried with MgSO4, filtered and the filtrate 
evaporated to dryness. The residue was purified by column chromatography 
(CH Cl2 2/MeOH, 9/1) and precipitated from hexane to yield 10 (2.2 g, 95 %) as a 
yellow-white solid. 
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Molecular formula: C H ClN O13 13 8 4
Molecular weight: 380.75 
1H-NMR (300 MHz, CDCl ): 3
δ 2.12 (s, 3H, CH ), 2.92 (d, 3H, J = 5.0 Hz, CH3 3-N), 4.57 (d, 1H, J = 2.9 Hz, H-4’), 
4.86 (dd, 1H, J = 2.9 Hz and 5.6 Hz, H-3’), 5.87 (dd, 1H, J = 5.6 Hz and 7.0 Hz, H-2’), 
6.14 (d, 1H, J = 7.0 Hz, H-1’), 7.66 (d, 1H, J = 4.1 Hz, NH), 8.23 and 8.77 (2 x s, 2H, 
H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H O): 2
+H ClN O  [M+H] : 381.0826, found 381.0825. calculated for C13 14 8 4
 
9-[2-O-Acetyl-3-azido-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-2,6-
dichloropurine (11) 
9 (200 mg, 0.69 mmol) was coupled with silylated 2,6-dichloropurine in analogy to the 
procedure described for 10, to yield the the title compound 11 (200 mg, 70 %). 
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Molecular formula: C H Cl N O13 12 2 8 4
Molecular weight: 415.20 
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 1H-NMR (300 MHz, CDCl ): 3
δ 2.10 (s, 3H, CH ), 2.63 (d, 3H, J = 4.7 Hz, CH3 3-N), 4.52 (d, 1H, J = 5.6 Hz, H-4’), 
4.93 (t, 1H, J = 5.6 Hz, H-3’), 5.96 (t, 1H, J = 4.7 Hz, H-2’), 6.37 (d, 1H, J = 3.8 Hz, H-
1’), 8.16 (d, 1H, J = 4.4 Hz, NH),8.99 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H O): 2
+calculated for C H Cl N O Na [M+Na] : 437.0256, found 437.0252. 13 12 2 8 4
 
(3S,4S,5R)-4-azido-5,6-diacetyl-1-methyl-2-oxopiperidin-3-yl acetate (12) 
8 (0.75 g, 3.0 mmol) was dissolved in 75 % HOAc (30 mL). The solution was kept at 
60 °C and after 48 h the reaction mixture was evaporated to dryness. The residue 
was dissolved in a mixture of acetic anhydride/pyridine (50 mL, 2:3, v/v). After 3 h, 
the mixture was partitioned between CH Cl  (100 mL) and 7 % NaHCO2 2 3 (150 mL). 
The aqueous layer was washed with CH Cl2 2 (150 mL) and the combined organic 
layers were dried with MgSO4, filtered and evaporated in vacuo. Treatment with a 
hexane-EtOAc mixture allowed precipitation of 12 (0.6 g, 61 %) as a white solid. 
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Molecular formula: C H N O12 16 4 7
Molecular weight: 328.28 
1H-NMR (300 MHz, CDCl ): 3
δ 2.11, 2.16 and 2.34 (3s, 9H, CH ), 2.91 (s, 3H, CH3 3-N), 4.35 (t, 1H, J = 3.4 Hz, H-
4), 5.24 (dd, 1H, J = 3.8 Hz and 4.7 Hz, H-3), 5.57 (d, 1H, J = 2.9 Hz, H-5), 6.09 (d, 
1H, J = 5.0 Hz, H-2). 
 
(3S,4S,5R,6S)-5-acetyl-4-azido-6-(6-chloropurin-9-yl)-1-methyl-2-oxopiperidin-3-
yl acetate (13) 
Coupling reaction of 12 (0.58 g, 1.8 mmol) using the procedure described for 10 
yielded 13 (710 mg, 93 %). 
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Molecular formula: C H ClN15 15 8O5
Molecular weight: 422.79 
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 1H-NMR (300 MHz, CDCl3): 
δ 1.99 and 2.30 (2s, 6H, 2 x CH ), 2.66 (s, 3H, CH3 3-N), 4.51 (t, 1H, J = 2.8 Hz, H-3’), 
5.82 (d, 1H, J = 7.9 Hz, H-5’), 5.97 (dd, 1H, J = 2.6 Hz and 7.9 Hz, H-4’), 6.01 (d, 1H, 
J = 2.9 Hz, H-2’), 8.24 and 8.79 (2 x s, 2H, H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN15 16 8O5 [M+H] : 423.0932, found 423.0934. 
 
 
2.7.3 Preparation of the 3’-azidomethyl modified nucleoside scaffold 
 
1,2-O-Isopropylidene-5-O-(tert-butyldimethylsilyl)-α-D-xylofuranose (14) 
1,2-O-Isopropylidene-α-D-xylofuranose 1 (35.4 g, 186mmol) and DMAP (5.6 g, 46 
mmol) were dissolved in pyridine (300 mL), cooled in an ice bath and TBSCl (28 g, 
186 mmol) was added. The reaction mixture was stirred at 0 °C for 30 min and then 
allowed to warm to rt. After 2 h H2O (40 mL) was added and the reaction mixture was 
evaporated in vacuo. The residue was extracted with EtOAc, washed with H2O, dried 
over MgSO4, filtered, evaporated to dryness and chromatographed on silica gel 
(pentane/EtOAc, 6/4) to give 14 (41.4g, 73 %) as a colourless oil. 
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Molecular formula: C H SiO14 28 5
Molecular weight: 304.46 
1H-NMR (300 MHz, DMSO-d6): 
δ 0.00 (s, 6H, (CH3)2Si), 0.82 (s, 9H, tert-Bu), 1.18 and 1.32 (2 x s, 6H, 2 x CH3), 3.61 
(dd, 1H, J = 6.3 Hz and -10.7 Hz, H-5B), 3.77 (dd, 1H, J = 5.2 Hz, H-5A), 3.93 (m, 
2H, H-3 and H-4), 4.32 (d, 1H, J = 3.7 Hz, H-2), 5.16 (d, 1H, J = 4.8 Hz, 3-OH), 5.76 
(d, 1H, J = 3.7 Hz, H-1). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C14H29SiO5 [M+H]+: 305.1784, found 305.1785. 
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 3-Deoxy-1,2-O-isopropylidene-3-methylene-5-O-(tert-butyldimethylsilyl)-α-D-
ribofuranose (15) 
Oxalyl chloride (6.5 mL, 74.8 mmol) was dissolved in dry CH2Cl2 (200 mL) and 
cooled to -55 °C. DMSO (10.6 mL, 150 mmol) was added (temperature kept below -
55 °C) and the mixture was stirred for 5 min. A solution of 14 (20.72 g, 68 mmol) in 
dry CH2Cl2 (100 mL) was added dropwise over 5 min and stirring continued at -55 °C 
for 30 min. Subsequently, TEA (31.3 mL, 225 mmol) in dry CH2Cl2 (60 mL) was 
added and the reaction mixture was kept at -55 °C for 40 min. After warming to rt 
over a 2.5 h period the reaction mixture was quenched with H2O and extracted with 
CH2Cl2. The organic phase was washed with brine, dried over MgSO4, filtered and 
evaporated. The resulting brown oily residue was used for the next reaction without 
further purification. 
 
A suspension of NaH (5.7 g, 238 mmol) in DMSO (310 mL) was heated at 65 °C 
under N2-atmosphere until all the NaH had dissolved. The solution was cooled to 
room temperature and methyltriphenylphosphonium bromide (95 g, 265 mmol) was 
added under vigorous stirring. After 1.5 h, a mixture of the crude keton (previous 
reaction) in DMSO (100 mL) was added and the reaction mixture was stirred for 2.5 
h. The reaction was quenched by pouring it in ice-water (1.5 L) and extracted with 
pentane (4 x 500 mL). The combined organic phase was dried over MgSO4, filtered, 
evaporated and chromatographed on silica gel (pentane/EtOAc, 97/3) to afford 15 
(11.3 g, 56 %) as a foam. 
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Molecular formula: C H SiO15 28 4
Molecular weight: 300.47 
1H-NMR (300 MHz, CDCl3): 
δ 0.00 (s, 6H, (CH3)2Si), 0.83 (s, 9H, tert-Bu), 1.34 and 1.45 (2 x s, 6H, 2 x CH3), 3.63 
(dd, 1H, J = 3.8 Hz and -10.7 Hz, H-5B), 3.71 (dd, 1H, J = 4.1 Hz, H-5A), 4.71 (m, 
1H, H-4), 4.84 (dq, 1H, J = 1.5 Hz, 2.6 Hz and 4.1 Hz, H-2), 5.22 (t, 1H, J = 1.8 Hz, 3-
CHb), 5.38 (dd, 1H, J = 1.2 Hz and 2.4 Hz, 3-CHa), 5.81 (d, 1H, J = 4.1 Hz, H-1). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C15H29SiO4 [M+H]+: 301.1834, found 301.1829. 
 29
 3-Deoxy-3-C-hydroxymethyl-1,2-O-isopropylidene-5-O-(tert-butyldimethylsilyl)-
α-D-ribofuranose (16) 
To a stirring solution of 1 M borane/THF complex (68 mL) in anhydrous THF at 0 °C 
under N2-atmosphere and was added dropwise15 (8.7g, 29 mmol) in THF (60 mL). 
The mixture was kept at rt for 3 h and after cooling a THF/H2O (1/1) solution (45 mL), 
2 N NaOH (54 mL) and 30 % H2O2 (45 mL) were subsequently added. The turbid 
mixture was stirred at rt for 2 h when Et2O (300 mL) was added. The Et2O phase was 
separated, washed with H2O (100 mL) and brine (100 mL), dried over MgSO4, 
filtered, concentrated in vacuo and purified by silica gel chromatography 
(pentane/EtOAc, 9/1 → 6/4) to give 16 (6 g, 65 %) as a semi-solid. 
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Molecular formula: C H SiO15 30 5
Molecular weight: 318.49 
1H-NMR (300 MHz, CDCl3): 
δ 0.00 (s, 6H, (CH3)2Si), 0.81 (s, 9H, tert-Bu), 1.23 and 1.43 (2 x s, 6H, 2 x CH3), 
2.02-2.11 (m, 1H, H-3), 3.57 (dd, 1H, J = 6.6 Hz and -10.6 Hz, 3-CHb), 3.76-3.82 (m, 
3H, 3-CHa, H-5B and H-5A), 3.96-4.02 (m, 1H, H-4), 4.66 (t, 1H, J = 4.3 Hz, H-2), 
5.70 (d, 1H, J = 4.0 Hz, H-1). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C15H31SiO5 [M+H]+: 319.1940, found 319.1935. 
 
3-C-Azidomethyl-3-deoxy-1,2-O-isopropylidene-5-O-(tert-butyldimethylsilyl)-α-
D-ribofuranose (17) 
Methanesulfonyl chloride (2 ml, 25 mmol) was added to a solution of 16 (3g, 9.5 
mmol) in pyridine (40 mL). The reaction mixture was stirred for 3h and the solvent 
was evaporated to dryness. The residue was dissolved in CH Cl2 2 (150 mL), washed 
with 7 % NaHCO3 solution (75 mL), H2O (75 mL), dried over MgSO4, filtered and 
evaporated to dryness to give a yellow syrup that was used without further 
purification. This syrup was dissolved in DMF (150 mL) and NaN3 (6.2 g, 95 mmol) 
was added. The reaction mixture was heated at 95 °C for 2 h. After concentration in 
vacuo, the residue was dissolved in CH2Cl2 (200 mL). The organic phase was 
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 washed with H2O, dried over MgSO4, filtered, evaporated and chromatographed on 
silica gel (pentane/EtOAc, 97/3) to give 17 (2.5 g, 77 %) as a yellowish syrup. 
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Molecular formula: C H SiN15 29 3O4
Molecular weight: 343.50 
1H-NMR (300 MHz, CDCl3): 
δ 0.00 (s, 6H, (CH3)2Si), 0.81 (s, 9H, tert-Bu), 1.28 and 1.45 (2 x s, 6H, 2 x CH3), 
2.20-2.30 (m, 1H, H-3), 3.37 (dd, 1H, J = 5.6 Hz and -12.2 Hz, 3-CHb), 3.54 (dd, 1H, 
J = 9.7 Hz, 3-CHa), 3.67 (dd, 1H, J = 3.8 Hz and -11.4 Hz, H-5B), 3.73 (dd, 1H, J = 
4.1 Hz, H-5A), 3.81 (dt, 1H, J = 3.9 Hz and 9.9 Hz, H-4), 4.66 (t, 1H, J = 4.3 Hz, H-2), 
5.75 (d, 1H, J = 3.52 Hz, H-1). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H SiN15 30 3O4 [M+H] : 344.2005, found 344.2011. 
 
3-C-Azidomethyl-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (18) 
To a solution of 17 (2.5 g, 7.28 mmol) in THF (80 mL), a 1M TBAF solution in THF 
(10 mL) was added. After 3h the reaction mixture was evaporated to dryness and the 
residue dissolved in EtOAc (200 mL). The organic layer was washed with water, 
dried over MgSO4, filtered, evaporated and purified by silica gel chromatography 
(pentane/EtOAc, 85/15) to give crude 18 (1.6 g, 96 %) as a colourless oil. 
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Molecular formula: C9H N15 3O4
Molecular weight: 229.24 
1H-NMR (300 MHz, DMSO-d6): 
δ 1.25 and 1.40 (2 x s, 6H, 2 x CH3), 2.11-2.21 (m, 1H, H-3), 3.38-3.60 (m, 4H, H-5B, 
H-5A, 3-CHb and 3-CHa), 3.73 (ddd, 1H, J = 3.4 Hz, 4.3 Hz and 10.2 Hz, H-4), 4.68 (t, 
1H, J = 4.4 Hz, H-2), 4.72 (t, 1H, J = 5.7 Hz, 5-OH), 5.75 (d, 1H, J = 3.8 Hz, H-1). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C9H16N3O4 [M+H]+: 230.1140, found 230.1133. 
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 3-C-Azidomethyl-3-deoxy-1,2-O-isopropylidene-5-O-toluoyl-α-D-ribofuranose 
(19) 
A solution of 18 (1.55 g, 6.7 mmol) in dry pyridine (90 mL) was treated with toluoyl 
chloride (1.3 mL, 10 mmol). After 2h sovents were evaporated in vacuo and the 
residue was partitioned between CH2Cl2 (200 mL) and H2O (80 mL). The organic 
layer was washed with 7 % NaHCO3, dried over MgSO4 and evaporated. Purification 
of the residue by column chromatography (pentane/EtOAc, 95/5) afforded 19 (2.2 g, 
94 %) as a white solid. 
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Molecular formula: C H N17 21 3O5
Molecular weight: 347.37 
1H-NMR (300 MHz, CDCl3): 
δ 1.35 and 1.53 (2s, 6H, 2 x CH ), 2.22 (m, 1H, H-3), 2.41 (s, 3H, Ar-CH3 3), 3.48 (dd, 
1H, J = 6.0 Hz and -12.2 Hz, 3-CH ), 3.70 (dd, 1H, J = 9.1 Hz, 3-CHb a), 4.17 (m, 1H, 
H-4), 4.38 (dd, 1H, J = 5.0 Hz and -12.3 Hz, H-5B), 4.58 (dd, 1H, J = 2.9 Hz, H-5A), 
4.75 (t, 1H, J = 4.3 Hz, H-2), 5.88 (d, 1H, J = 3.8 Hz, H-1), 7.24 and 7.97 (2d, 4H, J = 
8.0 Hz, Ar-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+H Ncalculated for C17 21 3O5Na [M+Na] : 370.1379, found 370.1384. 
 
3-C-Azidomethyl-3-deoxy-1,2-di-O-acetyl-5-O-toluoyl-D-ribofuranose (20) 
19 (2 g, 5.76 mmol) was dissolved in 75 % HOAc (40 mL) and heated overnight at 60 
°C. The reaction mixture was evaporated to dryness and the residue was dissolved in 
a mixture of acetic anhydride/pyridine (60 mL, 2:3, v/v). After 3 h the mixture was 
partitioned between CH2Cl2 (150 mL) and 7 % NaHCO3 (200 mL). The aqueous layer 
was washed with CH Cl2 2 (200 mL) and the combined organic layers were dried with 
MgSO4, filtered and evaporated in vacuo. Treatment with a hexane/EtOAc mixture 
allowed precipitation of 20 (1.42 g, 63 %) as a white solid. 
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Molecular formula: C H N18 21 3O7
Molecular weight: 391.38 
1H-NMR (300 MHz, CDCl3) of most polar anomer: 
δ 1.96 and 2.14 (2s, 6H, 2 x CH ), 2.41 (s, 3H, Ar-CH3 3), 2.71-2.80 (m, 1H, H-3), 3.50 
(dd, 1H, J = 6.6 Hz and -12.4 Hz, 3-CHb), 3.63 (dd, 1H, J = 8.5 Hz, 3-CHa), 4.33-4.60 
(2m, 3H, H-4 and 2 x H-5), 5.29 (d, 1H, J = 4.7 Hz, H-2), 6.14 (s, 1H, H-1), 7.24 and 
7.95 (2d, 4H, J = 8,1 Hz, Ar-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H N18 21 3O7Na [M+Na] : 414.1277, found 414.1268. 
 
9-(2-O-Acetyl-3-C-azidomethyl-3-deoxy-5-O-toluoyl-β-D-ribofuranosyl)-6-
chloropurine (21) 
20 (500 mg, 1.27 mmol) was coupled with silylated 6-chloropurine and purified in 
analogy to the procedure described for 10, to yield the the title compound 21 (503 
mg, 81 %). 
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Molecular formula: C H ClN21 20 7O5
Molecular weight: 485.89 
1H-NMR (300 MHz, CDCl3): 
δ 2.18 (s, 3H, CH3), 2.39 (s, 3H, Ar-CH3), 3.39-3.49 (m, 1H, H-3’), 3.62 (dd, 1H, J = 
6.0 Hz and -12.5 Hz, 3-CHb), 3.70 (dd, 1H, J = 7.9 Hz, 3-CHa), 4.43-4.48 (m, 1H, H-
4’), 4.53 (dd, 1H, J = 4.1 Hz and -12.3 Hz, H-5B’), 4.70 (dd, 1H, J = 2.6 Hz, H-5A’), 
5.97 (dd, 1H, J = 1.5 Hz and 5.8 Hz, H-2’), 6.01 (d, 1H, J = 1.5 Hz, H-1’), 7.16 and 
7.71 (2d, 4H, J = 8.1 Hz, Ar-H), 8.20 and 8.57 (2 x s, 2H, H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN21 21 7O5 [M+H] : 486.1292, found 486.1295. 
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 2.7.4 Preparation of the 3’-azidomethyl-5’-methylcarbamoyl nucleoside scaffold 
 
Methyl 3-azidomethyl-3-deoxy-1,2-isopropylidene-α-D-ribofuronamide (22) 
22 (1.3 g, 32 %) was prepared from 18 (3.6 g, 15.7 mmol) in analogy to the 
procedure described for 8. 
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Molecular formula: C H N10 16 4O4
Molecular weight: 256.26 
1H-NMR (300 MHz, CDCl3): 
1H NMR (CDCl3) δ 1.34 and 1.49 (2s, 6H, 2 x CH3), 2.15-2.25 (m, 1H, H-3), 2.80 (d, 
3H, J = 5.0 Hz, CH3-N), 3.64 (dd, 1H, J = 11.1 Hz and -12.1 Hz, 3-CHb), 3.87 (dd, 1H, 
J = 4.3 Hz, 3-CHa), 4.15 (d, 1H, J = 10.6 Hz, H-4), 4.73 (t, 1H, J = 3.8 Hz, H-2), 5.85 
(d, 1H, J = 5.5 Hz, H-1), 6.50 (br s, 1H, NH). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C10H17N4O4 [M+H]+: 257.1249, found 257.1253. 
 
Methyl 3-azidomethyl-3-deoxy-1,2-di-O-acetyl-D-ribofuronamide (23) 
23 (0.6 g, 40 %) was prepared from 22 (1.3 g, 5 mmol) in analogy to the procedure 
described for 9. 
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Molecular formula: C H N11 16 4O6
Molecular weight: 300.27 
1H-NMR (300 MHz, CDCl3) of most polar anomer: 
δ 2.06 and 2.13 (2 x s, 6H, 2 x CH3), 2.74-2.77 (m, 1H, H-3), 2.81 (d, 3H, J = 5.0 Hz, 
CH3-N), 3.55 (dd, 1H, J = 10.5 Hz and -12.3 Hz, 3-CHb), 3.91 (dd, 1H, J = 4.4 Hz, 3-
CHa), 4.28 (d, 1H, J = 9.7 Hz, H-4), 5.23 (d, 1H, J = 4.7 Hz, H-2), 6.12 (s, 1H, H-1), 
6.41 (d, 1H, J = 4.1 Hz, NH). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C11H17N4O6 [M+H]+: 301.1147, found 301.1141. 
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 9-[2-O-Acetyl-3-C-azidomethyl-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-
6-chloropurine (24) 
23 (0.6 g, 2 mmol) was used to prepare 24 (750 mg, 95 %) in analogy to the 
procedure described for 10. 
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Molecular formula: C H ClN14 15 8O4
Molecular weight: 394.78 
1H-NMR (300 MHz, CDCl3): 
δ 2.20 (s, 3H, CH3), 2.83 (d, 3H, J = 5.0 Hz, CH3-N), 3.38-3.48 (m, 1H, H-3’), 3.73 
(dd, 1H, J = 9.1 Hz and -12.6 Hz, 3’-CHb), 3.87 (dd, 1H, J = 4.4 Hz, 3’-CHa), 4.48 (d, 
1H, J = 9.4 Hz, H-4’), 5.62 (dd, 1H, J = 2.5 Hz and 6.6 Hz, H-2’), 6.09 (d, 1H, J = 2.3 
Hz, H-1’), 6.98 (d, 1H, J = 4.4 Hz, NH), 8.22 and 8.75 (2 x s, 2H, H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN14 16 8O4 [M+H] : 395.0982, found 395.0982. 
 
 
2.7.5 Preparation of the N6-substituted adenosine analogues 
 
General procedure for the “one pot” N6-substitution/deprotection 
An amount of the appropriate chloropurine and the appropriate amine salt (or 
ammonia in the case of 25) (1.5 eq.), were dissolved in EtOH (15 mL/mmol 
chloropurine) containing Et3N (1.25 eq.). The reaction mixture was refluxed overnight 
and evaporated to dryness. The residue was dissolved in 7 N NH3 in MeOH (ca. 30 
mL), stirred for 24 h at room temperature and evaporated in vacuo. The target 
compounds were purified by precipitation from MeOH and subsequent filtration in the 
case of 25-28, by chromatography on a silica gel column (elution with a suitable 
mixture of CH2Cl2-MeOH) to furnish 35-37, 41 and 42 as pure white solids. 
 
9-(3-C-Azidomethyl-3-deoxy-β-D-ribofuranosyl)-adenine (25) 
300 mg (0.62 mmol) of 21 yielded 80 mg (42 %) of 25. 
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Molecular formula: C H N11 14 8O3
Molecular weight: 306.29 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.58-2.67 (m, 1H, H-3’), 3.44 (dd, 1H, J = 5.7 Hz and -12.4 Hz, 3’-CHb), 3.53 (ddd, 
1H, J = 3.8 Hz and 5.9 Hz and -12.2 Hz, H-5B’), 3.65 (dd, 1H, J = 8.2 Hz, 3’-CHa), 
3.73 (ddd, 1H, J = 3.0 Hz and 5.1 Hz, H-5A’), 3.99 (dt, 1H, J = 3.2 Hz and 8.6 Hz, H-
4’), 4.54-4.58 (m, 1H, H-2’), 5.22 (t, 1H, J = 5.5 Hz, 5’-OH), 5.91 (d, 1H, J = 2.1 Hz, 
H-1’), 6.04 (d, 1H, J = 4.6 Hz, 2’-OH), 7.29 (s, 2H, 6-NH2), 8.13 and 8.39 (2 x s, 2H, 
H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C11H15N8O3 [M+H]+: 307.1267, found 307.1270. 
Elemental analysis (C H N11 14 8O3.1/4 H2O) C,H,N. 
 
9-(3-C-Azidomethyl-3-deoxy-β-D-ribofuranosyl)-N6-methyladenine (26) 
400 mg (0.82 mmol) of 21 yielded 180 mg (68 %) of 26. 
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Molecular formula: C H N12 16 8O3
Molecular weight: 320.31 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.58-2.68 (m, 1H, H-3’), 2.93 (br s, 3H, N(6)-CH3), 3.44 (dd, 1H, J = 5.6 Hz and -
12.31 Hz, 3’-CHb), 3.53 (ddd, 1H, J = 3.7 Hz, 5.7 Hz and -12.2 Hz, H-5B’), 3.64 (dd, 
1H, J = 7.9 Hz, 3’-CHa), 3.73 (ddd, 1H, J = 2.9 Hz and 5.3 Hz, H-5A’), 3.99 (dt, 1H, J 
= 3.2 Hz and 8.8 Hz, H-4’), 4.55 (dt, 1H, J = 2.1 Hz and 5.2 Hz, H-2’), 5.23 (t, 1H, J = 
5.4 Hz, 5’-OH), 5.92 (d, 1H, J = 2.3 Hz, H-1’), 6.05 (d, 1H, J = 5.0 Hz, 2’-OH), 7.78 (s, 
1H, N(6)-H), 8.22 and 8.39 (2 x s, 2H, H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C12H17N8O3 [M+H]+: 321.1423, found 321.1429. 
Elemental analysis (C H N12 16 8O3.2/3 H2O) C,H,N. 
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 9-(3-C-Azidomethyl-3-deoxy-β-D-ribofuranosyl)-N6-(3-iodobenzyl)adenine (27) 
340 mg (0.69 mmol) of 21 yielded 227 mg (62 %) of 27. 
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Molecular formula: C H IN18 19 8O3
Molecular weight: 522.31 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.59-2.68 (m, 1H, H-3’), 3.44 (dd, 1H, J = 5.6 Hz and -12.3 Hz, 3’-CHb), 3.54 (ddd, 
1H, J = 3.7 Hz, 5.6 Hz and -12.3 Hz, H-5B’), 3.64 (dd, 1H, J = 8.2 Hz, 3’-CHa), 3.73 
(ddd, 1H, J = 2.9 Hz and 5.3 Hz, H-5A’), 4.00 (dt, 1H, J = 3.2 Hz and 8.6 Hz, H-4’), 
4.55-4.59 (m, 1H, H-2’), 4.64 (br s, 2H, CH2-Ar), 5.20 (t, 1H, J = 5.6 Hz, 5’-OH), 5.93 
(d, 1H, J = 2.1 Hz, H-1’), 6.05 (d, 1H, J = 5.0 Hz, 2’-OH), 7.05 (t, 1H, J = 7.8 Hz, H-
5’’), 7.34 (d, 1H, J = 7.9 Hz, H-6’’), 7.56 (d, 1H, J = 8.2 Hz, H-4’’), 7.70 (s, 1H, H-2”), 
8.20 and 8.44 (2 x s, 2H, H-2 and H-8), 8.46 (br s, 1H, N(6)-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C18H20IN8O3 [M+H]+: 523.0704, found 523.0698. 
Elemental analysis (C H IN18 19 8O3) C,H,N. 
 
9-(3-C-Azidomethyl-3-deoxy-β-D-ribofuranosyl)-N6-(5-chloro-2-methoxybenzyl)-
adenine (28) 
300 mg (0.62 mmol) of 21 yielded 100 mg (35 %) of 28. 
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Molecular formula: C H ClN19 21 8O4
Molecular weight: 460.88 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.61-2.70 (m, 1H, H-3’), 3.45 (dd, 1H, J = 5.7 Hz and -12.3 Hz, 3’-CHb), 3.55 (ddd, 
1H, J = 3.7 Hz, 5.4 Hz and -12.2 Hz, H-5B’), 3.65 (dd, 1H, J = 8.1 Hz, 3’-CHa), 3.75 
(ddd, 1H, J = 2.9 Hz and 5.0 Hz, H-5A’), 3.83 (s, 3H, Ar-OCH3), 4.01 (dt, 1H, J = 3.2 
Hz and 8.7 Hz, H-4’), 4.63 (m, 3H, H-2’ and CH2-Ar), 5.16 (t, 1H, J = 5.4 Hz, 5’-OH), 
5.95 (d, 1H, J = 2.1 Hz, H-1’), 6.01 (d, 1H, J = 5.0 Hz, 2’-OH), 7.01 (d, 1H, J = 8.8 Hz, 
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 H-3’’), 7.08 (br s, 1H, H-6’’), 7.24 (dd, 1H, J = 2.6 and 8.8 Hz, H-4’’), 8.19 (br s, 2H, 
H-2 and N(6)-H), 8.44 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN19 22 8O4 [M+H] : 461.1452, found 461.1460. 
Elemental analysis (C H ClN O19 21 8 4) C,H,N. 
 
9-[3-Azido-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (35) 
300 mg (0.79 mmol) of 10 yielded 250 mg (60 %) of 35. 
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Molecular formula: C H IN18 18 9O3
Molecular weight: 535.31 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.68 (d, 3H, J = 4.4 Hz, CH3-N), 4.33 (d, 1H, J = 3.2 Hz, H-4’), 4.48 (dd, 1H, J = 3.2 
Hz and 5.3 Hz, H-3’), 4.66 (br s, 2H, CH2-Ar), 4.96 (q, 1H, J = 5.4 Hz and 10.9 Hz, H-
2’), 5.99 (d, 1H, J = 6.5 Hz, H-1’), 6.28 (d, 1H, J = 5.3 Hz, 2’-OH), 7.09 (t, 1H, J = 7.8 
Hz, H-5’’), 7.35 (d, 1H, J = 7.9 Hz, H-6’’), 7.57 (d, 1H, J = 8.2 Hz, H-4’’), 7.71 (s, 1H, 
H-2’’), 8.27 and 8.45 (2 x s, 2H, H-2 and H-8), 8.53 (br s, 1H, N(6)-H), 8.62 (d, 1H, J 
= 4.7 Hz, NH). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C18H19IN9O3 [M+H]+: 536.0657, found 536.0658. 
Elemental analysis (C H IN18 18 9O3.3/2 H2O) C,H,N. 
 
9-[3-C-Azidomethyl-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(3-iodo-
benzyl)adenine (36) 
300 mg (0.75 mmol) of 24 yielded 360 mg (73 %) of 36. 
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Molecular formula: C H IN19 20 9O3
Molecular weight: 549.33 
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 1H-NMR (300 MHz, DMSO-d6): 
δ 2.63 (d, 3H, J = 4.4 Hz, CH3-N), 2.75-2.84 (m, 1H, H-3’), 3.50 (dd, 1H, J = 5.9 Hz 
and -12.3 Hz, 3’-CHb), 3.71 (dd, 1H, J = 7.9 Hz, 3’-CHa), 4.33 (d, 1H, J = 8.5 Hz, H-
4’), 4.63 (m, 3H, H-2’ and CH2-Ar), 6.03 (d, 1H, J = 2.1 Hz, H-1’), 6.15 (d, 1H, J = 4.7 
Hz, 2’-OH), 7.09 (t, 1H, J = 7.8 Hz, H-5’’), 7.35 (d, 1H, J = 7.6 Hz, H-6’’), 7.57 (d, 1H, 
J = 7.9 Hz, H-4’’), 7.71 (s, 1H, H-2’’), 8.24 (m, 2H, H-2 and NH), 8.43 (br s, 1H, N(6)-
H), 8.55 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C19H21IN9O3 [M+H]+: 550.0813, found 550.0803. 
Elemental analysis (C H IN19 20 9O3.3/2 H2O) C,H,N. 
 
2-Chloro-9-[3-azido-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (37) 
200 mg (0.48 mmol) of 11 yielded 210 mg (77 %) of 37. 
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Molecular formula: C H ClIN O18 17 9 3
Molecular weight: 569.75 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.69 (d, 3H, J = 4.1 Hz, CH3-N), 4.35 (d, 1H, J = 2.9 Hz, H-4’), 4.47 (t, 1H, J = 4.1 
Hz, H-3’), 4.60 (brs, 2H, CH2-Ar), 4.92 (app d, 1H, J = 4.9 Hz, H-2’), 5.92 (d, 1H, J = 
6.2 Hz, H-1’), 6.31 (d, 1H, J = 4.7 Hz, 2’-OH), 7.12 (t, 1H, J = 7.8 Hz, H-5’’), 7.35 (d, 
1H, J = 7.3 Hz, H-6’’), 7.59 (d, 1H, J = 7.9 Hz, H-4’’), 7.74 (s, 1H, H-2’’), 8.25 (d, 1H, J 
= 4.1 Hz, NH), 8.49 (s, 1H, H-8), 8.99 (brs, 1H, N(6)-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClIN18 17 9O3Na [M+Na] : 592.0087, found 592.0092. 
Elemental analysis (C H ClIN18 17 9O3.1/2 H O) C,H,N. 2
 
9-[3-Azido-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(5-chloro-2-
methoxybenzyl)adenine (41) 
300 mg (0.79 mmol) of 10 yielded 251 mg (67 %) of 41. 
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Molecular formula: C H ClN19 20 9O4
Molecular weight: 473.88 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.68 (d, 3H, J = 4.7 Hz, CH3-N), 3.83 (s, 3H, Ar-OCH3), 4.34 (d, 1H, J = 3.2 Hz, H-
4’), 4.49 (dd, 1H, J = 3.2 Hz and 5.3 Hz, H-3’), 4.65 (br s, 2H, CH2-Ar), 4.97 (q, 1H, J 
= 5.6 Hz and 11.1 Hz, H-2’), 6.00 (d, 1H, J = 6.5 Hz, H-1’), 6.29 (d, 1H, J = 5.3 Hz, 2’-
OH), 7.00 (d, 1H, J = 9.08 Hz, H-3’’), 7.08 (br s, 1H, H-6’’), 7.24 (dd, 1H, J = 2.8 Hz 
and 8.6 Hz, H-4’’), 8.25 (s, 1H, H-2), 8.35 (br s, 1H, N(6)-H), 8.47 (s, 1H, H-8), 8.62 
(d, 1H, J = 4.7 Hz, NH). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN19 21 9O4 [M+H] : 474.1404, found 474.1400. 
Elemental analysis (C H ClN O19 20 9 4.1/2 H2O) C,H,N. 
 
9-[3-Azidomethyl-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(5-chloro-
2-methoxybenzyl)adenine (42) 
300 mg (0.75 mmol) of 24 yielded 300 mg (82 %) of 42. 
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Molecular formula: C H ClN20 22 9O4
Molecular weight: 487.91 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.63 (d, 3H, J = 4.4 Hz, CH3-N), 2.76-2.85 (m, 1H, H-3’), 3.50 (dd, 1H, J = 5.9 Hz 
and -12.4 Hz, 3’-CHb), 3.71 (dd, 1H, J = 7.8 Hz, 3’-CH ), 3.83 (s, 3H, Ar-OCHa 3), 4.32 
(d, 1H, J = 8.8 Hz, H-4’), 4.60 (br s, 3H, CH2-Ar and H-2’), 6.04 (s, 1H, H-1’), 6.21 (d, 
1H, J = 4.7 Hz, 2’-OH), 7.00 (d, 1H, J = 8.8 Hz, H-3’’), 7.05 (br s, 1H, H-6’’), 7.24 (dd, 
1H, J = 2.6 Hz and 8.5 Hz, H-4’’), 8.21 (s, 1H, H-2), 8.30 (d, 1H, J = 4.7 Hz, NH), 8.36 
(br s, 1H, N(6)-H), 8.60 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN20 23 9O4 [M+H] : 488.15661, found 488.1559. 
Elemental analysis (C H ClN O20 22 9 4.1/2 H2O) C,H,N. 
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 General procedure for the synthesis of the amino modified adenosine 
analogues from their azido precursors 
The azido nucleoside was dissolved in dry pyridine (8 mL/mmol) and PhP3 (1.6 eq.) 
was added to the solution. After stirring at room temperature for 1.5 h, concentrated 
NH4OH (3 mL/mmol) was added. The reaction mixture was stirred for another 2 h, 
evaporated to dryness and purified by silica gel chromatography (CH2Cl2-MeOH). 
 
9-(3-C-Aminomethyl-3-deoxy-β-D-ribofuranosyl)-adenine (29) 
60 mg (0.20 mmol) of 25 furnished 35 mg (64 %) of 29 as a white solid. 
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Molecular formula: C H N11 16 6O3
Molecular weight: 280.29 
1H-NMR (300 MHz, DMSO-d6): 
δ  2.31-2.40 (m, 1H, H-3’), 2.65 (dd, 1H, J = 6.2 Hz and -12.6 Hz, 3’-CHb), 2.89 (dd, 
1H, J = 7.3 Hz, 3’-CHa), 3.56 (dd, 1H, J = 3.2 Hz and -11.9 Hz, H-5B’), 3.68 (dd, 1H, 
J = 4.0 Hz, H-5A’), 3.98 (dt, 1H, J = 3.7 Hz and 9.4 Hz, H-4’), 4.50 (dd, 1H, J = 1.5 Hz 
and 5.3 Hz, H-2’), 5.88 (d, 1H, J = 1.5 Hz, H-1’), 7.27 (s, 2H, 6-NH2), 8.12 and 8.36 (2 
x s, 2H, H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C11H17N6O3 [M+H]+: 281.1362, found 281.1370. 
Elemental analysis (C H N11 16 6O3) C,H,N. 
 
9-(3-C-Aminomethyl-3-deoxy-β-D-ribofuranosyl)-N6-methyladenine (30) 
100 mg (0.31 mmol) of 26 furnished 64 mg (70 %) of 30 as a white solid. 
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Molecular formula: C H N12 18 6O3
Molecular weight: 294.32 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.26-2.35 (m, 1H, H-3’), 2.62 (dd, 1H, J = 6.5 Hz and -12.6 Hz, 3’-CHb), 2.87 (dd, 
1H, J = 7.0 Hz, 3’-CHa), 2.93 (br s, 3H, N(6)-CH3), 3.56 (dd, 1H, J = 3.5 Hz and -11.9 
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 Hz, H-5B’), 3.67 (dd, 1H, J = 4.3 Hz, H-5A’), 3.99 (dt, 1H, J = 3.8 Hz and 9.1 Hz, H-
4’), 4.50 (dd, 1H, J = 1.6 Hz and 5.1 Hz, H-2’), 5.88 (d, 1H, J = 1.8 Hz, H-1’), 7.75 (s, 
1H, N(6)-H), 8.21 and 8.34 (2 x s, 2H, H-2 and H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C12H19N6O3 [M+H]+: 295.1518, found 295.1513. 
Elemental analysis (C H N12 18 6O3.3/2 H2O) C,H,N. 
 
9-(3-C-Aminomethyl-3-deoxy-β-D-ribofuranosyl)-N6-(3-iodobenzyl)adenine (31) 
200 mg (0.38 mmol) of 27 furnished 131 mg (69 %) of 31 as a white solid. 
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Molecular formula: C H IN18 21 6O3
Molecular weight: 496.31 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.26-2.35 (m, 1H, H-3’), 2.62 (dd, 1H, J = 6.3 Hz and -12.5 Hz, 3’-CHb), 2.86 (dd, 
1H, J = 6.7 Hz, 3’-CHa), 3.56 (dd, 1H, J = 3.4 Hz and -12.0 Hz, H-5B’), 3.68 (dd, 1H, 
J = 4.1 Hz, H-5A’), 3.99 (dt, 1H, J = 3.8 Hz and 9.1 Hz, H-4’), 4.51 (d, 1H, J = 4.98 
Hz, H-2’), 4.63 (br s, 2H, CH2-Ar), 5.89 (d, 1H, J = 1.5 Hz, H-1’), 7.09 (t, 1H, J = 7.6 
Hz, H-5’’), 7.33 (d, 1H, J = 7.9 Hz, H-6’’), 7.56 (d, 1H, J = 7.3 Hz, H-4’’), 7.70 (s, 1H, 
H-2’’), 8.19 and 8.40 (2 x s, 2H, H-2 and H-8), 8.44 (br s, 1H, N(6)-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C18H22IN6O3 [M+H]+: 497.0799, found 497.0793. 
Elemental analysis (C H IN18 21 6O3) C,H,N. 
 
9-(3-C-Aminomethyl-3-deoxy-β-D-ribofuranosyl)-N6-(5-chloro-2-methoxybenzyl)-
adenine (32) 
90 mg (0.17 mmol) of 28 furnished 54 mg (64 %) of 32 as a white solid. 
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Molecular formula: C H ClN19 23 6O4
Molecular weight: 434.89 
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 1H-NMR (300 MHz, DMSO-d6): 
δ 2.29-2.38 (m, 1H, H-3’), 2.65 (dd, 1H, J = 6.3 Hz and -12.5 Hz, 3’-CHb), 2.89 (dd, 
1H, J = 7.0 Hz, 3’-CHa), 3.57 (dd, 1H, J = 3.5 Hz and -11.9 Hz, H-5B’), 3.69 (dd, 1H, 
J = 4.1 Hz, H-5A’), 3.83 (s, 3H, Ar-OCH3), 4.01 (dt, 1H, J = 3.9 Hz and 9.0 Hz, H-4’), 
4.55 (dd, 1H, J = 1.2 Hz and 5.0 Hz, H-2’), 4.65 (br s, 2H, CH2-Ar), 5.91 (d, 1H, J = 
1.5 Hz, H-1’), 7.00 (d, 1H, J = 8.8 Hz, H-3’’), 7.07 (d, 1H, J = 2.3 Hz, H-6’’), 7.24 (dd, 
1H, J = 2.6 Hz and 8.8 Hz, H-4’’), 8.18 (br s, 2H, H-2 and N(6)-H), 8.40 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN19 24 6O4 [M+H] : 435.1547, found 435.1546. 
Elemental analysis (C H ClN O19 23 6 4.1/4 H2O) C,H,N. 
 
9-[3-Amino-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(3-iodobenzyl)-
adenine (38) 
176 mg (0.33 mmol) of 35 furnished 30 mg (18 %) of 38 as a white solid. 
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Molecular formula: C H IN18 20 7O3
Molecular weight: 509.31 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.67 (d, 3H, J = 4.4 Hz, CH3-N), 3.56 (t, 1H, J = 5.4 Hz, H-3’), 4.11 (d, 1H, J = 5.6 
Hz, H-4’), 4.36 (t, 1H, J = 4.6 Hz, H-2’), 4.65 (br s, 2H, CH2-Ar), 6.01 (d, 1H, J = 3.8 
Hz, H-1’), 7.09 (t, 1H, J = 7.8 Hz, H-5’’), 7.35 (d, 1H, J = 7.9 Hz, H-6’’), 7.56 (d, 1H, J 
= 7.6 Hz, H-4’’), 7.71 (s, 1H, H-2’’), 8.24 (s, 1H, H-2), 8.44 (m, 2H, NH and N(6)-H), 
8.55 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C18H21IN7O3 [M+H]+: 510.0752, found 510.0757. 
Elemental analysis (C H IN18 20 7O3.1/2 H2O) C,H,N. 
 
9-[3-C-Aminomethyl-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (39) 
100 mg (0.18 mmol) of 36 furnished 45 mg (48 %) of 39 as a white solid. 
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Molecular formula: C H IN19 22 7O3
Molecular weight: 523.34 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.41-2.47 (m, 1H, H-3’), 2.64 (d, 3H, J = 4.7 Hz, CH3-N), 2.76 (dd, 1H, J = 5.3 Hz 
and -12.3 Hz, 3’-CHb), 2.90 (dd, 1H, J = 7.6 Hz, 3’-CHa), 4.34 (d, 1H, J = 8.8 Hz, H-
4’), 4.55 (dd, 1H, J = 2.1 Hz and 5.3 Hz, H-2’), 4.66 (br s, 2H, CH2-Ar), 6.00 (d, 1H, J 
= 2.4 Hz, H-1’), 7.09 (t, 1H, J = 7.8 Hz, H-5’’), 7.35 (d, 1H, J = 7.9 Hz, H-6’’), 7.56 (d, 
1H, J = 7.6 Hz, H-4’’), 7.71 (s, 1H, H-2’’), 8.22 (s, 1H, H-2), 8.29 (d, 1H, J = 4.7 Hz, 
NH), 8.42 (br s, 1H, N(6)-H), 8.62 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C19H23IN7O3 [M+H]+: 524.0908, found 524.0912. 
Elemental analysis (C H IN19 22 7O3.3/4 H2O) C,H,N. 
 
2-Chloro-9-[3-amino-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (40) 
200 mg (0.35 mmol) of 37 furnished 140 mg (74 %) of 40 as a white solid. 
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Molecular formula: C H ClIN O18 19 7 3
Molecular weight: 543.75 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.67 (d, 3H, J = 4.7 Hz, CH3-N), 3.54 (t, 1H, J = 5.6 Hz, H-3’), 4.11 (d, 1H, J = 5.9 
Hz, H-4’), 4.31 (t, 1H, J = 4.1 Hz, H-2’), 4.59 (brs, 2H, CH2-Ar), 5.95 (d, 1H, J = 3.5 
Hz, H-1’), 7.11 (t, 1H, J = 7.8 Hz, H-5’’), 7.35 (d, 1H, J = 7.6 Hz, H-6’’), 7.59 (d, 1H, J 
= 7.6 Hz, H-4’’), 7.73 (s, 1H, H-2’’), 8.15 (d, 1H, J = 4.1 Hz, NH), 8.61 (s, 1H, H-8), 
8.93 (brs, 1H, N(6)-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C18H20ClIN7O3 [M+H]+: 544.0362, found 544.0366. 
Elemental analysis (C H ClIN18 19 7O3) C,H,N. 
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 9-[3-Amino-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(5-chloro-2-
methoxybenzyl)adenine (43) 
176 mg (0.33 mmol) of 41 furnished 29 mg (20 %) of 43 as a white solid. 
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Molecular formula: C H ClN19 22 7O4
Molecular weight: 447.88 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.67 (d, 3H, J = 4.7 Hz, CH3-N), 3.57 (t, 1H, J = 5.4 Hz, H-3’), 3.83 (s, 3H, Ar-
OCH3), 4.12 (d, 1H, J = 5.9 Hz, H-4’), 4.38 (t, 1H, J = 4.5 Hz, H-2’), 4.65 (br s, 2H, 
CH2-Ar), 6.02 (d, 1H, J = 4.1 Hz, H-1’), 7.00 (d, 1H, J = 8.8 Hz, H-3’’), 7.08 (br s, 1H, 
H-6’’), 7.20 (dd, 1H, J = 2.6 Hz and 8.8 Hz, H-4’’), 8.23 (s, 1H, H-2), 8.29 (br s, 1H, 
N(6)-H), 8.44 (d, 1H, J = 5.0 Hz, NH), 8.57 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN19 23 7O4 [M+H] : 448.1499, found 448.1483. 
Elemental analysis (C H ClN O19 22 7 4.3/2 H2O) C,H,N. 
 
9-[3-Aminomethyl-3-deoxy-5-(methylcarbamoyl)-β-D-ribofuranosyl]-N6-(5-
chloro-2-methoxybenzyl)adenine (44) 
150 mg (0.31 mmol) of 42 furnished 100 mg (70 %) of 44 as a white solid. 
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Molecular formula: C H ClN20 24 7O4
Molecular weight: 461.91 
1H-NMR (300 MHz, DMSO-d6): 
δ 2.40-2.48 (m, 1H, H-3’), 2.64 (d, 3H, J = 4.7 Hz, CH3-N), 2.76 (dd, 1H, J = 5.1 Hz 
and -12.8 Hz, 3’-CHb), 2.90 (dd, 1H, J = 7.9 Hz, 3’-CH ), 3.83 (s, 3H, Ar-OCHa 3), 4.34 
(d, 1H, J = 9.1 Hz, H-4’), 4.55 (dd, 1H, J = 1.6 Hz and 5.1 Hz, H-2’), 4.62 (br s, 2H, 
CH2-Ar), 6.01 (d, 1H, J = 1.8 Hz, H-1’), 7.00 (d, 1H, J = 8.8 Hz, H-3’’), 7.04 (s, 1H, H-
6’’), 7.24 (dd, 1H, J = 2.6 Hz and 8.8 Hz, H-4’’), 8.20 (s, 1H, H-2), 8.35 (br d, 2H, J = 
4.7 Hz, NH and N(6)-H), 8.68 (s, 1H, H-8). 
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 Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN20 25 7O4 [M+H] : 462.1652, found 462.1657. 
Elemental analysis (C H ClN O20 24 7 4.3/2H2O) C,H,N. 
 
Procedure for the amidation of 31 and 32 
To a solution of the appropriate amine in THF (10 mL/mmol) were added 50 % 
aqueous NaOAc solution (10 mL/mmol) and acetyl chloride (1.0 eq.). After 
completion of the reaction (6 h), THF and brine were added. The organic phase was 
separated, washed with water, dried over MgSO4 and concentrated in vacuo. 
Precipitation from MeOH and subsequent filtration furnished the product as a white 
solid. 
 
69-(3-Acetamidomethyl-3-deoxy-β-D-ribofuranosyl)-N -(3-iodobenzyl)adenine (33) 
70 mg (0.14 mmol) of 31 yielded 48 mg (63 %) of 33. 
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Molecular formula: C H IN20 23 6O4
Molecular weight: 538.35 
1H-NMR (300 MHz, DMSO-d6): 
δ 1.77 (s, 3H, CH3), 2.46 (m, 1H, H-3’), 3.08-3.16 (m, 1H, 3’-CHb), 3.24-3.30 (m, 1H, 
3’-CHa), 3.54 (ddd, 1H, J = 3.4 Hz, 5.3 Hz and -12.5 Hz, H-5B’), 3.77 (ddd, 1H, J = 
2.6 Hz and 5.0 Hz, H-5A’), 3.97 (dt, 1H, J = 2.8 Hz and 9.4 Hz, H-4’), 4.41 (t, 1H, J = 
4.0 Hz, H-2’), 4.63 (br s, 2H, CH2-Ar), 5.22 (t, 1H, J = 5.3 Hz, 5’-OH), 5.85 (d, 1H, J = 
4.4 Hz, H-1’), 5.93 (d, 1H, J = 1.2 Hz, 2’-OH), 7.09 (t, 1H, J = 7.8 Hz, H-5’’), 7.34 (d, 
1H, J = 7.6 Hz, H-6’’), 7.56 (d, 1H, J = 7.9 Hz, H-4’’), 7.70 (s, 1H, H-2’’), 7.89 (t, 1H, J 
= 5.4 Hz, 3’-C-NH), 8.20 (s, 1H, H-2), 8.47 (2s, 2H, H-8 and N(6)-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C20H24IN6O4 [M+H]+: 539.0905, found 539.0890. 
Elemental analysis (C H IN20 23 6O4.3/2 H2O) C,H,N. 
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 69-(3-Acetamidomethyl-3-deoxy-β-D-ribofuranosyl)-N -(5-chloro-2-methoxy-
benzyl)adenine (34) 
10 mg (0.023 mmol) of 32 yielded 6.6 mg (60 %) of 34. 
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Molecular formula: C H ClN21 25 6O5
Molecular weight: 476.92 
1H-NMR (300 MHz, DMSO-d6): 
δ 1.79 (s, 3H, CH3), 3.10-3.19 (m, 1H, H-3’), 3.27-3.36 (m, 1H, 3’-CHb), 3.51-3.60 (m, 
1H, 3’-CH ), 3.77-3.84 (m, 5H, H-5B’, H-5A’ and Ar-OCHa 3), 4.00 (m, 1H, H-4’), 4.45 
(app s, 1H, H-2’), 4.65 (brs, 2H, CH2-Ar), 5.22 (t, 1H, J = 5.1 Hz, 5’-OH), 5.87 (d, 1H, 
J = 4.4 Hz, H-1’), 5.95 (d, 1H, J = 1.5 Hz, 2’-OH), 7.02 (d, 1H, J = 8.8 Hz, H-3’’), 7.07 
(s, 1H, H-6’’), 7.25 (dd, 1H, J = 2.8 Hz and 8.7 Hz, H-4’’), 7.90 (t, 1H, J = 5.3 Hz, 3’-
C-NH), 8.20 (s, 1H, H-2), 8.26 (brs, 1H, N(6)-H), 8.49 (s, 1H, H-8). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN21 26 6O5 [M+H] : 477.1653, found 477.1641. 
Elemental analysis (C H ClN O21 25 6 5.1/2H2O) C,H,N. 
 
 
2.7.6 Synthesis of the thymidine analogues modified at the 2’- and 3’-position 
 
1-(3-Azido-3-deoxy-β-D-ribofuranosyl)thymine (45) 
A mixture of thymine (838 mg, 6.7 mmol) in HMDS (120 mL), TMSCl (0.85 mL) and 
dry pyridine (12 mL) was refluxed overnight. After evaporation in vacuo, 4 (2.1 g, 5.5 
mmol) in dry 1,2-dichloroethane (50 mL) and TMSOTf (1.2 mL, 6.7 mmol) were 
added to the residue. After stirring for 5 h at rt, CH2Cl2 (50 mL) and cooled 7 % 
NaHCO3 solution (100 mL) were added to the reaction mixture. The organic layer 
was separated, washed twice with H2O (100 mL), dried with MgSO4, filtered and 
evaporated to dryness. The residue was dissolved in 0.15N NaOCH3 in CH3OH (100 
mL), stirred for 1 h, and neutralised with a H2O/HOAc (9:1) solution. The mixture was 
evaporated in vacuo, purified by column chromatography (CH2Cl2/MeOH, 95/5) and 
precipitated from CH3OH to yield 1.52 g (80 %) of the title compound. 
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  calculated %  found % 
Compound C H N  C H N 
42.51 4.70 36.05  42.86 4.60 35.84 25 
43.37 5.26 33.72  43.62 4.99 33.55 26 
41.39 3.67 21.45  41.40 4.00 21.11 27 
49.52 4.59 24.31  49.60 4.73 24.11 28 
47.14 5.75 29.98  47.05 5.88 29.64 29 
44.85 6.59 26.15  44.95 6.58 26.35 30 
43.56 4.26 16.93  43.90 4.58 16.60 31 
51.94 5.39 19.13  52.07 5.31 19.13 32 
42.49 4.64 14.86  42.26 4.42 14.53 33 
51.91 5.39 17.29  51.78 5.03 17.11 34 
3.76 22.42  3.51 22.11 35 38.45 38.94 
39.60 4.02 21.87  39.68 3.87 21.78 36 
37.36 3.13 21.78  37.62 2.94 21.56 37 
41.71 4.08 18.92  41.82 4.25 18.59 38 
42.51 4.41 18.26  42.83 4.34 17.90 39 
39.76 3.52 18.03  39.47 3.34 17.66 40 
47.26 4.38 26.11  46.94 4.09 26.44 41 
48.34 4.67 25.37  48.52 4.44 29.97 42 
48.05 5.31 20.65  48.27 5.18 20.73 43 
49.13 5.57 20.05  48.86 5.19 19.90 44 
 
Table 2.2 Elemental analysis of final products 25-44. 
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Molecular formula: C H N10 13 5O5
Molecular weight: 283.24 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.77 (d, 3H, J = 1.2 Hz, 5-CH3), 3.54 (dd, 1H, J = 3.2 Hz and -12.3 Hz, H-5B’), 
3.63 (d, 1H, J = 3.0 Hz, H-5A’), 3.84 (q, 1H, J = 3.3 Hz and 7.8 Hz, H-4’), 4.06 (app t, 
1H, J = 5.1 Hz, H-3’), 4.40 (t, 1H, J = 5.7 Hz, H-2’), 5.29 (br s, 1H, 5’-OH), 5.74 (d, 
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 1H, J = 5.7 Hz, H-1’), 6.13 (br s, 1H, 2’-OH), 7.69 (d, 1H, J = 1.2 Hz, H-6), 11.35 (br 
s, 1 H, N(3)-H). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.85, 61.50, 61.81, 74.37, 82.44, 88.27, 110.16, 136.77, 151.41, 164.34. 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H N10 13 5O5Na [M+Na]  306.0814; found 306.0798. 
 
O-2,2’-Anhydro-1-(3-azido-3-deoxy-5-O-trityl-β-D-arabinofuranosyl)thymine (47) 
45 (1.43 g, 5.1 mmol) and trityl chloride (1.55 g, 5.6 mmol) were dissolved in dry 
pyridine (15 mL). The reaction mixture was heated at 65 °C for 7 hours, stirred 
overnight at room temperature and evaporated to dryness. The residue was 
dissolved in CH2Cl2 (150 mL) and washed subsequently with 7 % NaHCO3 solution 
(150 mL) and water (150 mL). The organic layer was dried over MgSO4, filtered and 
evaporated to dryness. The residue was chromatographed on a silica gel column 
prepared in CH Cl2 2/MeOH (99/1) and eluted with CH Cl2 2/MeOH (97/3) to give 2.46 g 
(93 %) of 1-(3-Azido-3-deoxy-5-O-trityl-β-D-ribofuranosyl)thymine. 
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Molecular formula: C H N29 27 5O5
Molecular weight: 525.57 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.42 (d, 3H, J = 0.9 Hz, 5-CH3), 3.19 (dd, 1H, J = 2.9 Hz and -11.0 Hz, H-5B’), 
3.29 (dd, 1H, J = 3.8 Hz, H-5A’), 3.97 (m, 1H, H-4’), 4.30 (q, 1H, J = 5.4 Hz and 10.8 
Hz, H-3’), 4.57 (q, 1H, J = 5.0 Hz and 10.1 Hz, H-2’), 5.76 (d, 1H, J = 5.4 Hz, H-1’), 
6.24 (d, 1H, J = 4.8 Hz, 2’-OH), 7.21-7.40 (m, 15H, trityl), 7.46 (d, 1H, J = 1.2 Hz, H-
6), 11.40 (s, 1H, N3-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H N29 27 5O5Na [M+Na]  548.1910; found 548.1910. 
 
Trifluoromethanesulfonyl chloride (1.0 mL, 9.36 mmol) was added to a cooled 
solution of 1-(3-Azido-3-deoxy-5-O-trityl-β-D-ribofuranosyl)thymine (2.46 g, 4.68 
mmol) and DMAP (2.30 g, 18.7 mmol) in dry CH2Cl  (50 mL). After 2 hours the 2
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 reaction was quenched with water (15 mL) and extracted. The organic layer was 
washed with a 7 % NaHCO solution, dried over MgSO3 4, filtered and evaporated to 
dryness to give a white semi-solid that was purified on a silica gel column 
(CH2Cl2/MeOH, 97/3) to give 1.91 g (81 %) of 47. 
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Molecular formula: C H N29 25 5O4
Molecular weight: 507.55 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.79 (d, 3H, J = 0.9 Hz, 5-CH3), 2.77 (dd, 1H, J = 7.6 Hz and -10.6 Hz, H-5B’), 
3.04 (dd, 1H, J = 4.1 Hz, H-5A’), 4.38 (m, 1H, H-4’), 4.60 (dd, 1H, J = 1.8 Hz and 3.2 
Hz, H-3’), 5.43 (dd, 1H, J = 1.6 Hz and 5.7 Hz, H-2’), 6.31 (d, 1H, J = 5.7 Hz, H-1’), 
7.20-7.28 (m, 15H, trityl), 7.82 (d, 1H, J = 1.2 Hz, H-6). 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C29H26N5O4 [M+H]+ 508.1984; found 508.1982. 
 
1-(3-Azido-3-deoxy-5-O-trityl-β-D-arabinofuranosyl)thymine (48) 
A mixture of 47 (1.91 g, 3.76 mmol), 1N NaOH (10 mL) and 50 % EtOH (100 mL) 
was stirred at room temperature for 4 hours. The solution was neutralised with an 
acetic acid/EtOH mixture (1:1, v/v) to pH~7. The resulting white solid was collected 
by filtration and washed with water. The solid was then dissolved in CH Cl2 2, extracted 
with water, dried over MgSO4, filtered and evaporated to dyness to produce 1.74 g 
(88 %) of 48 as a white solid. 
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Molecular formula: C H N29 27 5O5
Molecular weight: 525.57 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.59 (d, 3H, J = 0.6 Hz, 5-CH3), 3.28 (dd, 2H, J = 4.1 Hz and -11.1 Hz, H-5B’ and 
H-5A’), 3.80 (app quinted, 1H, J = 4.1 Hz and 8.2 Hz, H-4’), 4.15 (t, 1H, J = 7.5 Hz, 
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 H-3’), 4.34 (m, 1H, H-2’), 6.07 (d, 1H, J = 6.2 Hz, H-1’), 6.10 (d, 1H, J = 5.6 Hz, 2’-
OH), 7.24-7.40 (m, 15H, trityl), 7.38 (d, 1H, J = 0.6 Hz, H-6), 11.34 (s, 1H, N3-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H N29 27 5O5Na [M+Na]  548.1910; found 548.1906. 
 
1-(3-Azido-3-deoxy-β-D-arabinofuranosyl)thymine (49) 
A suspension of compound 48 (0.5 g, 0.95 mmol) in 80 % HOAc (10 mL) was heated 
at 90 °C with stirring for 25 min. The solution was evaporated in vacuo to give a 
residue that was chromatographed on a silica gel column (CH2Cl2/MeOH, 95/5) to 
afford 0.2 g (79 %) of 49. 
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Molecular formula: C H N10 13 5O5
Molecular weight: 283.24 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.74 (s, 3H, J = 1.2 Hz, 5-CH3), 3.62 (m, 3H, H-4’, H-5B’ and H-5A’), 4.00 (t, 1H, J 
= 7.5 Hz, H-3’), 4.32 (t, 1H, J = 6.6 Hz, H-2’), 5.29 (br s, 1H, 5’-OH), 5.99 (d, 1H, J = 
6.2 Hz, H-1’), 6.07 (d, 1H, J = 0.6 Hz, 2’-OH), 7.58 (d, 1H, J = 1.2 Hz, H-6), 11.27 (s, 
1H, N3-H). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.84, 60.20, 64.84, 74.80, 80.26, 83.78, 108.70, 138.29, 151.14, 164.503. 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H N10 13 5O5Na [M+Na]  306.0814; found 306.0810. 
 
1-(3-Azido-2-chloro-2,3-dideoxy-β-D-ribofuranosyl)thymine (51) 
47 (310 mg, 0.61 mmol) was transferred into a sealable glass vial and 4 M HCl in 
dioxane (20 mL) was added. The vial was firmly sealed and temperature was raised 
to 75-80 °C for 24 hours. After cooling to room temperature the reaction mixture was 
evaporated in vacuo and purified on a silica gel column CH Cl2 2/MeOH (98/2) to give 
170 mg (92 %) of 51. 
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Molecular formula: C H ClN10 12 5O4
Molecular weight: 301.69 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.75 (d, 3H, J = 1.2 Hz, 5-CH3), 3.61 (ddd, 1H, J = 3.0 Hz, 5.0 Hz and -12.6 Hz, 
H-5B’), 3.75 (ddd, 1H, J = 3.1 Hz and 5.3 Hz, H-5A’), 3.99 (app quinted, 1H, J = 2.9 
Hz, 3.13 Hz and 6.0 Hz, H-4’), 4.57 (t, 1H, J = 5.7 Hz, H-3’), 4.92 (t, 1H, J = 5.1 Hz, 
H-2’), 5.47 (t, 1H, J = 4.7 Hz, 5’-OH), 5.93 (d, 1H, J = 4.7 Hz, H-1’), 7.80 (d, 1H, J = 
1.2 Hz, H-6), 11.46 (s, 1H, N3-H). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.92, 60.37, 61.10, 61.90, 83.12, 89.02, 110.23, 135.89, 151.17, 164.29. 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN10 13 5O4 [M+H]  302.0655; found 302.0658. 
 
1-(3-Azido-2,3-dideoxy-2-fluoro-β-D-ribofuranosyl)thymine (53) 
To a solution of 48 (1.59 g, 3.0 mmol) in toluene (30 mL) and pyridine (3 mL), DAST 
(1.5 mL, 11.3 mmol) was added and stirred at room temperature for 2 h before 
heating the reaction mixture to 50 °C. After 5 hours EtOAc (170 mL) was added and 
the organic layer washed successively with 7 % NaHCO3 (200 mL) and H2O (200 
mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
on a silica gel column prepared in CHCl3 and eluated with CHCl3/MeOH, 99/1 to give 
1.45 g (90 %) of 1-(3-Azido-2,3-dideoxy-2-fluoro-5-O-trityl-β-D-ribofuranosyl)thymine. 
NO NH
O
O
TrO
N3 F
32
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Molecular formula: C H FN29 26 5O4
Molecular weight: 527.56 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.52 (d, 3H, J = 0.9 Hz, 5-CH3), 3.24 (dd, 1H, J = 4.1 Hz and -11.1 Hz, H-5B’), 
3.35 (dd, 1H, J = 2.4 Hz, H-5A’), 4.12 (m, 1H, H-4’), 4.56 (ddd, 1H, J = 4.7 Hz, 9.5 Hz 
and J3’,F = 24.5 Hz, H-3’), 5.53 (dd, 1H, J = 4.8 Hz and J2’,F = 52.9 Hz, H-2’), 5.91 (dd, 
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 1H, J = 1.1 Hz and J1’,F = 21.6 Hz, H-1’), 7.24-7.40 (m, 15H, trityl), 7.51 (d, 1H, J = 
1.2 Hz, H-6), 11.51 (br s, 1H, N3-H). 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H FN29 26 5O4Na [M+Na]  550.1866; found 550.1862. 
 
1-(3-Azido-2,3-dideoxy-2-fluoro-5-O-trityl-β-D-ribofuranosyl)thymine (1.45 g, 2.75 
mmol) was detritylated to give 0.52 g (64 %) of 53 using the same procedure as 
described for 49. 
NO
F
NH
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O
OH
N3
32
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Molecular formula: C H FN10 12 5O4
Molecular weight: 285.24 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.74 (d, 3H, J = 1.2 Hz, 5-CH3), 3.60 (dd, 1H, J = 2.9 Hz and -12.6 Hz, H-5B’), 
3.79 (dd, 1H, J = 2.6 Hz, H-5A’), 3.98 (dt, 1H, J = 2.6 Hz and 8.8 Hz, H-4’), 4.30 (ddd, 
1H, J = 4.6 Hz, 8.9 Hz and J3’,F = 23.5 Hz, H-3’), 5.42 (ddd, 1H, J = 1.5 Hz, 4.5 Hz 
and J2’,F = 52.9 Hz, H-2’), 5.43 (br s, 1H, 5’-OH), 5.90 (dd, 1H, J = 1.6 Hz and J1’,F = 
19.2 Hz, H-1’), 7.74 (d, 1H, J = 1.2 Hz, H-6), 11.44 (br s, 1H, N3-H). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.76, 58.67 (J = 15.3 Hz), 59.76, 81.65, 88.38 (J = 34.8 Hz), 94.68 (J = 186.3 Hz), 
110.10, 136.89, 150.84, 164.51. 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H FN10 12 5O4Na [M+Na]  308.0771; found 308.0759. 
 
General procedure for the synthesis of the 3’-amine modified thymidine 
nucleosides from their 3’-azide precursors 
The 3’-azido modified nucleoside (1 mmol) was dissolved in dry pyridine (8 mL) and 
PhP3 (1.6 mmol) was added to the solution. After stirring at rt for 1.5 h, concentrated 
NH4OH (3 mL) was added. The reaction mixture was stirred for another 2 h, 
evaporated to dryness and purified by silica gel chromatography using a suitable 
mixture of CH2Cl2/MeOH. 
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 1-(3-Amino-3-deoxy-β-D-ribofuranosyl)thymine (46) 
500 mg (1.77 mmol) of 45 yielded 320 mg (71 %) of 46 as a white solid. 
 
NO
OH
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O
OH
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Molecular formula: C H N10 15 3O5
Molecular weight: 257.10 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.75 (s, 3H, 5-CH3), 3.21 (dd, 1H, J = 5.4 Hz and 7.7 Hz, H-3’), 3.60 (m, 2H, H-4’ 
and H-5B’), 3.74 (app d, 1H, J = -11.2 Hz, H-5A’), 3.86 (dd, 1H, J = 2.4 Hz and 5.3 
Hz, H-2’), 5.11 (br s, 1H, 5’-OH), 5.69 (d, 1H, J = 2.4 Hz, H-1’), 7.61 (s, 1H, H-6). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.85, 52.42, 60.74, 75.39, 85.55, 90.12, 109.29, 137.16, 151.13, 164.48. 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H N10 16 3O5Na [M+H]  258.1089; found 258.1095. 
 
1-(3-Amino-3-deoxy-β-D-arabinofuranosyl)thymine (50) 
120 mg (0.42 mmol) of 49 yielded 60 mg (54 %) of 50 as a white solid. 
NO NH
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Molecular formula: C H N10 15 3O5
Molecular weight: 257.25 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.73 (d, 3H, J = 1.2 Hz, 5-CH3), 3.05 (t, 1H, J = 6.2 Hz, H-3’), 3.50 (m, 1H, H-4’), 
3.61 (app t, 2H, J = 15.8 Hz, 2H, H-5B’ and H-5A’), 3.90 (br q, 1H, J = 5.0 Hz and 9.7 
Hz, H-2’), 5.04 (s, 1H, 5’-OH), 5.42 (d, 1H, J = 4.4 Hz, 2’-OH), 5.98 (d, 1H, J = 5.6 
Hz, H-1’), 7.60 (d, 1H, J = 1.2 Hz, H-6). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.88, 57.83, 60.99, 77.41, 84.54, 84.66, 107.97, 138.82, 151.15, 164.59. 
Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C10H16N3O5 [M+H]+ 258.1089; found 258.1084. 
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 1-(3-Amino-2-chloro-2,3-dideoxy-β-D-ribofuranosyl)thymine (52). 
90 mg (0.30 mmol) of 51 yielded 24 mg (30 %) of 52 as a white solid. 
NO
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Molecular formula: C H ClN10 14 3O4
Molecular weight: 275.69 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.73 (d, 3H, J = 0.9 Hz, 5-CH3), 1.85 (br s, 2H, 3’-NH2), 3.50 (dd, 1H, J = 5.3 Hz 
and 7.9 Hz, H-3’), 3.62 (ddd, 1H, J = 2.6 Hz, 4.7 Hz and -12.2 Hz, H-5B’), 3.75 (m, 
2H, H-4’ and H-5A’), 4.53 (dd, 1H, J = 2.4 Hz and 5.3 Hz, H-2’), 5.26 (t, 1H, J = 5.0 
Hz, 5’-OH), 5.94 (d, 1H, J = 2.6 Hz, H-1’), 7.99 (d, 1H, J = 1.5 Hz, H-6), 11.35 (s, 1H, 
N3-H). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.91, 52.06, 59.97, 84.69, 89.64, 91.10, 109.64, 136.22, 151.09, 164.42. 
Exact mass (ESI-MS, iPrOH:H2O): 
+calculated for C H ClN10 15 3O4 [M+H]  276.0750; found 276.0765. 
1-(3-Amino-2,3-dideoxy-2-fluoro-β-D-ribofuranosyl)thymine (54). 
120 mg, 0.42 mmol of 53 yielded 60 mg (55 %) of 54 as a white solid. 
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Molecular formula: C H FN10 14 3O4
Molecular weight: 259.24 
1H-NMR (300 MHz, DMSO-d6) 
δ = 1.72 (d, 3H, J = 1.2 Hz, 5-CH3), 3.32 (ddd, 1H, J = 4.3 Hz, 9.7 Hz and J3’,F = 28.6 
Hz, H-3’), 3.61 (m, 2H, H-4’ and H-5B’), 3.78 (dd, 1H, J = 1.76 Hz and -12.3 Hz, H-
5A’), 4.87 (dd, 1H, J = 4.1 Hz and J2’,F = 53.1 Hz, H-2’), 5.19 (br s, 1H, 5’-OH), 5.83 
(d, 1H, J1’,F = 18.2 Hz, H-1’), 7.86 (d, 1H, J = 1.2 Hz, H-6). 
13C-NMR (75 MHz, DMSO-d6) 
δ 12.82, 51.73 (J = 18.1 Hz), 59.54, 84.83, 88.30 (J = 35.7 Hz), 96.72 (J = 180.5 Hz), 
109.54, 136.80, 150.79, 164.52. 
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 Exact mass (ESI-MS, iPrOH:H2O): 
calculated for C10H15FN3O4 [M+H]+ 260.1046; found 260.1053. 
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 PART II 
BIOLOGICAL EVALUATION OF 
THE MODIFIED ADENOSINE ANALOGUES 
 
 
 
 
 
 
 
 
 
 
Biological results in this part were published in: 
 
 
Bioorg. Med. Chem. 2004, Accepted. 
J. Med. Chem. 2003, 46, 4847. 
J. Med. Chem. 2001, 44, 4125. 
 59
  
 60
 Chapter 3 
GENERAL BACKGROUND 
 
3.1 Adenosine receptors and G-protein coupled receptors 
 
Integral membrane G-protein coupled receptors (GPCRs or 7TM), a small subset of 
the human genome (2–3%),1 constitute about 50% of the drug targets that are of 
interest to the pharmaceutical industry.2 GPCRs are involved in the regulation of a 
wide range of body functions and hence used for treatment of diseases such as 
hypertension, cardiac dysfunction, depression, pain and schizophrenia.3
 
The GPCR superfamily can be subdivided into six classes, that share significant 
sequence similarity (see also Figure 3.1):3
- Class A, the rhodopsin/adrenergic receptors, consists of the majority 
of GPCRs identified to date. These GPCRs are activated by various 
ligands such as photons, odorants, hormones, neurotransmitters 
(ranging from small biogenic amines to peptides) and complex 
glycoproteins. Both structurally and functionally they are the best 
studied GPCRs. 
- Class B, the secretin/vasointestinal peptide (VIP) receptors, binds 
neuropeptides and peptide hormones. 
- Class C, the metabotropic glutamate receptor family, comprises at 
least six closely related subtypes of receptors that bind glutamate, the 
major excitatory neurotransmitter in the central nervous system. 
- Three additional GPCR classes are: the fungal pheromone P and a-
factor (STE2/MAM2) family (class D), the fungal pheromone A and M 
factor (STE3/MAP3) receptors (class E), and the cyclic adenosine 
monophosphate (cAMP) receptors of Dictyostelium (class F). 
 
Biophysically, GPCRs are characterized by their seven transmembranal (7TM) 
hydrophobic regions (each 20-25 amino acids in length). Seen from the top of the 
membrane, the 7TM domains form a barrel shape, perpendicularly oriented in a 
counter clockwise manner to the plane of the membrane. All GPCRs have an 
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 extracellular N-terminal region (from <10 to >100 amino acids) and an intracellular C-
terminal region. Intra- and extracellular loops (ILs and ELs) are 10-40 amino acids 
long, although the third intracellular loop (EL3) and C-terminal loop sequence can 
have over 150 residues. The overall size of GPCRs can vary significantly from <300 
to >1100 amino acids.3
 
 
 
Figure 3.1 The “world of human GPCRs”. A distribution of the 508 human GPCRs that have 
been discovered so far, grouped according to the type of natural ligand that binds to them. 
Orphan receptors are receptors of yet unknown function.3
 
 
In the GPCR superfamily the most conserved residues are located within the TM 
domains, making up the essential determinants of the receptors structure and 
function.4 However, the exact 3D structure of most GPCRs is still unknown, due to 
the technical difficulties regarding X-ray crystallography and NMR experiments on 
GPCRs. In fact, the recently published X-ray structure of rhodopsin5 is the only 3D 
structure of a GPCR available. Before the publication of the rhodopsin X-ray 
structure, the low-resolution cryo-electron microscopic structure of rhodopsin6 and 
the X-ray structure of bacteriorhodopsin7 (a proton pump and not a GPCR) were the 
only major advancements in GPCR structural information. 
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For most GPCRs, rhodopsin6 is used as a template for homology modeling 
techniques.8 With homology modeling the 3D structure of an unknown protein can be 
created, based on the known structure(s) of related protein(s). The accuracy of the 
prediction relies on the number of structures that serve as a template and their 
homology to the protein of interest (typically >35% sequence identity).9-11 This 
method has proven successful in modeling globular proteins, like kinase enzymes. 
However, applying homology modeling to GPCRs is hampered by the low sequence 
identity between most GPCRs and rhodopsin (or bacteriorhodopsin). Differences 
between rhodopsin and bacteriorhodopsin, and their use as GPCR (modeling) 
templates are much debated in recent critical reviews.8
 
In this thesis (Chapters 4-6) we focus on adenosine receptors (AR), a subfamily of 
class A GPCRs to which also rhodopsin belongs (see above). Since the discovery of 
the hypotensive and bradycardiac effects of adenosine, ARs have become an 
interesting field of research.12 Today, four adenosine receptor subtypes (A1, A , A2A 2B 
and A3) are known. As shown in Figure 3.2, AR subtypes can be differentiated 
according to their preferred mechanism of signal transduction: A1AR and A3AR 
interact with G  heterotrimeric G-proteins, whereas A AR and Ai 2A 2BAR couple with Gs, 
resulting respectively in the inhibition (for A AR and A AR) and stimulation (for A1 3 2AAR 
and A AR) of adenylate cyclase. A AR and A2B 2B 3AR can, in addition, also activate 
phospholipase C by activation of Gq.12,13
 
12,14The A3AR is the most recently identified AR subtype (Chapter 4).  A3AR ligands 
are potentially interesting therapeutic agents for the treatment of ischemic and 
inflammatory diseases.14 Ligand-binding sites of A1AR, A AR, and A2A 2BAR were 
(previously) experimentally characterized by site-directed mutagenesis (SDM).15-19 
For the TM region of the human A 20-223AR an (improved) model was build,  based on 
the high resolution crystal structure of bovine rhodopsin5 (Figure 3.3). However, the 
molecular basis for ligand recognition in the A3AR, remained unclear. Creation of the 
A3 “neoceptor” by Dr. Kenneth A. Jacobson and co-workers,23 provided new insights 
into the molecular recognition in the adenosine receptors.
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Figure 3.2 Signal transduction pathways associated with activation of the human adenosine 
receptors.3
 
 
To further investigate the ligand-A3AR interactions, SDM was used to study the role 
of a number of residues in TM domains 3,6 and EL2, predicted (by previous 
molecular modeling)24   to be involved in the ligand recognition. These SDM studies 
showed Trp243 in the A3AR to be critical for receptor activation, but not for agonist 
binding, a finding that further refined the rhodopsin-based model of ligand-A3AR 
interactions.25
 
 
Note on the residue indexing in this work 
 
To facilitate comparison of aligned residues in related GPCRs, residues are 
supplemented with an index, according to the van Rhee-convention.32 The most 
conserved residue in a TM region X is given the index number (X.50). Residues 
within the given TM are then indexed relative to the “50” position. Note that the “50” 
position is not necessarily the residue in the middle of the TM region. For example, in 
the hA3AR His272 has the index (7.43) as it is located in TM7, seven residues apart 
from the conserved Pro279 (7.50). 
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Figure 3.3 A Stereoview of the complete topology of human A3AR obtained by a homology 
modeling approach. B Stereoview of the human A3AR transmembrane helical bundle model 
viewed perpendicular to the helical axes (left) and along the helical axes from the 
extracellular end (right).3
 
 
3.2 Chemical genetics: situating the “neoceptor-neoligand” concept 
 
1The approximately 40,000 genes in the human genome  represent a great challenge 
in “post-genomic” drug discovery. Logically there is much interest in the development 
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 of technologies that can (functionally) validate potential drug targets and/or yield 
pharmacological information about their mechanism of action. 
 
The power of genetic approaches for the study of target function is their high 
specificity, i.e. the ability to affect a single protein in a whole organism (hence the 
popularity of knockout mice for target validation). However, genetics has its 
drawbacks:26
- Genetic approaches affect the entire protein target, which makes it 
difficult to determine the difference between effects resulting from the 
loss of the entire protein (i.e. as a functional scaffold of the cell) and 
effects resulting from the loss of the proteins intrinsic activity (i.e. 
signal transduction, enzyme activity, ...). 
- Difficult temporal control. Both gene knockouts and RNA-based 
approaches (antisense and RNAi) modulate protein levels rather 
slowly, which can be problematic for the study of processes such as 
signal transduction that have millisecond time scales. 
- Gene knockouts often result in a lethal phenotype.  
 
Chemical approaches, on the other hand, also have advantages and disadvantages. 
Small molecules influence protein function in a (pharmacologically) controllable way, 
but in most cases suffer from a lack of specificity. When using a purely chemical 
approach, it is often difficult to determine the true action of small molecules on an 
individual target, as “off-target” effects can contribute to toxicity or even positive 
biological effects.26
 
So, where genetics offer target specificity, chemistry offers temporal control over the 
proteins targeted. Experimental systems that incorporate the advantages of both 
approaches, are expected to represent powerful tools for target validation (in drug 
discovery) and protein functional studies. 
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 3.2.1 Orthogonal chemical genetics 
 
Recently several studies have shown the advantages of combining (orthogonal) 
chemistry and genetics (Figure 3.4).27 These experiments are all based on the same 
“lock-and-key” design approach:  
- Step 1; a (small) molecule that binds to the protein of interest, i.e. the 
“key”, is synthetically modified to eliminate its ability to bind to its wild- 
type target. This designed compound is said to be “orthogonal” when it 
can no longer interact with its natural (protein) target or, ideally, with 
any other target in the cell (Figure 3.4A). 
- Step 2; the (protein) target of interest, i.e. the “lock”, is engineered to 
accept the orthogonal compound (Figure 3.4A). However, it is crucial 
that the mutation in the protein only affects the binding of the 
orthogonal compound, but does not alter the function of the protein in 
any other way. On the other hand, when the engineered lock no longer 
accepts the natural ligand, the target protein itself becomes orthogonal 
(Figure 3.4B and 3.4C). 
 
28Since the pioneering work of Hwang and Miller  numerous ligand-receptor, protein-
protein interaction and enzymatic systems have been studied using orthogonal 
chemical genetic techniques.26,27,29
 
 
3.2.2 Receptors activated solely by synthetic ligands (RASSL)  
 
GPCRs control many physiological processes and therefore constitute an important 
class of therapeutically interesting targets (see above).2 Although, many (specific) 
ligands for these receptors are known, the (chemical) control of GPCRs is 
complicated by the presence of endogenous ligands, that can activate or inhibit 
signalling events. To simplify the study of individual GPCRs, Conklin and co-
workers30 started to use engineered receptors that respond only to synthetic ligands 
(RASSLs) and not to their endogenous native ligands. 
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Figure 3.4 Definition of orthogonal ligands and proteins. A Step 1; a (small) molecule that 
binds to the protein of interest, i.e. the “key”, is synthetically modified to eliminate its 
ability to bind to its wild- type target. Step 2; the (protein) target of interest, i.e. the 
“lock”, is engineered to accept the orthogonal compound. B and C When the 
engineered lock no longer accepts the natural ligand, the target protein itself 
becomes orthogonal. 
 
 
23With the “neoceptor-neoligand” approach,  we envisaged to take the RASSL 
concept a step further by preparing synthetic ligands that are orthogonal, i.e. 
unresponsive, towards (ideally all) endogenous GPCRs. Using the adenosine 
receptor family as a model system the selective stimulation of an engineered 
(H272E) adenosine A3AR mutant by synthetic (3’-modified) adenosine analogues 
was investigated. With ongoing efforts to further improve the potency and selectivity 
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 of these A3AR ligands, this RASSL approach can become a powerful method for 
functional validation of GPCRs. 
 
Similar chemical genetic strategies have been reported for the design and synthesis 
of ligands for engineered nuclear hormone receptors, a family of transcriptional 
regulators that have both DNA binding and ligand-dependent transactivation 
properties.31 We are convinced that the development of orthogonal ligand-receptor 
pairs will become important tools for the selective stimulation of a single member in a 
large family of receptors (whether GPCRs or other receptors).  
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 CHAPTER 4 
EXPLORING HUMAN ADENOSINE A3AR COMPLEMENTARITY AND ACTIVITY FOR 
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 4.1 Introduction 
 
G protein-coupled receptors (GPCRs) with their typical seven-helix transmembrane 
(7TM) domains, constitute a large group of integral membrane proteins. Interacting 
with structurally diverse extracellular signals, GPCRs provide a molecular link for 
activation (or inhibition) of intracellular processes via given signal transduction 
pathways1 and represent the most prominent family of validated drug targets.2
 
The regulatory actions of adenosine are mediated by four subtypes of GPCRs called 
adenosine receptors (ARs) that are ubiquitously expressed in the body and can be 
distinguished as A1, A2A, A2B and A3 receptors.3 Activation of the A3AR subtype, 
which is distributed in various organs (lung, liver, kidney, heart and brain)4 has been 
shown to mediate adenylate cyclase inhibition5 6 7 and phospholipase C  and D  
stimulation. All four AR subtypes have been characterised on a pharmacological level 
as well as on a molecular level.8 ARs from different species show a high amino acid 
sequence homology (82-93%) with the only exception being the A3AR subtype, which 
only exhibits 74% primary sequence homology between rat and human or sheep.9-10  
 
To be of therapeutic value, synthetic AR ligands need to be highly selective for a 
given receptor subtype and tissue targeted. Although several agonists have been 
synthesized that are selective for the known ARs subtypes,3,11 so far the only AR 
agonist approved for clinical use is adenosine itself. Here we focus on the human 
(h)A3AR subtype, the most recently identified member of the AR family.12-14
 
15,16The A AR plays a crucial role in some of the physiological effects of adenosine.3  
In addition to cardio-17-19 20,21 and cerebroprotective effects,  hA3AR agonists may be 
therapeutically useful for the treatment of stroke,22 23 inflammation  and in cancer 
therapy.24 While full agonists maximally stimulate the receptor, partial agonists show 
reduced intrinsic activity, may exhibit fewer side effects25,26 and may induce less 
receptor down-regulation and desensitisation than full agonists.15 Partial A3AR 
agonists can act as cardioprotective agents.27 Selective antagonists for the A3AR 
promise to be useful in the regulation of cell growth28,29 30and as anti-asthmatic,  
cerebroprotective20,31 32and anti-inflammatory agents.
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 12Since its discovery in 1991,  the development of agonists of the A3AR has been an 
active area of research. Many variations have been made on the adenosine scaffold 
in view of potent and selective A 11,15,333AR binding.  Generally, substitution at the 2’- 
and 8- positions has affinity- and efficacy-lowering effects.11,15 Known A3AR-selective 
alterations relevant to our work are N6-modifications, such as 3-iodobenzyl 
(IB)11,15,33,34 or 5-chloro-2-methoxybenzyl (CMB),35 and smaller substituents like a Cl 
or CN at the 2-position33-35 of the purine moiety. Both the 2- and N6-purine 
modifications have been described with and without the 5’-methylcarbamoyl (MEC)33 
insertion in the nucleoside sugar moiety. Combinations of these groups are often 
additive in their potency enhancement and resulted in potent and moderately 
selective A 363AR agonists, such as Cl-IB-MECA and IB-MECA,  which are still used as 
reference tools for pharmacological study of the A3AR. 
 
Investigated to a lesser extent are 3’-modifications of the ribofuranosyl moiety.37,38 
We and others have shown that a 3’-amino substitution opens perspectives towards 
influencing the hA 39,403AR selectivity.  This stimulated us to investigate the effect on 
both affinity and efficacy of this 3’-amino modification when combined with the above 
mentioned variations at the 5’-, 2- and N6-positions (Figure 4.1, derivatives 14, 16 
and 19). By introducing an α-oriented methylene spacer (the so-called branching) 
between the 3’-carbon of the ribofuranosyl moiety and the amine function (Figure 4.1, 
derivatives 5-8, 15 and 20), we aimed to modulate the hydrogen bond donating 
effects of the 3’-amine, known to be crucial from our neoceptor work (Chapters 5 and 
6).39,41 6We wanted to provide more insight into the effect of 3’, 5’, 2- and N -positional 
variations of the adenosine scaffold on hA3AR affinity and to investigate the impact of 
such a combined substitution pattern on the hA3AR efficacy. 
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Figure 4.1 3’, 5’, 2- and N6-modified adenosine analogues discussed in this Chapter. 
 
 
4.2 Results and discussion 
 
4.2.1 Chemistry 
 
The synthesis of the 3’, 5’, 2- and N6-substituted adenosine analogues 1-20 is 
described in Part I. 
 
 
4.2.2 Biological activity 
 
All analogues evaluated (i.e. 1-20) are depicted in Figure 4.1. Modifications of the 
adenosine scaffold known to increase hA3AR binding affinity and selectivity among 
adenosine agonists include: a 5’-uronamide moiety (as in 11-20) and substitutions at 
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the 2- (as in 13 and 16) and N6-positions (as in 2-4 and 6-20). We investigated the 
influence on hA3AR affinity and intrinsic activity of combining these 5’, 2- and N6-
modifications with the amino(methyl) substitution at the 3’-position that we39,41 and 
others40 recently reported. 
 
Generally, substitution of the 2’- and 3’-hydroxyl groups of the ribofuranose moiety  of 
AR agonists has been avoided. It has been demonstrated that modification of the 2’-
position, compared to the 3’-position, had a negative impact on both potency and 
intrinsic activity.37,38,42 However, a 3’-amino modification was recently shown to be 
beneficial for hA3AR selectivity depending on the overall substitution pattern of the 
adenosine nucleoside.40 This prompted us to investigate the boundaries of this 3’-
amino substitution by insertion of a methylene spacer between the ribofuranose ring 
and the amine functional group. 
 
 
4.2.2.1 Affinity and Selectivity 
 
Looking at the analogues that exhibited < 1 μM affinities (in Table 4.1), it was clear 
that the 5’-uronamide modification for both the direct and branched-chain amine (as 
in 11-20 vs. 1-10) improved the overall affinity. With exception of 3 and 7, all 
compounds evaluated showed very good selectivity for the hA3AR subtype. In the 
simple 3’-amino series the most potent compound 19 (Ki = 27 nM) showed a 300-fold 
selectivity over the A1AR, compared to a 22-fold selectivity for its N6-iodobenzyl 
substituted analogue 14. Introduction of a chloro atom at the 2-position resulted in 
the selective and moderately potent (Ki = 132 nM) partial agonist 16. All branched-
chain analogues on the other hand had a good hA3AR selectivity profile, but 
displayed weak binding characteristics, e.g. analogue 20 with a Ki of 557 nM having 
the highest affinity in this series. Introduction of the methylene spacer also affected 
intrinsic activity (see section 4.2.2.2.). In both the 3’-amino and 3’-aminomethyl series 
the affinity of the azido precursors was lower. This affinity difference was striking 
especially for the N6-iodobenzyl substituted analogues: 11 (Ki = 2260 nM) vs. 14 (Ki = 
137 nM) and 13 (Ki = 4270 nM) vs. 16 (Ki = 132 nM). 
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Table 4.1. Binding affinity (A1AR, A2AAR, or A3AR) or functional activation (A2BAR and A3AR) of the adenosine derivatives at human adenosine 
receptors, n = 3 , unless noted. 
 
NO
N
N
OHR2
R1
N
N
H
R4
R3
 
Compound R1 R2 R3 R4 hA1ARa hA2AARb hA2BARc hA3ARd
cAMP 
hA3ARg
h CH2OH NH2 H H 14% 6% --- 442,000±121,000 53±5 
1 CH2OH CH2N3 H H 25% 38% --- 53±1% 1.1±0.9 
5 CH2OH CH2NH2 H H 39% 33% --- 43±1% 23±8 
2 CH2OH CH2N3 CH3 H 69% 51% --- 20,600e 2.7±1.6 
6 CH2OH CH2NH2 CH3 H 42% 22% --- 48±3% 48±6 
h CH2OH NH2 3-IB H 93% 70% --- 870±180 --- 
3 CH2OH CH2N3 3-IB H 27% 28% --- 61±1% 6.8±1.7 
7 CH2OH CH2NH2 3-IB H 72% 22% --- 8700e 9.2±2.1 
9 CH2OH CH2NHAc 3-IB H 38% 0% --- 31,500e 20±5 
8 CH2OH CH2NH2 CMB H 61% 20% 0% 13,800±1400 18±3 
10 CH2OH CH2NHAc CMB H --- --- --- 4%f 1.4±0.2 
11 MeUron N3 3-IB H 64% 32% 0% 2260±480 0 
14 MeUron NH2 3-IB H 3080±380 67% 20% 137±41 37±5 
12 MeUron CH2N3 3-IB H 24% 0% 0% 23±1% 23±4 
15 MeUron CH2NH2 3-IB H 52% 6% 0% 1690±330 17±2 
13 MeUron N3 3-IB Cl 70% 29% 0% 4270±1400 0 
16 MeUron NH2 3-IB Cl 73% 50% 0% 132±60 30±6 
17 MeUron N3 CMB H 66% 34% 13% 376±83 0 
19 MeUron NH2 CMB H 8190±750 49% 7% 27±11 51±4 
18 MeUron CH2N3 CMB H 54% 43% 19% 755±40 0 
20 MeUron CH2NH2 CMB H 52% 2% 2% 557±164 30±6 
 
aKi (nM) or % inhibition of binding at 100 μM ([3H]R-PIA, 2.0 nM) in CHO cells expressing hA1AR. b% inhibition of binding at100 μM ([3H]CGS21680,15 nM) in 
HEK-293 cells expressing hA2AAR. 
c% activation (cAMP assay) at100 μM in CHO cells expressing hA2BAR (NECA is 100%). dKi (nM) or % inhibition at 100 
μM ([125I]I-AB-MECA, 0.5 nM) in CHO cells expressing hA3AR, unless noted. en = 1. fat 10 μM. gInhibition at 100 μM of forskolin-stimulated cAMP production 
at 10 μM, in CHO cells expressing the hA3AR, as a percentage of the response of the full agonist Cl-IB-MECA (n=2). haffinities previously reported in ref. 39. 
 Focusing on the N6 36-substituents, known to be important for hA3AR selectivity,  we 
observed a difference between the 3’-amino and branched-chain 3’-aminomethyl 
series, depending on the modification at the 5’-position. In the 5’-hydroxy 3’-amino 
series, 3’-amino-N6-iodobenzyladenosine (Ki = 870 nM) showed a significant 500-fold 
potency enhancement compared to 3’-aminoadenosine (Ki = 442 μM). In the 5’-
hydroxy branched-chain series (as in 1-10), however, contrary to what we recently 
reported for simple N6 35-substituted adenosine analogues,  N6-(5-chloro-2-
methoxybenzyl) substitution (as in 8, Ki = 13.8 μM) did not improve affinity over the 
N6-iodobenzyl modification (as in 7, K  = 8.7 μM). The reduction of hAi 3AR affinity 
upon acetamide formation (as in analogues 9 and 10) indicated that introduction of a 
3’-branching was the sterically maximal allowed modification. 
 
In the 5’-uronamide series, both for the 3’-amino and branched-chain 3’-aminomethyl 
analogues, the influence of N6-substitution on hA3AR binding was consistent with our 
previous findings,35 i.e. N6-iodobenzyl (as in 14, 15 and 16 with Ki = 137 nM, 1.7 μM 
and 132 nM respectively) was less affinity-enhancing than N6-(5-chloro-2-
methoxybenzyl) (as in 19 and 20 with K  = 27 nM and 557 nM respectively). i
 
 
4.2.2.2 Intrinsic activity 
 
The results of the cyclic AMP-assay (in Table 4.1) indicated that all analogues were 
strong partial agonists at best. In the simple 5’-hydroxy 3’-amino series, 3’-
aminoadenosine and 3’-amino-N6 39-iodobenzyladenosine are known full agonists.  
The 5’-uronamide analogues 14 and 19 were partial agonists, contrary to what was 
reported earlier.40
 
In the 3’-branched-chain series, comparison of the 5’-hydroxy derivatives 3, 7 and 9 
with the 5’-uronamides 12, 15 and 20, demonstrated a moderate influence of the 5’-
methyluronamide modification on intrinsic activity. Thus, in general, introduction of a 
3’-branching reduced the efficacy and, contrary to efficacy-reducing substitutions at 
the 2- and N6 33,38-positions,  this effect could only partially be overcome by 
modification of the 5’-position. 
 80
 A modification known to have contradictory effects on A3AR binding and intrinsic 
activity is the introduction of a chlorine at the 2-position.33 Comparing 14 with the 2-
chloro substituted 16, this modification did not alter the affinity nor the efficacy in this 
series. 
 
An overall conclusion is that, contrary to the 3’-aminomethyl modification, the simple 
3’-amino is better tolerated in terms of affinity and efficacy, resulting at best in 
(strong) partial agonists with moderate binding properties (as in analogues 14, 16 
and 19) and low hA3AR affinity antagonists for the branched-chain derivatives, with 
exception of 20. In both series, the azido precursors (as in compounds 1-3, 11-13, 17 
and 18) were full antagonists. 
 
The 3’-amino modification has hydrogen bond donor properties like the 3’-hydroxyl 
group,33,39 37 whereas for the 3’-azido, like the 3’-F,  this hydrogen bond pattern is no 
longer possible, resulting in a drop of efficacy.38 For the branched-chain series, this 
difference in efficacy between the 3’-azidomethyl and 3’-aminomethyl analogues was 
less clear, which is most likely due to the steric impact of this modification. 
 
 
4.3 Conclusion 
 
From a pharmacological point of view the modulation of hA3AR activity by selective 
agonists, partial agonists and antagonists is very important. We investigated the 
influence on affinity, selectivity and intrinsic activity of combined modifications at the 
3’- and 5’-positions of the ribofuranosyl moiety with purine modifications at the 2- and 
N6-positions. Various synthetic analogues displayed good hA3AR selectivity and 
moderate-to-high affinities. More interesting, however, was the ability to tune the 
efficacy depending on the substituent introduced at the 3’-position. A 3’-amino 
function (as in 14, 16 and 19) resulted in (strong) partial agonist activity, whereas the 
azide precursors (as in 11, 13 and 17) converted these analogues into antagonists. 
Introduction of a methylene spacer between these functionalities and the 
ribofuranose ring (as in 1-10, 12, 15, 18 and 20) had an overall efficacy- and affinity-
lowering effect. 
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 The (branched-chain) amino and azido modifications at the 3’-position presented 
here, open interesting perspectives towards tuning the efficacy and selectivity for the 
A3AR, starting from the adenosine agonist scaffold. Several analogues also represent 
valuable tools for the further exploration of the neoceptor concept, i.e. investigation of 
molecular complementarity at mutant A 39 41(Chapter 5)  and mutant A (Chapter 6)3 2A  
adenosine receptors. 
 
 
4.4 Experimental Part 
 
Biological evaluation was performed by the group of Dr. Kenneth A. Jacobson, at the 
Laboratory for Bioorganic Chemistry (NIDDK), NIH, Maryland, USA. For the detailed 
procedures on cell culture and membrane preparation, the binding assay and cyclic 
AMP accumulation assay we refer to the experimental part in our Bioorg. Med. 
Chem. research paper (2004, in press). 
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 5.1 Introduction 
 
Therapeutic intervention using agonists is subject to side effects related in part to the 
widespread occurrence of the corresponding receptor throughout the body.1,2 
Currently, the specificity of a given drug for a target organ is usually achieved 
through manipulation of its pharmacokinetic properties. Past attempts to overcome 
this problem included generation of prodrugs that were to be preferentially activated 
at the target organ, either through enhanced metabolic processes or through a 
unique enzymatic system characteristic to the organ.3 Our goal was to introduce and 
investigate a novel concept for therapeutic intervention at a specific anatomical 
and/or physiological locus, through a combination of receptor engineering, agonist 
design, and gene therapy. Elements of this potentially general approach include (a) 
engineering of a receptor protein to recognize synthetic ligands, for which it was 
selectively modified according to the molecular complementarity of the respective 
binding elements, while retaining its capacity for signal transduction (neoceptor); (b) 
synthesis of novel agonists that are not effective at the native receptor but do activate 
the engineered receptor (neoligand); and (c) a delivery vector to provide for selective 
expression of the neoceptor in the target area.  
 
One of the numerous cases where agonist therapy has been problematic due to the 
widespread occurrence of receptors is the adenosine receptor (AR) family. For 
example, the hypotensive and bradycardiac side effects of adenosine agonists have 
been in part responsible for the difficulty of developing adenosine-based therapeutics 
for cardio- and cerebropotection.1,3-6 The only adenosine agonist approved so far for 
clinical use has been adenosine itself, based on its short duration of action in the 
treatment of supraventricular tachycardia and in radionuclide imaging.7 Thus, 
engineering of novel receptor-ligand interactions in the adenosine receptor family, 
through specific tailoring of both the receptors and the ligands, would provide a 
suitable and relevant system for investigation of the neoceptor-neoligand concept.  
 
Adenosine is released in large amounts during ischemia and has been shown to be 
protective in the heart,8 5,9 brain,  and other organs. Adenosine, when elevated prior to 
ischemia in cardiac tissue,10,11 “preconditioned” the heart and protected it against 
injury during a subsequent period of prolonged ischemia. Synthetic agonists selective 
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 12for either A1AR or A AR simulated this preconditioning effect.3  The beneficial effects 
were seen following acute activation of A AR or chronic activation of A1 3ARs. In 
addition to cardioprotection, adenosine A3AR ligands have been proposed for the 
treatment of stroke,13 14 15 inflammation,  and glaucoma.  In a model of global brain 
ischemia in gerbils, both A1AR and A3AR selective agonists had protective effects,5 
as judged by the histochemical and behavioral outcome following recovery. Thus, 
there has been much interest in the development of new therapeutic agents acting at 
adenosine A3AR. 
 
Ligand recognition in adenosine receptors, principally A1AR and A2AAR, has been 
extensively investigated using mutagenesis and molecular modeling.16-20 The 
putative nucleoside binding site, which is highly homologous among subtypes of the 
adenosine receptors, is proposed to involve transmembrane helices (TMs) 3, 5, 6, 
and 7. Two conserved His residues (6.52 and 7.43, by the notation of van Rhee and 
Jacobson,21 see p. 61) in TMs 6 and 7 of A1AR and A2AAR are considered to be 
among the most important amino acids involved in binding to adenosine. An 
assembly of aromatic amino acid side chains in the human A2AAR, principally in TMs 
5 and 6, is proposed to recognize the adenine moiety. The ribose moiety is likely 
coordinated to hydrophilic residues in TMs 3 and 7.19,22,23 In fact, several hydroxyl-
containing residues, Thr88 (3.36) and Ser277 (7.42) of the human A2AAR, have been 
shown to be associated exclusively with agonist, but not antagonist, recognition.19,22
 
In the present study, we have utilized this hypothetical bound orientation of 
adenosine to identify a site on TM7 thought to be in proximity to the ribose moiety 
and amenable to introduction of a charged group intended for electrostatic interaction 
with the ligand. The site chosen was the conserved His (H272), which we have 
mutated to Glu. According to molecular modeling, this mutation would be expected to 
decrease the affinity of simple adenosine analogues,19,23,24 except when strategically 
modified by the introduction of an amino group on the ribose moiety. Since alteration 
of the ribose moiety substitution pattern was also known to greatly diminish the 
affinity at adenosine receptors,25 such substitution would ensure that the neoligand 
would not activate endogenous receptors at an effective concentration for the 
neoceptor. Our results suggested both the viability of the neoceptor-neoligand 
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 concept and the need for further optimization of the A3AR neoceptor-neoligand 
interactions. 
 
 
5.2 Results 
 
5.2.1 Design of a neoceptor: Creation of a mutant A3AR that is activated 
selectively by novel agonist derivatives 
 
On the basis of previous studies of ligand recognition in adenosine receptors,16,19,23,24 
a His residue in TM7 of the A3AR was selected as the site for mutagenesis, i.e. the 
introduction of a negative charge to be complementary to an amine derivatized 
ligand. We examined the recognition of both known adenosine ligands (Figure 5.1) 
and synthetic agonist analogues (Figure 5.2) designed as neoligands, for selective 
recognition by the H272E mutant receptor (see below). 
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Figure 5.1 Known A3AR agonists (1-5) and antagonists (6-8). Wild-type and mutant receptor 
affinities appear in Table 5.1. 
 89
 NO
N
N
OH
N
NH2
OH
NH2
NO
N
N
OH
N
NH2
NH2
OH
NO
N
N
OH
N
NH2
OH
N
H
NH
NH2
NO
N
N
OH
N
N
H
OH
NH2
NO
N
N
OH
N
N
H
OH
NH2
I
NO
N
N
N
N
H
N
H
NH2
I
O
Cl
NO
N
N
OH
N
NH2
N
H
NH2
ONH2
1'
2'3'
4'
5'
3 1
7
9NO
N
N
NH2
N
NH2
OH
OH
9 10 11
12 13 14
15 16  
 
Figure 5.2 Derivatives of adenosine (9-16) tested as novel A3AR agonists. Wild-type and 
mutant receptor affinities appear in Table 5.2. 
 
 
5.2.2 Mutant vs wild-type A AR for known adenosine receptor ligands 3
 
The receptor binding affinities of various adenosine agonist and antagonist 
derivatives were measured in standard binding assays using wild-type and H272E 
mutant human A 125  4263ARs. The high affinity of the radioligand [ I]I-AB-MECA  was 
retained in the mutant receptor, thus enabling the determination of the affinities of a 
wide range of competing ligands. Ki values for these ligands are shown in Table 5.1, 
and representative binding curves are shown in Figure 5.3. The closest mimic of 
adenosine itself was 2-chloroadenosine 2,27 which was 18-fold less potent in binding 
at the H272E mutant receptor than at the wild-type receptor. 
 
Table 5.1 Binding affinity of known adenosine agonists and antagonists at wild-type and 
mutant (H272E) human A3ARa,b
 
   (nM)   (nM) K Ki i
agonists WT H272E antagonists WT H272E 
 169±32 3200±770 253±87 3260±994 1 6 
 650±130 11600±4200 61.7±23.4 1690±343 2 7 
 4.3±1.6 20.1±3.6 110±45 20100±4500 3 8 
1.2±0.2 2.1±0.3    4 [125I]AB-MECA 
 1.6±0.3 9.9±2.6    5 
 
a bStructures provided in Figure 5.1. Results are from three independent experiments performed in 
duplicate, using [ I]AB-MECA at a concentration of 1 nM. 125
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Figure 5.3 Binding of known A3AR agonists and antagonists to wild type and mutant 
receptors ((■), wild type; (▲), H272E mutant receptor). 
 
 
In most other cases, the affinity of competing ligands 1-8 was significantly reduced in 
the mutant receptor. For example, compound 1 was 19-fold less potent at the mutant 
receptor than the wild-type receptor. The potent antagonist 8,19 which contains a 
distal amino group, was 180-fold less potent at the mutant than the wild-type 
receptor. Other ligands, such as potent A 13,283AR agonists 3 and the rigid analogue 5,  
were shifted to lower affinity in binding to the mutant receptor by smaller factors, i.e. 
5- and 6-fold, respectively. 
 
 
5.2.3 Synthesis of neoligands 
 
The amino derivatives of adenosine 9-10, the N6-substituted 13, and a 5′-uronamide 
16 were available from previous synthetic efforts.29-31,35 Derivative 11 was
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 commercially available from Sigma Chemical Co. Preparation of 3’-
guanidinoadenosine (12) is discussed in J. Med. Chem. 2001, 44, 4125. Synthesis of 
the N6-iodobenzyladenosine analogue 14 is described in Part I.  
 
 
5.2.4 Binding to mutant vs wild-type A AR 3
 
The receptor binding affinities of amine-functionalized adenosine derivatives were 
measured in standard binding assays using wild-type and H272E mutant human 
A 6,26,32,333AR expressed in COS-7 cells.  Ki values for these ligands are shown in 
Table 5.2, and representative binding curves are shown in Figure 5.4. 
 
Table 5.2 Binding affinity of amine-derivatized adenosine analogues at wild-type and mutant 
(H272E) human A a,b3AR and rat adenosine receptors
 
   (μM)  (μM) K Ki i
compound WT H272E compound WT H272E 
9 c   301±142 0.54±0.13   0.19±0.08 13 
442±121   75±32 0.87±0.18   0.32±0.10 10 14 
11 c   425±217 4.6±1.3     2.3±0.57 15 
12 130±340 33.3±7.1 16 19.6±3.10   9.6±3.5 
 
a bStructures provided in Figure 5.2. Results are from three independent experiments performed in 
duplicate, using [125I]AB-MECA at a concentration of 1 nM at human A3AR expressed in COS-7 cells 
cIC50 values of compounds 9 and 11 at the wild type receptor were estimated to be approximately 1 
mM. The inhibition of [125I]AB-MECA binding by 9 and 11 at the highest concentration examined (1 
mM) was 51 and 54%, respectively.  
 
 
The introduction of an amino group on the ribose moiety of adenosine resulted in 
either equipotency or enhanced binding affinity at the H272E mutant relative to wild-
type A3AR, depending on the position of the amino group. 3′-Amino-3′-
deoxyadenosine 10 proved to be 7-fold more potent at the H272E mutant than the 
wild-type receptor. Two other isomers, 2′-amino-2′-deoxyadenosine 9 and 5′-amino-
5′-deoxyadenosine 11, an inhibitor of adenosine kinase,34 did not display significantly 
enhanced affinity. The affinity of a 3′-guanidino analogue 12 was enhanced by 4-fold 
in the mutant versus wild-type receptors. A 2-aminoethyl analogue of 1, i.e. 1635 was 
only 2-fold more potent at the mutant receptor. A 3′-amino-N6-iodobenzyl analogue, 
14, showed a 3-fold enhancement at the mutant vs wild-type receptors, with a Ki 
value of 320 nM. 
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Figure 5.4 Binding of novel adenosine derivatives at wild-type and H272E mutant adenosine 
A3AR ((■), wild type; (▲), H272E mutant receptor). 
 
 
The ability of both mutant and wild-type receptors to activate second messengers 
was demonstrated. Both compounds 2 and 13 at 10 μM inhibited cyclic AMP 
production36 stimulated by forskolin in COS-7 cells expressing either the wild-type or 
H272E mutant receptor (Figure 5.5). Furthermore, both the wild-type and H272E 
mutant receptors in the presence of 10 μM of compound 3 were shown to fully 
activate phospholipase C (data not shown), as determined by the method reported.37 
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Figure 5.5 Cyclic AMP production by COS-7 cells expressing wild-type and H272E mutant 
human A3AR after addition of compound 2 (10 μM) or compound 13 (10 μM). Values are 
means (SEM of three independent experiments performed in duplicate. For values marked 
with an asterisk, P < 0.05 compared with control. 
 
 
5.2.5 Molecular modeling 
 
A model of the human A3AR was built in homology to the recently published X-ray 
structure of bovine rhodopsin.38 The model included the seven TMs and the second 
extracellular loop (EL2). In this model, residue His272 was within interaction distance 
from Glu19 (1.39) in TM1 (see Nπ-Oε distance, 2.40 Å; Figure 5.6A). An analogous 
interaction had already been proposed for the A AR,23,242A  in order to explain the 
observed involvement of both residues in agonist binding. In the present model, the 
carboxylate group of Glu19 appeared to interact also with Tyr265 (7.36) and Ser73 
(2.65), resulting in a relatively rigid juxtaposition of the imidazole moiety of His272 
relative to other elements of the ligand binding environment (Figure 5.6B). 
 
Examination of the optimized model of the 2-A3AR complex showed that the N6-
amine nitrogen was located within H-bonding distances of the amide oxygen of 
Asn243 (6.50) and Oγ of Ser247 (6.52). The 2′-hydroxy substituent of the ribose ring 
was adjacent to both the Oε of Gln167 and Nζ of Lys152. The corresponding          
3′-hydroxy substituent was within H-bonding distance from His272, and the 5’-oxygen 
interacted with Ser271 (7.42) and Asn274 (7.45) in TM7. Thus, 2 seemed to
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Figure 5.6 (A) Details of the putative H-bonding interactions among residues in proximity to 
the binding site of the human A3AR either in the native receptor (His in blue and white) or for 
the H272E mutant (Glu in yellow). H-bonding distances to the carboxylate group of Glu19 are 
shown. (B) Docked conformation of non selective adenosine agonist 2 showing its position 
with respect to critical residues in the putative binding site of the wild-type human A3AR. (C) 
Docked conformation of A3AR selective adenosine agonist 3 showing its position with respect 
to critical residues in the putative binding site of the wild-type human A AR. 3
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 be accommodated by interactions with residues of TMs 6 and 7 and of EL2, with both 
2′- and 3′-ribose hydroxy substituents proximal to basic residues. 
 
In the optimized model of the 3-A3AR complex (Figure 5.6C) the N6-benzyl 
substituent appeared to be wedged between TM5 and TM6, interacting with residues 
Phe182 (5.43), Ile186 (5.47), and Phe187 (5.48). Consequently, the whole ligand 
was displaced away from TM7, compared to the corresponding complex of 2. The N6 
was still within interaction distance from Ser247 but was over 5 Å away from the 
amide oxygen of Trp243. Furthermore, the 3′-hydroxy substituent did not seem to 
interact with His272 (the 3′-O-Nτ distance was 4.21 Å). Reorientation of the latter 
was prevented by interaction with Glu19 (see above). 
 
Modeling was used to test the hypothesis that an electrostatic interaction between 
the positively charged ligand and the now negatively charged ribose-binding region of 
the receptor led to the affinity enhancement of 10 at the H272E mutant receptor. 
Replacement of His272 by glutamate resulted in a structure with two adjacent 
carboxylates, one of which was most likely protonated. Since the mobility of Glu19 
was restricted by interactions with Tyr265 and Ser73, the carboxylate group of 
Glu272 was held in an orientation that prevented a direct H-bond interaction with the 
3′-hydroxy ribose substituent (Figure 5.6A). This was consistent with the 20-fold 
lower affinity of the H272E mutant toward agonists, such as 1 or 2, while the 
corresponding effect on the agonists related to 3 was much smaller. The notion that, 
due to the H272E mutation, a polar interaction was lost was also consistent with the 
15-20-fold affinity decrease of the mutant receptor toward the three antagonists 
examined (Table 5.1). In all of those cases, modeling suggested that Glu272 could 
not replace His in accommodating the A3AR ligands through H-bonding interactions. 
 
 
5.3 Discussion 
 
We have investigated an approach to target agonist therapy to a specific organ or 
tissue based on selective activation of mutant receptors by synthetic ligands. Toward 
this goal we have both mutated the A AR and chemically modified the corresponding 3
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 agonists, aiming to preserve the structural complementarity required for agonist 
function.  
 
On one hand, adenosine analogues carrying modifications of the ribose 2′- and 3′-
substituents were known to be mostly inactive as agonists.25 Thus, we concentrated 
on aminoadenosines in order to avoid activation of the wild-type A3AR. On the other 
hand, simple aminoadenosines were nearly isosteric with the corresponding 
adenosines, implying that the former could act as agonists, provided a proper 
juxtaposition of its binding elements with those of an appropriate receptor could be 
achieved. For instance, introduction by mutagenesis of an acidic residue within the 
ligand binding site could have resulted in an electrostatic interaction with the amine 
substituent of the ligand. 
 
Position 272 on TM7 of the human A3AR (7.43) was selected for such mutagenesis, 
since it appeared to play an important role across the GPCR family. In rhodopsin, this 
is the location of the Lys residue that forms a Schiff base with retinal. In all four of the 
adenosine receptors this site is occupied by His, which has been proposed to be 
critical for recognition of the ribose or ribose-like moiety common to all adenosine 
agonists thus far reported. At the A3AR, His at this site was proposed as the basis for 
enhanced affinity of xanthine-7-ribosides relative to the parent xanthines.27 In the 
A1AR, mutation of this His to Ala resulted in decreased affinity of both agonists and 
antagonists. In the A2AAR, this site has been mutated to Ala with the loss of high-
affinity binding of both agonists and antagonists,19 while mutation to Tyr preserved 
the ability to bind ligands.24 Thus, substitution that preserved H-bonding capability 
was allowed at this critical site. Substitution of His272 with Glu was the first example 
of a non aromatic residue at this position in adenosine receptors that still allowed 
ligand recognition. It was especially surprising in light of the proposal that in the 
human A2AAR this His appeared to be coupled spatially to a Glu in TM1 through the 
formation of a H-bond.24 
 
The affinities of the aminoadenosine analogues 9-16, for the H272E mutant A3AR 
were higher than for the corresponding wild type, demonstrating that in principle 
A3AR could be engineered for selective interaction with synthetic agonists. In 
particular this was evident from the 7-fold affinity enhancement of 10 toward the 
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 mutated receptor. Thus, the notion that the H272E mutant A3AR could be selectively 
activated in the presence of wild-type A3AR appeared feasible. 
 
The role of residue His272 in accommodating A AR3  agonists and antagonists, as well 
as the consequences of its replacement by glutamate were investigated by molecular 
modeling19,23 of the ligand-receptor complexes. The 3′-amino group was intended for 
a direct electrostatic interaction with the negatively charged ribose-binding region of 
the mutant receptor, yet molecular modeling did not support this notion. In brief, the 
higher affinity of 3′-amino-3′-deoxyadenosine at the engineered A3AR appeared to 
result from the lack of a repulsion (positively charged ligand and a positively charged 
His272 side chain in the WT receptor), rather than the attractive force of opposite 
charges. It is also possible that a water molecule fills the space between the 3′-amino 
group and Glu272, thus allowing water mediated H-bonding. 
 
Previous models of an interaction between His278 of A2AAR (position equivalent to 
272 in the A 233AR)  and adenosine suggested the involvement of both of the ribose 
secondary hydroxy substituents on binding. Yet substitution of glutamate at position 
272 had a larger effect on 10 than on 9, indicating that His/Glu272 interacted 
predominantly with the 3′-ribose substituent. Conversely, for aminoadenosines where 
N6 was substituted by a cycloalkyl (13) or iodobenzyl (14, 15), the effect of Glu272 
was small, irrespective of the position of the amino ribose substituent (Table 5.2).  
 
From molecular models of the human A3AR complexed with 10 (Figure 5.7) it 
appears that the nearly 1000-fold lower affinity, relative to 2, results from a loss of a 
H-bond interaction of the 3′-hydroxy substituent and the electrostatic repulsion of the 
3′-amine substituent and His272. Replacement at position 272 by glutamate did not 
restore binding with the 3′-substituent. As already mentioned Glu272 was not 
available for direct contact with the ligand due to an interaction with Glu19. The gain 
of affinity for the aminoadenosines seemed therefore to depend on relief of 
electrostatic repulsion, being more pronounced for 10 than for 13 and 14, where the 
ligands would be displaced toward TM5 (including the 3′-amine substituent). 
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Figure 5.7 Docked conformation of the neoligand 10 in relation to the helical bundle and EL2 
of the wild-type human A3AR (A) and H272E mutant human A3AR (B). View from the the 
extracellular region (showing TM side chains mentioned in the text). 
 
 
The notion that Glu272 did not interact directly with the ligands was consistent with 
the finding that the A3AR affinity toward N-benzyl-substituted analogues (i.e. 3, 4 and 
5) was less sensitive to the nature of the residue at position 272. On the other hand, 
the corresponding affinity toward 2 was 20-fold lower (Table 5.1). Furthermore, the 
affinity of the H272E mutant A3AR toward 2 was only 7-fold higher than that toward 
the 3′-amino derivative 10, suggesting that the binding environments for the two 
ligands were similar. In fact, the lower affinity toward 10 was likely due to repulsive 
interactions with Lys152, which, according to our model, was vicinal to the 2′-hydroxy 
substituent. This proximity may also be responsible for the low affinity of the human 
A3ARs toward the aminoadenosine 9. 
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 The lack of Glu272 participation in ligand accommodation, in particular in interaction 
with 3′-aminoadenosines, due to its interaction with Glu19 suggests that replacement 
of Glu19 by a residue that would not restrict the mobility of Glu272 may result in a 
receptor with considerably higher affinity toward aminoadenosines such as 10 and 
14. Replacement of Ser73 by a non polar residue such as Ala, on the other hand, 
may allow enhanced mobility of the Glu272-Glu19 assembly toward TM7 (see 
above), bringing the Glu272 carboxylate within interaction distance of the ligands. 
Thus, the doubly mutated H272E/E19X and H272E/S73X mutant A3ARs may be 
more suitable as neoceptors for the aminoadenosine neoligands. Alternatively, on 
neoligand level, the introduction of a methylene spacer between the ribose sugar 
moiety and the amine function (by-passing the restricted mobility of Glu272), should 
enhance the affinity of aminoadenosines such as 10 and 14. In fact this is what 
inspired us to synthesize the branched-chain derivatives mentioned in Chapter 4. 
Unfortunately, due to stable expression problems of the A3 neoceptor, these 
analogues have not been evaluated yet for this purpose. 
 
The notion that GPCRs can be engineered to accommodate unnatural ligands has 
been investigated in other cases. Schwartz and co-workers39,40 engineered GPCRs 
to have the ability to bind zinc ions through complexation with multiple His residues. 
More recently Conklin and co-workers41 engineered the κ opioid receptor to respond 
exclusively to small molecule ligands and not to the receptor’s natural ligand. In this 
study, impressive selectivity toward bremazocine was achieved, demonstrating the 
extent to which receptor properties could be modified without compromising 
functionality. Strader and co-workers42 also studied the microscopic complementarity 
of functionality in receptor binding. However, no attempt was made to modify both the 
receptors and the ligands in the manner proposed in the present study. 
 
The feasibility of a tailor-made agonist (neoligand) to interact selectively with a 
mutant receptor (neoceptor) opens interesting perspectives for a (futuristic) 
therapeutic approach, in which such a neoceptor would be introduced specifically into 
a target organ through gene transfer.43,44 Gene transfer to the heart has been 
demonstrated,45-47 and gene therapy toward the goal of cardioprotection has already 
been proposed.4 The transfection of the A1AR or A3AR into a cardiac myocyte culture 
enhances the protective effect of either endogenous adenosine or an exogenously 
 100
 added, synthetic agonist of the appropriate receptor. By this approach, a neoceptor 
could be genetically delivered to a target organ, followed by the administration of a 
selective, tailor-made ligand, as needed. 
 
 
5.4 Experimental section 
 
Biological evaluation and molecular modeling was performed by the group of Dr. 
Kenneth A. Jacobson, at the Laboratory for Bioorganic Chemistry (NIDDK), NIH, 
Maryland, USA. For the detailed procedures on the preparation of mutant receptors, 
radioligand binding studies, cyclic AMP assay and molecular modeling we refer to the 
experimental part in our J. Med. Chem. paper (2001, 44, 4125). 
 
 
5.4.1 Chemistry 
 
Commercially available compounds 1-3, 6, 8 were from Sigma Chemical Co. 
Compound 528 was available from previous synthetic efforts. Compound 751 was the 
gift of Prof. Ad IJzerman of the LACDR, Leiden, The Netherlands. 
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 CHAPTER 6 
MODELING THE ADENOSINE RECEPTORS: 
AR AGONISTS AND ANTAGONISTS COMPARISON OF THE BINDING DOMAINS OF A2A
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 6.1 Introduction 
 
As mentioned in Chapter 3-5 adenosine receptors (ARs), classified as A1, A2A, A2B, 
and A3 subtypes, represent a physiologically and pharmacologically important family 
of G protein-coupled receptors (GPCRs).1
 
A2AAR agonists are also potentially useful for the treatment of cardiovascular 
diseases, such as hypertension, ischemic cardiomyopathy, inflammation, and 
atherosclerosis,2 and A2AAR antagonists have been proposed as novel therapeutics 
for Parkinson’s disease and may also be active as cognition enhancers, 
neuroprotective and anti-allergic agents, analgesics, and positive inotropics.3-5 
Although the physiological effects mediated through the A2AAR have been 
extensively investigated, only a few molecular modeling studies, which used a low-
resolution rhodopsin template,6,7 have explored the binding properties of agonists 
and antagonists at the A2AAR. The development of more potent and/or selective 
A AR agonists and antagonists is still being pursued intensively. 2A
 
Extensive mutagenesis was carried out for both the A AR and A1 2AAR and to a lesser 
extent for the A2BAR and A3AR.1,8 9 The retinal binding site of rhodopsin,  a G protein-
coupled photoreceptor, and the putative ligand binding sites on ARs, as deduced by 
using mutational analysis, overlap extensively. Most of the essential residues 
required for recognition of AR agonists and/or antagonists, which bind within the 
transmembrane helical domains (TMs) 3, 5, 6, and 7,1 coincide largely with the 
corresponding amino acids of the binding site of cis-retinal in rhodopsin, although 
there are additional interaction sites within TMs 6 and 7 of the ARs. 
 
In this chapter, a three-dimensional model of the A2AAR was studied, based on the 
high-resolution structure of rhodopsin as a template.7 We describe a comparison of 
the binding characteristics of A2AAR agonist and antagonist ligands (Figure 6.1). We 
also made comparisons to our previously A 10,11 3AR model (Chapter 5), which was 
derived with similar methods. Finally, the model was tested experimentally by making 
complementary changes in the structures of agonist ligands (e.g. introduction of 
amino groups into known ligands, resulting in adenosine derivatives 5-8; Figure 6.2) 
and the A 12 AR, to form neoceptor-neoligand pairs.2A
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Figure 6.1 Structures of the known A2AAR agonists and antagonists used in initial receptor 
docking. 1, CGS15943, non selective antagonists; 2, A2AAR-selective antagonists; 3, non 
selective agonist; 4, A AR-selective agonist (rA AR: 3.5 nM, rA2A 2A 1AR: 1017 nM, A1AR/A2AAR: 
291).18
 
 
6.2 Results and discussion 
 
6.2.1 Synthesis of neoligands 
 
The amino derivatives 5 was commercially available from Sigma Chemical Co. and 8 
was available from previous synthetic efforts.13 Synthesis of adenosine nucleoside 
analogues 6 and 7, modified at the 3’- and N6-position, is described in Part I. 
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Figure 6.2 Structures of the A2AAR agonists containing amino groups for electrostatic 
interaction with negatively charged side chains of mutant A2AARs. Compounds 5, 6, and 8 
were used in the previous neoceptor study of the A 173AR.
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 6.2.2 Construction of the A2AAR molecular model 
 
Construction of the A2AAR molecular model and molecular modeling was performed 
by the group of Dr. Kenneth A. Jacobson, at the Laboratory for Bioorganic Chemistry 
(NIDDK), NIH, Maryland, USA. For the detailed procedures regarding these topics we 
refer to J. Med. Chem. 2003, 46, 4847. 
 
 
6.2.3 Binding of a known agonist and antagonist to mutant human A2AARs 
 
A variety of negatively charged side chains were substituted in the A2AAR at 
hydrophilic positions in TMs 3 and 7 predicted to be in proximity to the bound ribose 
moiety. Radioligand binding studies showed that T88D and T88E mutant receptors 
were able to bind the non selective AR antagonist 1 but not the non selective AR 
agonist 3 (Figure 6.3 and Table 6.1). Similarly, the T88A mutation was already shown 
to substantially decrease agonist but not antagonist affinity.14 For the Q89D mutant 
receptor, the binding affinity of agonist 3 was increased approximately 14-fold. Its Ala 
mutation also increased agonist and antagonist binding affinity and its H/R mutation 
affected only antagonist affinity.14 However, S277E, H278D, and H278E mutations 
did not affect the binding of either the agonist 3 or the antagonist 1. These findings 
contrasted with the selective decrease of agonist affinity in the S277A mutant 
receptor and the inability of the H278A mutant receptor to bind either agonist or 
antagonist radioligand.6 A total of six mutations-T88D, T88E, Q89D, S277E, H278D, 
and H278E-did not alter the binding affinity of the antagonist 1. 
 
 
6.2.4 Ligand docking 
 
A crystallographic determination of the human A2AAR structure would be a better 
method by which to analyze the conformational implications of our mutagenesis 
experiments; however, presently no structure is available. While such studies are 
underway,15 no structure of close homology to the receptor is available. Thus, we 
resorted  to  the  widely  used,   however  imprecise,   method   of   rhodopsin-based
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Figure 6.3 Effect of the antagonist CGS15943 1 and agonist NECA 3 on the binding of the 
radiolabeled antagonist [3H]ZM241385 to the human A2AAR. Membranes (10-20 μg of 
protein) from COS-7 cells transfected with wild type (■) or mutant receptors of T88D (▼), 
T88E (♦), Q89D (●), S277E (□), H278D (▲), or H278E (▼) were incubated with 1.0 nM 
[3H]ZM241385 in duplicate, together with increasing concentrations of the competing 
compounds, in a final volume of 0.4 mL of Tris HCl buffer (50 mM, pH 7.4) at 25 °C for 120 
min. Results were from a representative experiment. 
 
 
homology modeling of Family 1 GPCRs. Rhodopsin-based homology modeling is not 
an automatic method for obtaining a realistic structure for a given GPCR, but rather 
requires time-consuming custom treatment according to known pharmacological 
data.16 Here, both agonists and antagonists were docked in the human A2AAR model. 
In general, docking of agonists to GPCR models is subject to even greater 
uncertainty than antagonist since the template consists of the inactive state of 
rhodopsin.  
 
Table 6.1 Binding affinity of the antagonist 1 and the non selective agonist 3 at WT and 
mutant human A a ARs2A
 
 (nM) or % displacement  Ki
mutant receptor 1 3 
0.84±0.22 21.4±8.7 WT 
0.91±0.09 T88D 20% at 10 μM 
0.67±0.17 T88E   0% at 10 μM 
   0.35±0.12 1.5±0.4 Q89D 
1.0±0.3 29.2±6.3 S277E 
0.41±0.14 19.1±3.4 H278D 
0.52±0.06 24.6±8.3 H278E 
 
aMembranes from COS-7 cells transfected with WT or mutant A2AAR cDNA were incubated with 1.0 
nM [3H]ZM241385 in duplicate, together with increasing concentrations of the competing compounds, 
in a final volume of 0.4 mL of Tris HCl buffer (50 mM, pH 7.4) at 25 °C for 120 min. The Ki values are 
expressed as mean ± standard error from three independent experiments. 
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 Often multiple modes of docking of a given agonist or antagonist ligand are 
observed.17 Selection of preference of one docking mode in such cases is based on 
diverse pharmacological data, rather than on computational results alone. In the 
present study, the introduction of complementary functional groups on the ligand and 
receptor is meant to overcome the problem of ambiguity of docking modes in GPCR 
modeling. 
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Figure 6.4 The complex of the A2AAR with agonists and antagonists: (A) 1, a non selective 
antagonist; (B) 2, an A2AAR-selective antagonist; (C) 3, a non selective agonist; (D) 4, an 
A AR-selective agonist. All ligands are represented in yellow. The amino acids of the A2A 2AAR 
that are depicted in red and orange participated in the hydrophilic and hydrophobic 
interactions, respectively. 
 
 
The most general structural distinction between agonists and antagonists is that only 
an agonist requires a ribose ring, or more specifically, the 3′- and 5′-ribose 
substituents that interact directly with the A2AAR. To explain the different binding 
properties of antagonists and agonists at the A AR, representative ligands were 2A
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 were docked within the human A2AAR model. The result showed overlapped binding 
modes for antagonists and agonists (Figures 6.4 and 6.5). 
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Figure 6.5 Detailed interactions with 1 (A) and 3 (B) in the putative A2AAR binding site. The 
residues in the double-squared box are highly conserved among G protein-coupled 
receptors, and those in the single-squared box are conserved amino acids among ARs. 
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 6.2.5 Agonist binding 
 
Our present model is consistent with several experimental results concerning 
recognition of ribose-containing ligands (i.e. adenosine agonists): (1) The hydrophilic 
interactions at S277 (7.42)  and H278 (7.43) were required for high-affinity binding of 
agonists but not antagonists.14 The toleration of ligand binding in the S277E and 
H278D/E mutant receptors suggested that the acidic residues in the mutant receptors 
retained the ability to form an H-bond with the ligand, i.e. at the 3′-OH group. With 
respect to the 5′-carbonyl group of 3, the model suggested that a weak H-bond, or 
alternately a water mediated H-bond, was possible. (2) Radioligand binding studies 
(Figure 6.3 and Table 6.1) showed that T88D and T88E mutant receptors were able 
to bind the antagonist 1 but not the agonist 3. Similarly, the T88A mutation was 
already shown to substantially decrease agonist but not antagonist affinity.14 Thus the 
reason that mutation of T88 was specific for diminishing the affinity of the ribosides 
appeared to be the proximity of this residue to agonists but not antagonists based on 
the docking result. (3) Replacement of H278 with other aromatic residues was not 
tolerated in ligand binding.6 
 
To better understand the increase of A2AAR selectivity on substitution of the             
2-position of the adenine ring, we performed the docking of the (E)-2-phenylpentenyl 
derivative of NECA 4.18 Additional hydrophobic interactions between the 
phenylpentenyl moiety at the 2-position of the adenine ring and the hydrophobic 
pocket formed from TM4 and TM5 increased the A2AAR affinity, similar to the result 
shown for the A2AAR-selective antagonist binding. The interaction sites of the 
additional phenyl rings were very close to each other. The superimposition of the 
bound conformations of the A2AAR-selective agonist 4 and antagonist 2 in their 
putative binding sites demonstrated the partial overlap of the binding sites of the 
adenine and triazolopyrimidine rings and their C-2 and N7 substituents (Figure 6.6). 
 
The A2AAR complex with its agonist showed a preference for the intermediate 
conformation about the glycosydic bond. There might be subtle differences in binding 
requirements, conformational preferences, and local environments among subtypes 
of ARs, although most of the amino acid sequences in the putative binding sites (TM 
regions) are conserved among the four types of ARs. The electrostatic potential 
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 maps of the A AR and A2A 3AR showed some differences in the shape and 
electrostatic nature of their binding sites near the second extracellular loop (Figure 
6.7). 
 
 
 
Figure 6.6 Superimposition of the bound conformations of the A2AAR-selective antagonist 2 
and agonist 4 in the putative binding sites. The colors represent atom type. 
 
 
6.2.6 Conformational hypothesis for activation of the A2AAR 
 
Agonist binding was significantly different than antagonist binding in the region of the 
ribose ring, as expected from the requirement for a ribose ring in the agonist but not 
in the antagonist. Thus, the putative ribose-binding region is probably involved in 
receptor activation. For the A3AR,10 Jacobson and co-workers tried to gain insight 
into the distinct structural requirements for binding and activation by using ligand 
effects on cyclic AMP production in intact CHO (Chinese hamster ovary) cells and 
docking a few adenosine analogues. An interesting result concerned the conserved 
W243 (6.48) side chain in the A3AR, which was involved in recognition of the 
classical (non nucleoside) A3AR antagonists but not adenosine-derived ligands and 
which displayed a characteristic movement (counter clockwise rotation, as viewed 
from the exofacial side) exclusively upon docking of agonists.10 We concluded 
similarly for the A2AAR that a significant distinction between agonists and antagonists 
was whether ligand binding could effect the movement of W246 (6.48) side chain 
(Figure 6.4). Additional binding of the ribose 5′-substituents shown in the agonist 
complex induced the movement of the side-chain of W246 (6.48). That 
conformational change might disrupt a network of H-bonding of W246 (6.48), as well 
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Figure 6.7 Electrostatic potential map made with the Grasp program. Putative binding sites 
of the A AR (top) and A2A 3AR (bottom), with the second extracellular loop removed from the 
extracellular view. NECA 3 is represented as a stick model. Blue and red color potential 
indicates the electronic positive and negative, respectively. 
 
 
 as hydrophobic interactions of W246 (6.48) with residues from TMs 3, 6, and 7, thus 
facilitating a conformational change upon receptor activation. If the A2AAR behaves 
like the A 10AR,3  then flexibility of the ribose moiety and specific recognition elements 
at the 3′- and 5′-positions, to permit the movement of TM6, would be important for 
agonism at the A2AAR. The modeling result indicated that the overall flexibility and 
binding elements of the ribose ring were important for distinguishing the receptor 
interactions of agonists and antagonists. It also correlated with recent studies19 
based on electron paramagnetic resonance and fluorescence spectroscopy, which 
suggested an outward movement of the cytoplasmic end of TMs 3 and 6, as well as 
an anticlockwise rotation of TM6 around its helical axis as viewed from the 
extracellular side. 
 
 115
 6.2.7 Amino derivatives of adenosine as neoligands for neoceptors derived 
from the A2AAR 
 
10The current model, like the A AR model,3  suggested the ribose moiety was in 
proximity to hydrophilic residues of TM3. This hypothesis was tested experimentally 
by making complementary changes in the structures of the agonist ligand (i.e. 
introducing a positively charged ammonium group) and the receptor (i.e. introducing 
a negatively charged carboxylate group) to provide a new electrostatic interaction as 
the basis of neoceptor-neoligand pairs. Four amino derivatives (Figure 6.2) were 
tested in binding to a variety of Asp and Glu mutant receptors (Table 6.2). The 5′-
aminoethyluronamide 8 (equivalent to appending an amino group at the end of the 5′-
substituent of 3) displayed a large selective enhancement in binding to the T88D 
mutant receptor (Figure 6.8). Also, compound 7 displayed a significant enhancement 
of affinity at the same mutant receptor. However, other possible electrostatic 
interactions of the ribose 3′-amino groups of compounds 6 and 7 with negatively 
charged mutant receptors, such as H278E, as suggested in the model, were not 
supported in the binding assay. 
 
Table 6.2 Binding affinity of amino derivatives of adenosine (see Figure 6.2) at wt and 
mutant human A a ARs2A
 
  (μM) Ki
mutant receptor 5 6 7 8 
543±51   67±13   79±16 46.1±4.2 WT 
     407±142 18±7   6.5±1.9 4.4±1.6 T88D 
   57±19   492±161 57±8   64±28 T88E 
   52±9   6.4±0.9   58±18 3.6±1.0 Q89D 
  604±125   88±36   67±11 41±8 S277E 
  -   87±36   59±19 121±32 H278D 
     - 64±5 56±6 72±14 H278E 
 
aMembranes from COS-7 cells transfected with WT or mutant A2AAR cDNA were incubated with 1.0 
nM [3H]ZM241385 in duplicate, together with increasing concentrations of the competing compounds, 
in a final volume of 0.4 mL of Tris HCl buffer (50 mM, pH 7.4) at 25 °C for 120 min. The Ki values are 
expressed as mean ± standard error from three independent experiments. 
 
 
12For the docking studies of neoceptor and neoligand,  three mutant receptors (i.e. 
T88D, S277D, and H278E) were optimised through a molecular dynamics (MD) 
procedure after the mutation of each side chain. T88, S277, and H278 residues in the 
inactive state of A AR preferred the gauche (g) rotamer conformation, which also2A
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Figure 6.8 Effect of the amino derivatives of adenosine 5, 6, 7 and 8 on the binding of the 
radiolabeled antagonist [3H]ZM241385 to the human A2AAR. Membranes (10-20 μg of 
protein) from COS-7 cells transfected with wild type or T88D mutant receptor. Membranes 
were incubated with 1.0 nM [3H]ZM241385 in duplicate, together with increasing 
concentrations of the competing compounds, in a final volume of 0.4 mL of Tris HCl buffer 
(50 mM, pH 7.4) at 25 °C for 120 min. Results were from a representative experiment. The Ki 
values were from three independent experiments and are listed in Table 6.2. 
 
 
occurred in the bound state of the A2AAR/3 complex. However, in the T88D mutant 
receptor, the side chain of aspartate residue was in the trans (t) form, because of 
new H-bonding of the carboxylate group with N181 (5.42). Thus, there was a local 
conformational change with respect to the wild type in the position and direction of 
the aspartate side chain. This conformational change was consistent with the binding 
profile of the neoceptor. Initially, on the basis of the model of the unoccupied native 
A2AAR, the 5′-amino derivative 5 was expected to display an enhanced affinity for the 
neoceptor T88D. However, 5 did not display an increase of binding affinity, whereas 
compound 8 with the extended ammonium group was enhanced in affinity. 
 
The docking result of compound 8 (Figure 6.9A) suggested the possibility of the salt 
bridge and H-bonding between acidic residues of D88 and the terminal ammonium
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 ion, but the loss of H-bonding at the 3′- and 5′-position, as suggested in 3 binding to 
the wild-type A AR. 2A
 
 
 
 
 
Figure 6.9 Complex of the T88D neoceptor with neoligand. (A) Compound 8 with 5′-
aminoethyluronamide group. (B) Compound 7 with a 3′-aminomethyl group (represented in 
the protonated form). The neoligands are represented as ball-and-stick models. The 
intermolecular H-bonding between neoceptor and neoligand is displayed as yellow color. The 
W246 (6.48) of the T88D A2AAR in red shows the movement of the indole side chain upon 
ligand binding. 
 
 
Compound 7 was additionally substituted at the N6-position and also displayed 
binding enhancement at the T88D mutant receptor. In the docking of 7, a different 
binding mode that was energetically unfavorable in the A2AAR/3 complex was 
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 suggested, because with side-chain geometry that was identical to that of the 
A2AAR/3 complex, it was impossible for the 3′-ammonium group of 7 to interact with 
the side chain of D88. In its complex, the conjugation of H-bonding between D88 and 
3′-ammonium ion through the 2′-OH group was suggested. An additional interaction 
of the N6-benzyl group of 7 with the second extracellular loop, especially through 
hydrophobic interaction with F168, was evident in the model (Figure 6.9B); however, 
there was no interaction of the 5′-OH with this neoceptor. The conformational search 
of compounds 6 and 7 indicated that the lowest-energy conformer of compound 7 
had more stable intramolecular H-bonding of the 2′-OH group and the 3′-ammonium 
ion than was displayed by compound 6. It was consistent with the experimental 
result: i.e. compound 7 showed a greater increase of binding affinity to its neoceptor 
than compound 6 did. Thus, we identified new neoceptor (T88D)-neoligand pairs 
consistent with the theoretical model, even though the binding affinities to the T88D 
neoceptor were still low compared to the endogenous ligand binding to the wild-type 
A2AAR. 
 
 
6.3 Conclusion 
he molecular modeling results provided insight into the binding requirements for 
 
T
AR. Structural differences between the Aagonists and antagonists at the A2A 2AAR 
and the A3AR include the microenvironment surrounding docked agonist. Structural 
similarities between the A AR and the A2A 3AR include the hydrophobic region 
surrounding W246 (6.48), and the proposed rotation of TM6 to induce receptor 
activation. The introduction of a hydrophilic moiety such as ribose into an otherwise 
hydrophobic region destabilizes the inactive ground state of the receptor and thus 
would facilitate activation. Furthermore, this study is intended to facilitate further 
design of adenosine analogues targeted for improved A2AAR affinity and selectivity, 
i.e. neoceptor-neoligand pairs.12 The identification of the T88D receptor as a new 
neoceptor that may be activated selectively by synthetic ligands, such as 7 and 8. 
Moreover, the putative electrostatic interaction, which enhances affinity by anchoring 
the ligand in the agonist binding site, also serves to validate the model. 
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 6.4 Experimental section 
 
Biological evaluation and molecular modeling was performed by the group of Dr. 
Kenneth A. Jacobson, at the Laboratory for Bioorganic Chemistry (NIDDK), NIH, 
Maryland, USA. For the detailed procedures on site-directed mutagenesis, the 
transient expression of wild-type and mutant receptors in COS-7 cells, membrane 
preparation, radioligand binding assay, radioligand binding studies and molecular 
modeling we refer to the experimental part in our J. Med. Chem. paper (2003, 46, 
4847). 
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 PART III 
BIOLOGICAL EVALUATION OF 
THE MODIFIED THYMIDINE ANALOGUES 
 
 
 
 
 
 
 
 
 
 
Biological results in this part were published in: 
 
 
Eur. J. Org. Chem. 2003, 15, 2911. 
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 CHAPTER 7 
GENERAL BACKGROUND 
 
7.1 Pseudororation and conformational flexibility of nucleosides 
 
Due to its inherent flexibility the sugar ring of nucleosides, in solution, rapidly 
equilibrates between two extreme forms of ring pucker (Figure 7.1): 
- the north (N) or C3’-endo-C2’-exo conformation, and 
- the opposite south (S) or C2’-endo-C3’-exo conformation. 
 
Complete conformational definition of a nucleoside usually involves the determination 
of three structural parameters:1
- (1) the glycosyl torsion angle χ (Figure 7.1A-D), which determines the 
syn or anti position of the base relative to the sugar moiety (syn when 
the C2 carbonyl of pyrimidines or N3 of purines lies over the sugar 
ring, anti when these atoms are oriented in the opposite direction); 
- (2) the torsion angle γ (Figure 7.1C), which defines the orientation of 
the 5’-hydroxyl with respect to C3’ (represented are the three main 
rotamers; 
- (3) the puckering of the furanose ring and its deviation from planarity, 
which are described by the phase angle of pseudorotation2 P (0-360°, 
Figure 7.1B) and the maximum out-of-plane pucker νmax. 
 
The value of P depends on the five endocyclic sugar torsion angles ν0-ν4 (see 
below). By convention, a phase angle P = 0° corresponds to a N conformation, with a 
symmetrical twist form 3 2T2, whereas the S antipode, T3, possesses phase angle P = 
180°. The conformation of the furanose ring around the pseudorotational cycle 
alternates every 18° between envelope (E) and twist (T) conformations. The 
superscripts and subscripts represent, respectively, atoms displaced above and
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Figure 7.1 Pseudorotational cycle (center) illustrating the nucleoside ring pucker parameter 
P and description of other nucleoside structural parameters. Different twist (T) or envelope 
(E) form are obtained for every 18° torsion in the furanose ring angles from P = 0° to 360°.              
A General view and labeling of ring torsion angles ν0-ν4. B Description of maximum out-of-
plane pucker parameter νmax. C Definition of angle γ. D Definition of angle χ for a purine 
nucleoside. 
 
 
below the C4’-O4’-C1’ plane (relative to other atoms). Atoms displaced on the same 
side as C5’ are called endo, those on the opposite side are called exo. Although P 
and the torsion angles γ and χ are interdependent, the preferred ring pucker is known 
to be the strongest conformational parameters and is determined by the interplay of 
the anomeric and gauche effect.1,3
 
A broad definition of the anomeric effect is: “In a fragment C-X-C-Y, where ligand X 
carries one or two lone pairs of electrons and Y represents an electronegative ligand, 
the gauche conformers along the central X-C bond are preferred over the trans 
form.”4 In nucleosides and related sugars this means that an electronegative ligand L 
at C1’ is driven to adopt the pseudoaxial position (gauche C4’-O4’-C1’-L). Preference 
for a pseudoaxial position at C1’ means a drive toward the N form in the β-D-series (S 
form in the α-D-series). In practice, matters are complicated by the stereo-electronic 
competition at the anomeric center (C1’),5 and the fact that the anomeric strength of a 
given aglycon varies with the chemical nature of nearby substituents.6 The gauche 
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 effect describes the tendency of a vicinal fragment X-C-C-Y to adopt a gauche 
conformation along the central C-C bond in cases where X and Y represent 
electronegative ligands or electron pairs (although dipole-dipole repulsions and steric 
factors can work in favor of the antiperiplanar form).  
 
A standard method for assessing the solution conformation of a furanose ring 
involves the NMR measurement of three-bond 1 1 3H- H coupling constants ( JHH, of the 
ring hydrogens) and subsequent analysis of these data with the program PSEUROT.7 
This program assumes a model of equilibration between the north and south 
pseudorotational conformers. With knowledge of the five endocyclic torsion angles of 
a given conformer (ν0-ν4, see Figure 7.1A), P can be calculated through the use of 
equation 1.1 1 The puckering amplitude νmax is related to P and ν0 through equation 2.
 
tan P = (ν2 +ν4) – (ν1 + ν3) / (3.077*ν0)          (equation 1) 
 
νmax = ν0 / cos P          (equation 2) 
 
PSEUROT calculates the P and νmax values of the two conformers (and their mole 
fraction) that best fit the experimental 3JHH data. This is done by correlation of the 
experimental 3 HH (exocyclic H-C-C-H dihedral angles φJHH i ) to the corresponding 
endocyclic torsion angles (ν 8), through a generalized Karplus equation,i  from which P 
is calculated. The correlation of φ HH with ν  given by via equation 3. i i
 
HH = (A  φi i *ν ) + Bi Bi i = 0, 1, 2, 3, 4          (equation 3) 
 
In the initial parametrization of PSEUROT, A  and Bi Bi constants were determined for β-
ribofuranosyl and 2-deoxy-β-ribofuranosyl rings through the analysis of a database  
containing the crystal structures of 178 nucleosides and nucleotides. Using these 
values, estimates of A
9
 and Bii B  for other ring systems (e.g. β-arabinofuranosyl 
systems) were made,10 11 and these values are included in the 6.2 version  of 
PSEUROT. More recently, computational methods have been used to determine 
these constants for other ring systems.14
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 In the solid state, usually only one of the two solution conformations is present due to 
the influence of crystal packing forces.1,9 Recent studies suggest that the majority of 
enzymes15 16 and receptors  have strict conformational requirements for nucleoside 
substrate binding, i.e. only one conformational form is favoured in the active site. So, 
conformational data of nucleosides, both from (solid) X-ray structure or (solution) 
NMR analysis, has to be interpreted with care (in structure-activity-relationship 
studies), since the binding conformation is likely to be altered by the enzyme. In 
Chapter 8, we conducted a conformational analysis on thymidine analogues as 
TMPKmt inhibitors. The prepared derivatives (designed to show improved TMPKmt 
affinity) were only moderately active. Hence, we investigated more closely their 
conformational preferences in solution and correlated these findings with their 
probable enzyme bound conformation.17
 
 
7.2 References and notes 
 
1 (i) Altona, C.; Sundaralingam, M. J. Am. Chem. Soc. 1972, 94, 8205. (ii) Altona, C.; 
Sundaralingam, M. J. Am. Chem. Soc. 1973, 95, 2333. (iii) Saenger, W. Principles of Nucleic 
Acid Structure; Springer-Verlag: New York, 1984. 
2 (i) Kilpatrick, J. E.; Pitzer, K. S.; Spitzer, R. J. Am. Chem. Soc. 1947, 69, 2483. (ii) Pitzer, K. 
S.; Donath, W. F. J. Am. Chem. Soc. 1959, 81, 3213. 
3 Plavec, J.; Tong, W.; Chattopadhyaya, J. J. Am. Chem. Soc. 1993, 115, 9734. 
4 (i) The Anomeric Effect and its Associated Stereoelectronic Effects; Thatcher, G. R. J., Ed.; 
ACS Symposium Series; American Chemical Society: Washington, DC, 1993. (ii) Kirby, A. J. 
The Anomeric Effect and Related Stereoelectronic Effects at Oxygen; Springer-Verlag: 
Berlin, 1983. 
5 Krol, M. C.; Huige, C. J. M.; Altona, C. J. Comput. Chem. 1990, 11, 765. 
6 (i) Thibaudeau, C.; Földesi, A.; Chattopadhyaya, J. Tetrahedron 1998, 54, 1867. (ii) 
Thibaudeau, C.; Plavec, J.; Chattopadhyaya, J. J. Org. Chem. 1996, 61, 266. 
7 (i) van Wijk, J.; Haasnoot, C. A. G.; de Leeuw, F. A. A. M.; Huckriede, B. D.; Westra 
Hoekzema, A.; Altona, C. PSEUROT 6.2 1993; Leiden Institute of Chemistry, Leiden 
University. (ii) de Leeuw, F. A. A. M.; Altona, C. J. Comput. Chem. 1983, 4, 428. (c) Altona, 
C. Recl. Trav. Chem. Pays-Bas 1982, 101, 413. 
8 (i) Haasnoot, C. A. G.; de Leeuw, F. A. A. M.; Altona, C. Tetrahedron 1980, 36, 2783. (ii) 
Haasnoot, C. A. G.; de Leeuw, F. A. A. M.; de Leeuw, H. P. M.; Altona, C. Org. Magn. 
 128
 Reson. 1981, 15, 43. (iii) Altona, C.; Francke, R.; de Haan, R.; Ippel, J. H.; Daalmans, G. J.; 
Westra Hoekzema, A. J. A.; van Wijk, J. Magn. Reson. Chem. 1994, 32, 670. (iv) van Wijk, 
J.; Huckriede, B. D.; Ippel, J. H.; Altona, C. Methods Enzymol. 1992, 211, 286. 
9 De Leeuw, H. P. M.; Haasnoot, C. A. G.; Altona, C. Isr. J. Chem. 1980, 20, 108. 
10 De Leeuw, F. A. A. M.; Altona, C. J. Chem. Soc., Perkin Trans. 2. 1982, 375. 
11 3 When only three vicinal JHH coupling constants along the ring bonds exist, two of the five 
conformational parameters must be kept fixed during the minimization. This fixing is usually 
not much of a problem when the equilibrium is strongly one-sided (major form >85%) but 
may lead to wide ranges of possible conformational parameters otherwise. These ranges can 
be narrowed by increasing the ratio of the number of data points vs the number of 
parameters. To achieve this, two different strategies can be employed: (i) measurement of 
the NMR spectra over a wide range of temperatures; (ii) the inclusion of other coupling 
information in the calculation. Chattopadhyaya and co-workers have recently developed a 
new Karplus-type relation between vicinal proton-fluorine coupling constants and the 
corresponding H-C-C-F torsion angles including correction terms for substituent.13 The latest 
PSEUROT release (version 6.3) incorporates the published Karplus parameters for 3JHF and 
allows simultaneous analysis of 3  and 3J JHH HF experimental coupling constants, which greatly 
facilitates the conformational analysis of fluorinated furanose rings because of the increase in 
the number of experimental data points over the puckering parameters P and ν 14max.  The 
conformational analysis of the thymidine analogues in Chapter 8 was performed with the 
PSEUROT 6.2, but NMR experiments were carried out at five temperature intervals (278K-
333K). 
12 Thibaudeau, C.; Plavec, J.; Chattopadhyaya, J. J. Org. Chem. 1998, 63, 4967. 
13 (i) van Wijk, J.; Haasnoot, C. A. G.; de Leeuw, F. A. A. M.; Huckriede, B. D.; Westra 
Hoekzema, A. J. A.; Altona, C. PSEUROT 6.3 1999; Leiden Institute of Chemistry, Leiden 
University. (ii) Mikhailopulo, I. A.; Pricota, T. I.; Sivets, G. G.; Altona, C. A. J. Org. Chem. 
2003, 68, 5897. 
14 (i) Thibaudeau, C.; Kumar, A.; Bekiroglu, S.; Matsuda, A.; Marquez, V. E. Chattopadhyaya, 
J. J. Org. Chem. 1998, 63, 5447. (ii) Plavec, J.; Tong, W.; Chattopadhyaya, J. J. Am. Chem. 
Soc. 1993, 115, 9734. (iii) Crnugelj, M.; Dukhan, D.; Barascut, J.-L.; Imbach, J.-L.; Plavec, J. 
J. Chem. Soc., Perkin Trans. 2 2000, 255. (iv) Callam, C. S.; Lowary, T. L. J. Org. Chem. 
2001, 66, 8961. (v) Houseknecht, J. B.; Altona, C.; Hadad, C. M.; Lowary, T. J. Org. Chem. 
2002, 67, 4647. 
15 (i) Marquez, V. E.; Siddiqui, M. A.; Ezzitouni, A.; Russ, P.; Wang, J.; Wagner, R. W.; 
Matteucci, M. D. J. Med. Chem. 1996, 39, 3739. (ii) Ezzitouni, A.; Marquez, V. E. J. Chem. 
Soc., Perkin Trans. 1 1997, 1073. (iii) Marquez, V. E.; Ezzitouni, A.; Russ, P.; Siddiqui, M. A.; 
Ford, H.; Feldman, R. J.; Mitsuya, H.; George, C.; Barchi, J. J. J. Am. Chem. Soc. 1998, 120, 
 129
 2780. (iv) Ford, H.; Dai, F.; Mu, L.; Siddiqui, M. A.; Nicklaus, M. C.; Anderson, L.; Marquez, 
V.; Barchi, J. J. Biochemistry 2000, 39, 2581. (v) Choi, Y.; George, C.; Strazewski, P.; 
Marquez, V. E. Org. Lett. 2002, 4, 589. (vi) Choi, Y.; George, C.; Comin, M. J.; Barchi, J. J.; 
Kim, H. S.; Jacobson, K. A.; Balzarini, J.; Mitsuya, H.; Boyer, P. L.; Hughes, S. H.; Marquez, 
V. J. Med. Chem. 2003, 46, 3292. (vii) Russ, P.; Schelling, P.; Scapozza, L.; Folkers, G.; De 
Clercq, E.; Marquez, V. E. J. Med. Chem. 2003, 46, 5045. 
16 (i) Jacobson, K. A.; Ji, X.-D.; Li, A.-H.; Melman, N.; Siddiqui, M. A.; Shin, K.-J.; Marquez, V. 
E.; Ravi, R. G. J. Med. Chem. 2000, 43, 2196. (ii) Kim, H. S.; Ravi, R. G.; Marquez, V. E.; 
Maddileti, S.; Wihlborg, A.-K. Erlinge, D.; Malmsjo, M.; Boyer, J. L.; Harden, T. K.; Jacobson, 
K. A. J. Med. Chem. 2002, 45, 208. (iii) Kim, H. S.; Ohno, M.; Xu, B.; Kim, H. O.; Choi, Y.; Ji, 
X. D.; Maddileti, S.; Marquez, V. E.; Harden, T. K.; Jacobson, K. A. J. Med. Chem. 2003, 46, 
4974. 
17 Van Rompaey, P.; Nauwelaerts, K.; Vanheusden, V.; Rozenski, J.; Munier-Lehmann, H.; 
Herdewijn, P.; Van Calenbergh, S. Eur. J. Org. Chem. 2003, 15, 2911. 
 
 130
 CHAPTER 8 
MYCOBACTERIUM TUBERCULOSIS THYMIDINE MONOPHOSPHATE KINASE 
INHIBITORS: BIOLOGICAL EVALUATION AND CONFORMATIONAL ANALYSIS OF         
2’- AND 3’-MODIFIED THYMIDINE ANALOGUES 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published in part in: 
 
Philippe Van Rompaey, Koen Nauwelaerts, Veerle Vanheusden, Jef Rozenski, Hélène Munier-
Lehmann, Piet Herdewijn and Serge Van Calenbergh 
 
Eur. J. Org. Chem. 2003, 15, 2911-2918. 
 131
  
 132
 8.1 Introduction 
 
Each year Mycobacterium tuberculosis, the intracellular parasite that causes 
tuberculosis (TB), kills approximately 2 million people.1 The World Health 
Organization (WHO) declared TB a global health emergency and estimates that 
between 2002 and 2020 approximately 1000 million people will be newly infected and 
36 million will die from TB.2,3 Major contributors to the resurgence of this pulmonary 
disease and its worsening impact are the breakdown in health services, the 
pandemic of AIDS and the emergence of multidrug-resistant (MDR)-TB.3 The 
immune system can “wall off” the bacilli, allowing TB to stay dormant for years and to 
emerge when the immune system is weakened. This explains why TB is a leading 
cause of death among HIV-positive persons.3,4 The current treatment strategy of TB 
is based on an intensive 6 to 8-month regimen of multiple antibiotics such as 
rifampicine, isoniazid, pyrazinamide and ethambutol or streptomycin.5 However, 
Mycobacterium tuberculosis strains resistant to some or all of these major anti-TB 
drugs have emerged and are associated with high death rates of 50-80%.6 The 
“MDR” prefix refers to the simultaneous resistance to at least isoniazid and 
rifampicin, the two most potent anti-TB drugs, caused primarily by inconsistent, 
partial or improper treatment regimens. 
 
These facts impose the need to identify new targets and to develop new anti-TB 
drugs in order to optimise and/or shorten the current TB treatment and to combat 
resistance. In that light, Mycobacterium tuberculosis thymidine monophosphate 
kinase (TMPKmt), an essential enzyme of nucleotide metabolism that catalyses the 
reversible phosphorylation of thymidine monophosphate (dTMP) to thymidine 
diphospate (dTDP), has recently been introduced as a novel potential target for 
chemotherapeutic intervention.7,8 Although the global fold of the TMPKmt enzyme is 
similar to that of other TMPK isozymes, it has a low degree of amino acid sequence 
identity with the E. coli (26 %), yeast (25 %) and human (22 %) isozymes, making it 
an attractive target for blocking mycobacterial DNA synthesis.8
 
The X-ray structure of the dTMP-TMPKmt complex (Figure 8.1) indicated that the 
main binding interactions between dTMP and the enzyme involve both its pyrimidine 
base (i.e. stacking interaction with Phe70 and O4 and N3 participating in hydrogen
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Figure 8.1 Schematic representation of the most important amino acid residues of TMPKmt 
interacting with dTMP (in black). The main bonding forces between dTMP and the enzyme 
are: (i) a stacking interaction between the pyrimidine ring and Phe70, (ii) a hydrogen bond 
between O4 of thymine and the Arg74 side-chain, which results in a preference for thymine 
over cytosine, (iii) a hydrogen bond between Asn100 and N3 of the thymine ring, (iv) a 
hydrogen bond between the 3’-hydroxyl of dTMP and the terminal carboxyl of Asp9, that in 
its turn interacts with the magnesium ion that is responsible for positioning the phosphate 
oxygen of dTMP, and (v) hydrogen bonds and an ionic interaction between the                    
5’-O-phosphoryl and Tyr39, Arg95 and Mg2+  , respectively. The presence of Tyr103 close to 
the 2’-position is believed to render the enzyme catalytically selective for 2’-deoxy 
nucleotides versus ribo nucleotides. 
 
 
bonding with Arg74 and Asn100) and its ribofuranose ring moiety (i.e. hydrogen bond 
between the 3’-hydroxyl of dTMP and the terminal carboxyl of Asp9).8 The presence 
of a tyrosine residue (Tyr103) close to the 2’-position allows the enzyme to 
discriminate between 2’-deoxynucleotides and ribonucleotides, only transforming the 
former.8 Also this X-ray analysis revealed the substrate to adopt the “Southern” 
conformation.8  
 
The fact that thymidine (dT) and 3’-azido-3’-deoxythymidine (AZT) proved to be 
competitive inhibitors of TMPKmt with low μM affinity,9 led towards the synthesis and 
biological evaluation of several dT nucleoside and nucleotide analogues.9-11 In this 
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 paper we continue our search for nucleosidic TMPKmt inhibitors by combining 
favourable modifications at C-3’ (N3, NH2) with the beneficial effects observed upon 
introduction of an α-chloro or α-fluoro substituent at C-2’ (Figure 8.2).10,11 Using NMR 
spectroscopy and pseudorotational analysis, we examined the solution state 
conformation of the sugar ring of the synthesized analogues to gain better insight into 
the molecular determinants of TMPKmt inhibition. 
 
O
OH
N NH
O
O
R OH
O
OH
N NH
O
O
OH
R
O
OH
N NH
O
O
R Cl
O
OH
N NH
O
O
R F
1 R = NH2
2 R = N3
3 R = NH2
4 R = N3
5 R = NH2
6 R = N3
7 R = NH2
8 R = N3  
 
Figure 8.2 2’- and 3’-modified thymidine analogues discussed in this Chapter. 
 
 
8.2 Results and Discussion 
 
8.2.1 Chemical Synthesis 
 
The synthesis of the 2’- and 3’-modified thymidine analogue (1-8) is described in  
Part I. 
 
 
8.2.2 TMPKmt affinity (Inhibition studies) 
 
Results of the binding studies are presented in Table 8.1. The 3’-azido and 3’-amino 
substituents are intended for direct interaction with Asp 9. With the 2’-modifications 
we explored if an α-chloro or α-fluoro substituent in the vicinity of Tyr103 would be 
sterically tolerated. 
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 Table 8.1 Kinetic parameters of Mycobacterium tuberculosis thymidylate kinase with the     
2’- and 3’-modified thymidine analogues 
 
O
OH
N N
O
O
R3
R1 R2  
R1 R2 R3 Analogue  (μM) Ki
9dT OH H H 27 
9AZT N H H 28 3
N OH H 740 1 3
NH OH H 750 2 2
N H OH 215 3 3
NH H OH 1260 4 2
N Cl H 170 5 3
NH Cl H 145 6 2
N F H 118 7 3
NH F H 190 8 2
 
 
As expected, the introduction of the 2’-hydroxyl function in 1 and 2 had adverse 
effects on the affinity, due to an unfavourable interaction with the nearby tyrosine 
residue (Tyr103). Indeed, the affinity markedly improves when the 2’-hydroxyl adopts 
the opposite arabino configuration in 3 (Ki = 215 μM), or when the 2’-ribo-hydroxyl (in 
1 and 2) is replaced by a chloro or fluoro atom in 5 (and 6) and 7 (and 8), 
respectively. The incorporation of a fluoro atom into the sugar moiety of nucleosides 
has great impact on the biological and chemical characteristics of these molecules.12 
The strong electronegative fluorine alters the electronic properties of the molecule 
and specifically tunes the conformation of the furanose ring.12 Also, the 2’-α-fluoro 
atom in 7 (and 8) isosterically replaces a hydrogen atom and is known to greatly 
enhance the stability of the glycosidic bond.13 Still, the affinity for 5 (and 6) and 7 
(and 8) is moderate, i.e. > 100 μM. This was not expected, since earlier work of our 
group suggested “to combine a 2’-chlorine and 3’-azido group”.10 Furthermore, the 3’-
amino analogues 6 and 8, showed no enhanced TMPKmt affinity compared to their 
3’-azido forms 5 and 7, indicating that the positively charged 3’-amine is not optimally 
oriented to form an ionic interaction with Asp9. These results prompted us to 
investigate the preferred puckering of the furanose ring of the 2’- and 3’-modified 5 
(and 6) and 7 (and 8) pairs. 
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 8.2.3 NMR spectroscopy 
 
NMR spectroscopy in D2O permits extension of the results to the in vivo/ in vitro 
situation and was used for the pseudorotational analysis14 of nucleosides 5 (and 6) 
and 7 (and 8). The complete conformational analysis of a nucleoside (or nucleotide) 
usually comprises the determination of three principal structural parameters: (1) the 
glycosidic torsion angle χ, which determines the syn or anti position of the base 
relative to the sugar moiety; (2) the torsion angle γ, which determines the orientation 
of the 5’-hydroxyl with respect to the C3’; and (3) the puckering of the furanose ring 
and its deviation of planarity, described by the phase angle of pseudorotation P (0-
360°) and the maximum out-of-plane pucker νmax (30-46°).14 Here, we only focussed 
on the latter, since (a) the ring puckering is known to be the main determinant in 
controlling the γ- and χ-angles;15 (b) most probably a strong preference for a specific 
C4′-C5′ rotamer (γ-angle) is induced by the enzyme upon binding; and (c) as 
evidenced by the crystal structure data,8 TMPKmt binds its substrates with the base 
in the anti position (χ-angle). 
 
In solution, the relative strengths and interplay of important anomeric and gauche 
effects15,16 drive the preference of the flexible furanose ring moiety of N-nucleosides 
between the north (N) and south (S) type puckered pseudorotamers. By convention, 
a phase angle P = 0° corresponds to the absolute N conformation possessing a 
symmetrical twist form 3T2 (C3’-endo-C2’-exo), whereas the S antipode twist, 2T3 
(C2’-endo-C3’-exo), is represented by P = 180°.14 Along the pseudorotational cycle, 
the conformation of the furanose ring alternates between envelope (E) and twist (T) 
conformations every 18°. We measured vicinal proton-proton coupling constants 
(J ) of 5 (and 6) and 7 (and 8) at 500 MHz in D, J and J1’,2’ 2’,3’ 3’,4’ 2O (ca. 40mM) in a 
278-333 K range at pD 7.4 (Table 8.2.). 
 
Subsequently, we used the computer program PSEUROT 6.217 to calculate, at each 
temperature interval, the best fit of five conformational parameters, i.e. P and νmax for 
both N and S conformers and the mole fraction of S (XS), based on the three 
experimental coupling constants (Table 8.2 and Table 8.3). 
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 a b3Table 8.2 coupling constants (Hz)  and population of S conformersJH,H  at five distinct 
temperatures in the range from 278 to 333 K 
 
aTemp (K) 3J1’,2’ 3J2’,3’ 3  (%)bJ X3’,4’ S
    5 
278 4.70 5.55 6.21 45 
288 4.76 5.59 6.25 45 
300 4.92 5.61 6.39 46 
318 5.06 5.63 6.43 47 
333 5.20 5.67 6.49 48 
     
    6 
278 2.12 4.93 8.17 16 
288 2.30 4.94 8.11 17 
300 2.50 4.94 7.91 20 
318 2.66 4.95 7.80 21 
333 2.69 4.95 7.73 22 
     
    7 
278 1.27 4.73 9.31 3 
288 1.54 4.78 9.24 5 
300 1.66 4.81 9.19 7 
318 1.69 4.88 9.07 8 
333 1.72 4.89 9.05 8 
     
    8 
278 4.30 9.70 ≤ 1.00 ≤ 1 
4.49 9.92 288 ≤ 1.00 ≤ 1 
4.79 9.97 300 ≤ 1.00 ≤ 1 
4.81 10.01 318 ≤ 1.00 ≤ 1 
4.82 10.07 333 ≤ 1.00 ≤ 1 
 
a3JH,H recorded at 500 MHz in D2O at pD 7.4. bThe PSEUROT program (version 6.2)17 has 
been used to derive populations as well as geometries of N and S coformers (Table 8.3) at 
stated temperature. 
 
 
The preferred solution state conformation of 5, 6, 7, and 8 is determined by a variety 
of factors, but is primarily influenced by the class and positioning of the 2’- and 3’-
substituents and the complex interplay of the resulting four gauche interactions, i.e. 
O4’-C4’-C3’-R3, O4’-C1’-C2’-R2, R2-C2’-C3’-R3 and N1-C1’-C2’-R2. The mole 
fraction of S at 30 °C (XS) shows these analogues prefer the “northern” type ring 
puckering (Table 8.4). In combination with the 3’-azide modification, the 2’-chloro 
derivative 5 (PN = -2.7°, νmax, N = 37.5°) virtually adopts a 3T2 (C3’-endo-C2’-exo twist) 
conformation, whereas the 2’-fluoro analogue 7 (PN = 28.7°, νmax, N = 34.6°) exhibits a 
conformation that lies between a 3 3E (C3’-endo envelope) and T4 (C3’-endo-C4’-exo 
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 Table 8.3 Optimized pseudorotational parameters and errors of pseudorotational analysisa 
based on 3JH,H measured at five distinct temperatures in the range of 278 to 333 K 
 
Rms 
(Hz)
Analogue PN 
(deg) 
Pνmax, N 
(deg) 
S 
(deg) 
νmax, S 
(deg) b
-2.7 37.5 132.7 38.8 0.110 5 
7.7 38.4 162.7 38.2 0.020 6 
c7 28.7 34.6 146.1 36.0c 0.042 
c8 31.2 36.5 151.8 30.0c 0.172 
 
a 17 3The least-squares minimization program PSEUROT (version 6.2)  has been used for JH,H 
and equilibrium populations of N↔S equilibrium at various temperatures, see Table 8.2. bThe 
rms deviation represents the deviation of calculated and experimental 3JH,H:                       
rms = [1 / nΣ[J cexpt theor 2 1/2 – J  (Pi i N, νmax, N, PS, ν )] ]  max, S The pseudorotational parameter was 
kept fixed during optimisation. 
 
 
twist). For the 3’-amino modified compounds, the puckering of the 2’-chloro derivative 
6 (PN = 7.7°, νmax, N = 38.4°), is in between a 3 3 (C3’-endo-C2’-exo twist) and T2 E 
(C3’-endo envelope), whereas the 2’-fluoro derivative 8 (PN = 31.2°, νmax, N = 36.5°) is 
close to a 3T4 (C3’-endo-C4’-exo twist). Our results show that when 3’-azido/amino 
and 2’-chloro/fluoro modifications are combined, the pseudo-axial position of the 2’-
halogens and the resulting O4’-C1’-C2’-R2 gauche effect are directing the furanose 
ring towards the “northern” hemisphere of the pseudorotational circle. This O4’-C1’-
C2’-R2 gauche interaction and its drive towards the N-type conformers is cooperative 
with the anomeric effect16 and, as evidenced by the XS-values of 5 (and 6) (≤ 46 %) 
vs. 7 (and 8) (≤ 6 %) (Table 8.4), relates to the electronegativity of the 2’-substituents. 
This is in line with previous findings.12,18 12 Marquez et al.  proved the pseudorotational 
equilibrium to be governed by the α- or β-oriented fluorine atoms at the 2’- or 3’-
position and their tendency to adopt a pseudo-axial orientation. Furthermore, the 
comparative solution conformation analysis of both 3’-α-fluoro-thymidine (FLT) and 
AZT clearly demonstrated that the small, electronegative 3’-fluorine atom was 
practically locked in the pseudo-axial position (due to the strong O4’-C4’-C3’-F 
gauche interaction), whereas the sterically larger 3’-azide showed no clear positional 
preference.12 Here however, without proper energetic quantification of the various 
stereoelectronic effects in 5 (and 6) and 7 (and 8), we can only postulate that the 
O4’-C1’-C2’-Cl/F gauche effect dominates the opposite O4’-C4’-C3’-N3/NH2 gauche 
effect and decreases as size increases and/or electronegativity decreases (cf. 5 (and 
6) vs. 7 (and 8). Only the S-type conformers of 5 and 6 are relevant (for 7 (and 8) XS 
≤ 6 %). The 2’-chloro-3’-azido modified 5 (P  = 132.7°, νS max, N = 36.5°) has a 
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 2conformation in between a 1E (C1’-exo envelope) and T1 (C2’-endo-C1’-exo twist), 
whereas the 3’-amino derivative 6 (PS = 162.7°, ν  = 36.5°) has a perfect 2max, N E (C2’-
endo envelope) S-type conformation. 
 
Table 8.4 Values for ΔH° and ΔS° of the N↔S conformational equilibria as obtained through 
van’t Hoff plots, ΔG° and population of the S conformer at 303 K 
 
c Analogue ΔHa 
(kJ/mol) 
ΔSa b XΔG S
(%) (J/mol K) (kJ/mol) 
1.8 4.6 0.38 46 5 
5.7 6.8 3.6 19 6 
13.7 22.4 7.0 6 7 
21.1 1.2 20.7 8 ≤ 1 
 
aΔH° and ΔS° were calculated from the slope and intercept of the line obtained through the 
least-squares fitting procedure of ln (XS/XN) to the reciprocal of temperature:                        
ln (XS/XN) = -(ΔH° / R) (1 / T) + (ΔS° / R). R is the gas constant (8.31 J/mol K). bCalculated 
Gibbs free energy at 303 K (ΔG° = ΔH° -TΔS°). cThe population of the S conformer at 303 K 
through the relation XS/XN = K = exp(-ΔG303 / RT). 
 
 
X-ray crystallographic analysis of TMPKmt complexed dTMP shows that the furanose 
ring of the substrate is biased towards the “south”.8,10 The preference of 5 (and 6) 
and 7 (and 8) for the opposite “northern” conformation results in the pseudo-
equatorial positioning of the 3’-azide/amine and can explain their moderate affinity for 
TMPKmt. The 3’-hydroxyl function of dTMP interacts directly with an aspartate 
residue (Asp9) in the TMPKmt binding site.8 The positional shift of the 3’-azido/amino 
substituents, when puckered in N, might result in an ineffective contact with this Asp9 
and hence lower the affinity. The introduction of a methylene spacer between the 3’-
azido/amino group and the C3’, the so-called “branched chain”, might restore the 
hampered interaction with Asp9 and consequently improve the affinity. 
 
 
8.2.4 N↔S energy calculations 
 
Generally, in the solid state, mainly influenced by crystal packing forces,19 only one of 
the two solution conformations (N or S) is present.15 Similarly, when a nucleoside (or 
nucleotide) binds to its target only one form is expected to be present. Although the 
N↔S energy difference is ≈ 4 kcal/mol for classic nucleosides and nucleotides,15 it 
can explain their differences in binding affinity.20 We estimated the enthalpy (ΔH°) 
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 and the entropy (ΔS°) of the N↔S two-state pseudorotational equilibrium for 5 (and 
6) and 7 (and 8) from the slopes and intercepts of the van’t Hoff plots [ln (Xs/Xn) vs. 
1/T] (Table 8.4). The signs of the thermodynamic parameters (ΔH°, ΔS° and ΔG°) are 
arbitrary chosen so that positive values indicate the drive of N↔S equilibrium to N, as 
is the case for 5 (and 6) and 7 (and 8), whereas negative values would describe the 
drive towards S. 
 
Note that at 30 °C the ΔH° and ΔS° contributions to the ΔG° of the pseudorotational 
equilibrium in 5 (and 6) and 7 (and 8) are quite different and that it is the significant 
ΔH° contribution that drives the pseudorotational equilibrium to the “north”. Although 
the ΔG°-values for 5 and 6 are positive, their ΔH° contribution to ΔG° is rather low 
(1.8 kJ/mol and 5.7 kJ/mol respectively) and indicates the N↔S equilibrium can be 
easily driven towards S by the enzyme upon binding. More likely, their rather poor 
affinity, i.e. Ki ≈ 150 μM (Table 8.1), results from the steric clash between the larger 
2’-α-chloro atom with Tyr103. In case of 5 (and 6) however, this effect is not so 
dramatic as for the 2’-α-hydroxyl in 1 and 2, which probably relates to the greater 
hydrophobicity of the chloro atom. The ΔH° contributions of 7 and 8 (13.7 kJ/mol and 
21.1 kJ/mol respectively), on the other hand, suggest that the N↔S equilibrium is 
strongly biased towards N, the antipodal conformation of the S puckering preferred 
by TMPKmt.8 Such an energy gap might not easily be overcome by TMPKmt and, 
together with the ineffective pseudo-equatorial position of the 3’-azide/amine, 
plausibly accounts for the moderate Ki-values of 7 and 8. This conformational rigidity 
of 7 is also a possible explanation for the lack of anti-HIV-1 activity.21 The strong 
tendency of 7 to adopt a N-type puckering probably hampers the activation of this 
nucleoside to its triphosphate counterpart by cellular kinases, known to prefer S 
conformers as substrates.22 
 
 
8.3 Conclusion 
 
In search for new treatment strategies against tuberculosis, Mycobacterium 
tuberculosis thymidine monophosphate kinase (TMPKmt) was previously introduced 
as a potential target for the rational design of inhibitors. Stimulated by the fact that 
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 thymidine and 3’-α-azido-thymidine proved to be potent inhibitors, we further 
elaborated our research towards the rational design of new leads based on the 
TMPKmt crystal structure. This work describes the synthesis and biological 
evaluation of a number of 2’-and 3’-modified thymidine analogues (1-8). 
 
As expected the combination of 3’-azide/amine and 2’-α/β-hydroxyl substitutions, i.e. 
for 1 (and 2) and 3 (and 4), decreased the affinity significantly due to interaction with 
a tyrosine residue (Tyr103) known to be in the vicinity of the 2’-position. To our 
surprise the combination of 3’-azide/amine and 2’-chloro/fluoro substituents (5 (and 
6) and 7 (and 8)), known to be beneficial for the TMPKmt affinity when introduced 
separately, only resulted in moderate binding properties. This prompted us to 
investigate the conformational aspects of these thymidine analogues. In solution the 
sugar ring of nucleosides and nucleotides is known to exist in a rapid dynamic 
equilibrium, between the extreme “northern” (N) and the opposite “southern” (S) 
conformations. When a nucleoside or a nucleotide binds to its target enzyme, like in 
the crystal, only one of the two solution conformations is expected to be present in 
the active site. Through the NMR spectral parameters of 5 (and 6) and 7 (and 8), i.e. 
vicinal coupling constants (J), and their subsequent analysis with the PSEUROT 
program we indicated these analogues to be biased strongly towards the N 
conformation of the furanose ring. Via van’t Hoff plots we also calculated the energy 
(ΔH°, ΔS° and the resulting ΔG°) for the N↔S equilibria of 5 (and 6) and 7 (and 8). 
Keeping the binding affinity of these derivatives in mind, our conformational analysis 
and energy calculations show to have important implications on: (i) the appropriate 
positioning of the 2’- and 3’- substituents; (ii) the ability of the enzyme to induce an S-
type puckering on its ligand. 
 
The discrepancy between the conformation of the substrate from the target X-ray 
structure and the solution state conformation of the analogues examined, indicates 
the danger of only using crystal structural data for the formulation of structure-activity 
relationships. These findings will allow us to further rationally design other 2’- and 3’-
modified thymidine analogues, considering the influence of the planned modification 
(at the 2’- and 3’-position) on both potential binding interactions and conformational 
preference.
 142
 8.4 Experimental Section 
 
8.4.1 TMPK assay 
 
Biological evaluation was performed by Dr. Hélène Munier-Lehmann, at the 
Laboratoire de Chemie Structurale des Macromolecules (Institut Pasteur), Paris, 
France. For the detailed procedure on the TMPKmt assay we refer to the 
experimental part in our Eur. J. Org. Chem. research paper (2003,15, 2911). 
 
 
8.4.2 Pseudorotational analysis 
 
NMR samples were prepared with 3 mg of compounds 5 (and 6) and 7 (and 8), 
dissolved in 250 μl D2O and pD was adjusted to 7.4 (same conditions used during 
the TMPKmt assay). High resolution 1D 1H spectra were recorded on a Varian 500 
MHz Unity spectrometer, operating at 499.505 MHz. Quadrature detection was 
achieved by States-Haberkorn hypercomplex mode.23 Coupling constants were 
examined for all four analogues between 278 K and 333 K. The ring conformations of 
the synthetic nucleosides were analysed with the program PSEUROT 6.217 (DOS 
version) running on a Pentium II 350-MHz personal computer. This version includes 
an improved generalized Karplus equation for the iterative generation of coupling 
constants based on the experimental data as described by Donders et al.24 The 
standard values for substituent electronegativities (supplied with the 6.2 version)17 
were used in the iterations. For the azide function the λ-value of 0.85 was used.12 For 
the calculations an iterative strategy was adopted in which the pseudorotational 
parameters, obtained for each set of coupling constants, were calculated repeatedly 
after minor changes were systematically made in the starting parameters. If there 
was reason to believe that a specific derivative preferred a particular ring puckering, 
the minor conformer was held fixed during the iteration. The quality of the data was 
measured in the RMS deviation of the calculated and experimental coupling 
constants. In general, the RMS deviation (between the experimental and calculated 
coupling constants) was less than 0.2, indicating the parameterisation of the program 
was well suited to the input data (Table 8.3). 
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 8.4.3 N↔S energy calculations 
 
For each compound, the mole fraction of S (XS) at each temperature interval (Table 
8.2.), obtained from the PSEUROT17 analysis, was used to make the van’t Hoff plots 
(not shown here). The slopes and intercepts of these van’t Hoff plots were 
subsequently used to calculate the ΔH° and ΔS° of the N↔S two-state 
pseudorotational equilibrium of compounds 5 (and 6) and 7 (and 8) (Table 8.4). The 
correlation coefficients (R²) of the van’t Hoff plots are: 0.96 (5), 0.93 (6), 0.81 (7) and 
0.92 (8). ΔG° and XS were calculated at 303 K using the determined ΔH° and ΔS° 
values (Table 8.4). 
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 SUMMARY 
 
In this work we have described the synthesis (Part I, Chapter 1-2) of various 
adenosine and thymidine analogues (Figure 1) and evaluated their behaviour on 
adenosine receptors (ARs, Part II, Chapter 3-6), a subfamily of G-protein coupled 
receptors, and as inhibitors of thymidine monophosphate kinase (Part III, Chapter 7-
8), a potential drug target for treatment of tuberculosis. 
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Figure 1 Overview of the modifications made on the adenosine (A) and thymidine (B) 
nucleoside scaffolds 
 
 
In Part II we focussed on the human adenosine A  receptor (A3 3AR) subtype, the 
most recently identified member of the ARs. Since its discovery, many variations 
have been made on the adenosine nucleoside scaffold in view of potent and 
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 selective A3AR binding. Known A3AR selective alternations are (Figure 1A): N6-
modifications and smaller substituents at the 2-position of the purine moiety, both 
with and without the 5’-methylcarbamoyl insertion in the sugar moiety.  
 
In this thesis, we have examined the effect of combining these variations with 3’-
azido/amino(methyl) modifications, to provide more insight into the effect of 
combined substitution patterns on hA3AR affinity and efficacy. Several analogues 
showed moderate to high A3AR affinity and selectivity. Analogue 4.19 (K  hAi 3AR = 27 
nM and A1/A3 selectivity > 350) emerged as the best in this series. An interesting 
feature was that the intrinsic activity could be tuned by varying the substituent 
introduced at the 3’-position: 
- a 3’-amino function (as in 4.14, 4.16 and 4.19) resulted in (strong) partial 
agonist activity; 
- the azide precursors (as in 4.11, 4.13 and 4.17) converted these analogues 
into antagonists; 
- introduction of a methylene spacer “branching” (as in 4.1-10, 4.12, 4.15, 
4.18 and 4.20) abolished all efficacy. 
 
Moreover, we were interested in the role of these modified adenosine analogues as 
tools for the structure based exploration of ARs. By integrating organic synthesis and 
molecular engineering, we (in collaboration with the group of Dr. Kenneth A. 
Jacobson) investigated the molecular complementarity at both wild-type and mutant 
A (Chapter 5) and A3 2A (Chapter 6) adenosine receptors in the so-called “neoceptor-
neoligand” concept. In absence of high-resolution structural knowledge of GPCRs, 
this concept was successfully used to both structurally and functionally validate the 
rhodopsin based homology models of the A  and A2A 3 adenosine receptors with 
adenosine derivatives such as 4.7 and 5.14. 
 
In Chapter 5 we showed the affinities of the 3’-amino modified adenosine analogues 
(neoligands) to be higher for the H272E mutant A3AR (neoceptor) than for the 
corresponding wild type receptor, demonstrating that the A3AR (or a GPCR in 
general) could be engineered for selective interaction with synthetic agonists. 
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 In Chapter 6 we described the binding characteristics of A2AAR agonist and 
antagonist ligands, using a rhodopsin based three-dimensional model of the A2AAR 
TMs. In addition, we validated the model by making complementary changes in the 
structures of both agonist ligands and the A2AAR, to form new neoceptor(T88D)-
neoligand pairs. 
 
In Part III (Chapter 7-8) we briefly studied the potential of thymidine analogues, 
modified in 2’- and 3’-position (Figure 1B), as inhibitors of Mycobacterium 
tuberculosis thymidine monophosphate kinase, an enzyme under investigation as 
new anti-tuberculosis target. Surprisingly, these analogues showed only moderate 
binding affinity (i.e. Ki between 118 and 1260 μM), prompting us to investigate their 
conformational features (i.e. preferred ring puckering). This analysis showed that 
especially derivatives 8.7 and 8.8 (with respectively Ki = 118 and 190 μM) are 
strongly biased towards the “northern” ring conformation, whereas X-ray 
crystallography suggests a preference of TMPKmt for ligands with the opposite 
“southern” ring pucker. 
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 OVERVIEW OF EVALUATED COMPOUNDS 
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 APPENDIX: AMINO ACIDS 
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 SAMENVATTING 
 
In Deel I (Hoofdstuk 1-2) van dit werk beschreven we de synthese van 
gemodificeerde adenosine en thymidine analogen (zie Figuur 1). Deze verbindingen 
werden als moleculaire probes gebruikt voor de biologische evaluatie van adenosine-
receptoren (ARn, Deel II, Hoofdstuk 3-6), die behoren tot de G-proteïne gekoppelde 
receptor (GPCR) superfamilie, en als inhibitoren voor thymidine-monofosfaat kinase 
(Deel III, Hoofdstuk 7-8), een potentieel antituberculose doelwit. 
 
NO
N
N
OHOH
N
NH2
OH
Cl
NH
I
NHCH3
NH2
CH2NH2
O
N
H
CH3
N3
CH2N3
NH
Cl
MeO
2
6
3'
5'
A 
 
 
NH2
N3
N
NH
O
OH
O
O
OH
OH
OH
Cl F
3' 2'
1 3
B 
 
 
Figuur 1 Overzicht van de verrichte adenosine (A) en thymidine modificaties (B) 
 
 
Deel II richtte zich voornamelijk op de adenosine A  receptor (A3 3AR), de meest 
recente AR. Reeds vele structurele variaties van het adenosine-skelet werden 
onderzocht met het oog op A AR affiniteit en selectiviteit, waaronder N6-benzyl-3
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 substituties en kleinere functionele groepen in 2-positie van het purine gedeelte, al of 
niet in combinatie met de introductie van een 5’-methylcarbamoyl in het ribofuranose 
deel. 
 
Door bovengenoemde veranderingen aan het adenosine-skelet te combineren met 
3’-azido/amino(methyl)-modificaties (zie Figuur 1A), wilden we de invloed bestuderen 
van dergelijk (gecombineerd) substitutiepatroon op de A3AR selectiviteit, affiniteit en 
intrinsieke activiteit. Vele van de gesynthetiseerde analogen vertoonden matige tot 
hoge A3AR affiniteit en selectiviteit. Het beste derivaat uit deze serie was analoog 
4.19 (K  hAi 3AR = 27 nM en A1/A3 selectiviteit > 350). Interessant bij deze 
verbindingen was dat de intrinsieke activiteit gemoduleerd kon worden afhankelijk 
van de substituent in 3’-positie: 
- een 3’-aminogroep (zoals bv. 4.14, 4.16 en 4.19) resulteerde in (sterk) 
partieel agonisme; 
- de azide precursoren (zoals bv. 4.11, 4.13 en 4.17) waren allen 
antagonisten; en 
- introductie van een methylene-spacer zoals bij 4.1-10, 4.12, 4.15, 4.18 en 
4.20 ging ten koste van de intrinsieke activiteit. 
 
Ook bestudeerden we de rol van deze gemodificeerde adenosine analogen als tools 
voor het structuurgebaseerd onderzoek van ARn. Door organische synthese en 
moleculaire modeling te integreren in het “neoceptor-neoligand” concept, konden we 
(in samenwerking met dr. Kenneth A. Jacobson) meer inzicht verwerven in de 
moleculaire complementariteit van wild-type en gemuteerde A3 (Hoofdstuk 5) en A2A 
(Hoofdstuk 6) ARn. In afwezigheid van exacte structurele kennis van verschillende 
GPCRn, liet deze aanpak toe met behulp van verbindingen zoals 4.7 en 5.14 de 
(A AR en A2A 3AR) homologie modellen van de te valideren. 
 
Bovendien, toonden we in Hoofdstuk 5 aan dat de affiniteit van 3’-amino 
gemodificeerde adenosine analogen (neoliganden) hoger was voor de H272E 
gemuteerde A3AR (neoceptor) dan voor de wild-type A3AR. Hiermee bewezen we dat 
de A3AR (of GPCRn in het algemeen) ontworpen kunnen worden om selectief met 
synthetische liganden te interageren. 
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 In Hoofdstuk 6 beschreven we de verschillende A2AAR-bindingskarakteristieken 
voor agonisten en antagonisten op basis van het ontworpen 3-D homologie model. 
Een model dat gevalideerd werd door nieuwe neoceptor (T88D)-neoligand-paren te 
beschrijven. 
 
In Deel III (Hoofdstukken 7-8) bestudeerden we het potentieel van                      
2’,3’-gemodificeerde thymidine analogen als inhibitoren voor Mycobacterium 
tuberculosis thymidine-monofosfaat kinase, een nieuw antituberculose doelwit. De 
(onverwacht) lage affiniteit (d.i. Ki tussen 118 en 1260 μM) van deze verbindingen, 
spoorde ons aan om hun conformationele eigenschappen nader te bestuderen. De 
conformationele analyse van verbindingen 8.7 en 8.8 (respectievelijk met Ki’s = 118 
en 190 μM) toonde een mogelijk verband aan tussen de matige affiniteit en een 
suboptimale positionering van de 2’- en 3’-substituenten, toe te schrijven aan de 
uitgesproken voorkeur voor de noord conformatie. 
 159
